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ABSTRACT OF DISSERTATION 
COPLANAR PCB-INDUCED INFLAMMATION AND DIETARY INTERVENTIONS 
 
Diseases, such as cardiovascular disease (CVD), are linked to chronic low levels of 
inflammation.  This inflamed state is the product of risk factors including exposure to 
environmental pollutants, such as polychlorinated biphenyls (PCBs), which are 
correlated with increased risk for CVD and diabetes. In response to this health risk, our 
research addresses the mechanisms by which coplanar PCBs elicit an inflammatory 
response and the mitigation of PCB-induced inflammation through dietary intervention 
using docosahexaenoic acid (DHA), an omega-3 lipid. 
 
Investigators from the University of Kentucky Engineering Department are developing 
remediation technologies that detoxify PCBs through dechlorination. We studied the 
cellular toxicity of coplanar PCB 77 remediation products in primary vascular endothelial 
cells. The dechlorination products elicited different toxicological responses, which were 
less than the parent compound and contributed to the overall inflammatory response. 
The presence of PCB 77 at any concentration was sufficient to promote an inflammatory 
response, which was attenuated with complete dechlorination.  
 
PCB 77 is a good model for coplanar PCB-induced toxicity, but in environmental and 
human samples, coplanar PCB 126 is detected more frequently. Using different doses of 
PCB 126, we determined that acute exposure to 5 µmol PCB 126/kg mouse was 
sufficient to produce an inflammatory response without inducing a toxic wasting 
phenotype. PCB-induced inflammation was attenuated in vitro by DHA-derived 
neuroprostanes. Applying this information, we fed mice a DHA-enriched diet and 
exposed them to PCB 126.  Liver and adipose lipid profiles confirm an increase in 
omega-3 fatty acid composition and DHA metabolites, and changes in gene expression 
indicate a heightened anti-oxidant response in the presence of PCB-induced 
inflammation.  These data provide an overview of the in vivo response to a PCB-induced 
inflammation after DHA dietary feeding.  
 
We have demonstrated that PCB-induced endothelial dysfunction is propagated through 
lipid domains called caveolae. Caveolae are also signaling domains for toll-like receptor 
4 (TLR4), and receptor for lipopolysaccharide (LPS). Similar to PCBs, TLR4 signaling is 
inhibited by DHA. We compared the caveolae-associated signaling response after 
exposure to coplanar PCB 126 or LPS. The domain localization of caveolae was altered 
by both PCB 126 and LPS. Our study determined that PCB 126-induced inflammation 
was not inhibited by a TLR4-specific inhibitor, but caveolae-based signaling was critical 
to both PCB 126- and LPS-induced inflammation.  
 
Environmental pollutants, such as coplanar PCBs, are risk factors in the development of 
chronic diseases. Here we investigate possible signaling pathways associated with 
environmental toxicity and apply potential dietary interventions with omega-3 lipids.  
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Chapter One: Introduction  
1.1 Environmental pollution – PCB 
The unprecedented boom in chemical manufacturing had produced a legacy of chemical 
wastes and byproducts that flowed into streams and piled up in landfills. Scientists and 
the public began to awaken to the horror of a polluted world. Rachel Carson, a leader in 
the environmental movement, raised public awareness through her book Silent Spring; 
she writes,  
“The most alarming of all man’s assaults upon the environment is the 
contamination of air, earth, rivers, and sea with dangerous and even lethal 
materials. This pollution is for the most part irrecoverable; the chain of evil it 
initiates not only in the world that must support life but in living tissues is for the 
most part irreversible1.”   
In response to the public outcry and mounting scientific evidence about environmental 
and human health effects, Congress passed a series of environmental legislation, and 
the President established the Environmental Protection Agency (EPA)2.  Within this 
legislation, certain environmental pollutants were banned from manufacturing including 
polychlorinated biphenyls (PCBs). PCBs like many other contaminants from that era are 
distinguished by their stable chemical structure which includes a biphenyl and many 
configurations of chlorine substitutions that account for up to 209 possible congeners3 
(Figure 1.1). Produced in mixtures, called Aroclors, PCBs were widely marketed and 
used in applications in which their stability and low electrical conductivity were prized; 
these applications included dielectric fluid in capacitors and light ballasts and building 
materials such as paint and sealants4.  
The two major classes of PCBs are defined by the stereochemistry of the biphenyl bond 
(Figure 1.1)3, 5. The coplanar PCBs do not contain ortho-substitutions and exhibit dioxin-
like properties. The presence of coplanar PCBs in human and animal tissues are orders 
of magnitude lower than other congeners, but as a class of compounds they exhibit 
greater potential for toxicity, especially PCB 1266, 7. They are dioxin-like and bind the aryl 
hydrocarbon receptor (AhR) which activates cytochrome P450 (CYP) metabolizing 
enzymes, the expression of which are associated with increased cellular oxidative stress 
and inflammation8. Chlorine substitutions in the ortho- position cause steric hindrance for 
noncoplanar PCBs, which have different biological activity than the coplanar PCBs. 
Noncoplanar PCBs have an affinity for the constitutive androstane receptor (CAR)9, 
which activates CYP metabolizing enzymes, and are known to disrupt Ca2+ signaling in 
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the brain through the ryanodine receptors3, 10.  In addition, noncoplanar PCBs have been 
associated with certain metabolic disorders. For example, PCB 153 is a noncoplanar 
PCB that is present in high levels in human serum; it is associated with increased risk for 
nonalcoholic fatty liver disease and Type 2 diabetes11, 12. Congeners which are mono-
ortho-substituted, such as PCB 118, have reduced AhR activity and have molecular 
similarities to noncoplanar PCBs3, 5, 13. Our research has demonstrated that in 
comparison to noncoplanar PCBs, coplanar PCBs and mixed inducers promote oxidative 
stress and decrease endothelial barrier function, which is critical to inflammatory process 
that causes endothelial dysfunction and promotes the vascular inflammation that leads 
to atherosclerosis14. We have also demonstrated that certain nutrients either promote or 
inhibit coplanar PCB-induced endothelial cell dysfunction. For example, the omega-6 
fatty acid linoleic acid promotes coplanar PCB-induced inflammation, but when the ratio 
of omega-3 to omega-6 fatty acids is increased, the omega-3 fatty acids protect against 
PCB-induced oxidative stress and nuclear factor kappa B (NFкB) activation15, 16. As a 
result, the work in our laboratory has focused on the dioxin-like, coplanar PCBs. 
Pollutant toxicity is compared using toxic equivalency factors (TEFs) which designate a 
toxicity value based on a comparison to the toxicity of  2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD, dioxin). For PCBs, only coplanar PCBs (non-ortho substituted) exhibit 
dioxin-like qualities and are ligands had arylhydrocarbon receptor (AhR).  The major 
congeners in this class are PCB 77, PCB 126, and PCB 169 with TEFs in humans of 
0.0001, 0.1 and 0.01, respectively17. In addition, PCB 170 and PCB 180 have 
ethoxyresorufin-O-deethylase (EROD) activity that is sufficient for a TEF equivalency to 
be assigned. Based on the median TEF values of PCB 105, PCB 118, and PCB 156, the 
TEF for mono-ortho PCBs, containing one ortho substitution or a mixed congener, is 
0.0000318. Together, TEFs can be combined to develop toxic equivalents (TEQ) that 
may be applied when assessing limits in food sources, sediments, waterways, etc. 
However, the TEFs are based primarily on studies of oral exposure, which is often the 
source of exposure for both animals and humans18. As such, human exposure risk and 
risk attenuation continue to be primary concerns in environmental health research. 
PCB distribution in the body 
The concept of persistence and biomagnification in humans and animals is based on the 
ability of adipose tissue to act as a storage facility for persistent organic pollutants 
(POPs)19, 20. The degree of lipophilicity for a particular toxicant is determined by a log10 
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value of >6.0 for the solubility ratio of octanol to water21. POPs that exceed the 6.0 
lipophilicity threshold are soluble in dietary fat sources and are absorbed in the intestinal 
lumen with triacylglycerols into the lymphatic circulation22. After entry into the lymphatic 
system, they are incorporated into chylomicrons which transport the toxicants to other 
tissues including the primary storage depot, the adipose. PCBs display a range of 
affinities and distribute among LDL, HDL, and albumin fractions23, 24. Fortunately, the 
body has a mechanism for reducing its burden of PCBs and other POPs by utilizing 
enterohepatic circulation21. Through this cycle, POPs may be returned to circulation in 
the blood, be acquired by the liver which packages them with bile for excretion into the 
intestine. Once in the intestine, the pollutants will either be reabsorbed with the bile salts 
or be excreted in the feces. Through a similar pattern of circulation, POPs are also 
incorporated into mother’s breast milk, which serves as one of the first and most 
concentrated exposures for humans25, 26.  The circulation of these compounds is not an 
innocuous process, and PCBs or other compounds are able to interact with the tissues 
that are exposed during circulation including the vascular endothelium and the liver.  
PCBs and other dioxin-like compounds are associated with a wide range of human 
health outcomes, the mechanisms of which are still being explored. The immune, 
hepatic, neural, endocrine, vascular and reproductive systems are all affected in by PCB 
exposure27-29. 
Molecular interactions of coplanar PCBs with target receptors 
As dioxin-like compounds, coplanar PCBs are ligands for the AhR.  The transcription 
factor, AhR, is a member of the PER-ARNT-SIM (PAS) superfamily that has a helix-loop-
helix structure. This highly conserved protein requires ligand binding for activity and is a 
cellular sensor that has a critical function in development, especially of the liver and 
vascular systems, circadian rhythms, hypoxia, hormonal signaling, inflammation and 
other biological processes30. The AhR and its chaperone proteins including two HSP90 
units reside in the cytosol until ligand binding which causes the release of one HSP90 
and translocation into the nucleus where AhR dimerizes with ARNT (AhR nuclear 
translocator), releases the second HSP90, binds to a xenobiotic response element 
(XRE, also called the dioxin response element, DRE) and facilitates transcription29. The 
transcriptional changes directed by XRE binding facilitate cellular responses to 
environmental stimuli; however, when these signals are prolonged by strong ligand 
affinity, such as is the case of AhR binding with TCDD, disease processes are activated. 
AhR activity promotes expression of Phase I and Phase II metabolism and anti-oxidant 
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response enzymes, such as the Phase I enzyme cytochrome P450 1A1 (CYP1A1)31, 32. 
Ligands of the AhR require a degree of hydrophobicity, e.g. be lipophilic in nature, and 
exhibit certain electronegative and hydrogen bonding properties, and as follows, this 
includes a varied set of xenobiotic, endogenous and dietary compounds33. The 
xenobiotic ligands that meet the physical requirements of the AhR binding pocket 
represent a large number of environmental pollutants examples of which include the 
following: PCBs, dioxins, naphthalenes and PAHs (polycyclic aromatic hydrocarbons), 
such as benzo[a]pyrene. An equally extensive list of possible endogenous ligands have 
also been identified for the AhR; these include the following: indigoids (indigo and 
indirubin), 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE), 
equilenin (equine estrogen), metabolites of arachidonic acid, of heme and of tryptophan. 
From food sources, derivatives of indole-3-carbinol, found in cruciferous vegetables, and 
flavonoids, such as quercetin are potential ligands. The diversity of AhR ligands has led 
scientists to appreciate a number of functional roles for this transcription factor. Through 
endogenous ligand activation, the AhR is responsible for a number of developmental 
and cellular processes including cardiovascular, immune and neuronal systems34; for 
example, AhR deficient mice have incomplete liver vascularization33. Dietary 
polyphenols, like flavonoids, have been linked to the protective anti-oxidant response 
and initiate binding to alternative XRE binding sites. In contrast, xenobiotics, such as 
PCBs, hijack the endogenous functions of the AhR to produce an inflammatory 
response34. The AhR-induced inflammatory response is linked to the upregulation of 
detoxifying enzymes, such as CYP1A1, and cross-talk with the nuclear nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2) mediated anti-oxidant response35.    
The AhR induces CYP1A1 expression in response to coplanar PCBs and other ligands36, 
37. CYP1A1 activity includes the hydroxylation or epoxidation of the offending xenobiotic. 
When the reaction is unsuccessful and the enzyme “slips” or becomes uncoupled, a 
superoxide ion is released into the cell rather than being added to the compound38. 
Xenobiotics, such as PCBs, are not well metabolized, and their interaction with Phase I 
enzymes, like CYP1A1, leads to a greater release of reactive oxygen species (ROS), 
which significantly shift the redox balance of the cell39. Nrf2 regulated anti-oxidant 
enzymes, such as glutathione-S-transferase (GST) and NAD(P)H:quinine 
oxidoreductase (NQO1), serve to mitigate the increase in ROS, but when the oxidant 
capacity has been exceeded the cell initiates NFĸB and other redox sensitive 
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transcription factors to produce a heightened inflammatory cascade40, 41. NFĸB promotes 
the transcription of the chemokine monocyte chemoattractant protein 1 (MCP-1)42, 43, 
also called CCL2, and vascular cell adhesion molecule 1 (VCAM1)44, 45, which are key 
markers of endothelial cell dysfunction and the initiation of macrophage recruitment. The 
cytochrome P450 enzymes are part of Phase I metabolism during which the substrates 
are attacked at the site of a good leaving group which is replaced by hydroxyl, epoxide 
or carboxyl functional groups 46, 47.  This conversion is the first step in the transformation 
of the liphophilic molecule into a water soluble substrate that can be excreted through 
the kidneys. Phase II metabolizing enzymes that are upregulated through AhR activation 
include glutathione transferases, UDP-glucuronyltransferases and sulfotransferases48, 
which utilize the nucleophilic functional group to add a water soluble moiety such as a 
glucuronic acid, amino acid (glutathione, GSH) or sulfuric acid47. CYP metabolism of 
PCBs results in epoxide and hydroxylated products that are processed by the Phase II 
enzymes to generate all these metabolites3.  
1.2 PCBs and predisposition to inflammatory response  
Endothelial dysfunction 
As sensitive modulators of vascular homeostasis, endothelial cells both respond to the 
changing climate within the blood and regulate the vascular environment49. For the 
average American, this “climate” includes the following: dietary factors such as high 
levels of fatty acids, sodium, and glucose; lifestyle factors such as minimal physical 
activity; and exposure environmental pollutants from food, air, and built environments50, 
51. The endothelium responds to each of these factors by modulating the physiological 
environment including vasorelaxation through endothelial nitric oxide synthase (eNOS) 
signaling or inflammation through cytokine and adhesion molecule expression52, 53. The 
endothelial inflammatory response culminates in a change in function termed endothelial 
dysfunction in which cytokines like the chemokine monocyte chemoattractant protein-1 
(MCP-1) are secreted to recruit macrophages that are captured via adhesion molecules 
like VCAM1, and decreases in cell:cell junction integrity allow the macrophages to 
penetrate the endothelial cell barrier42, 54, 55.  Once in the intimal space, macrophages 
promote the inflammatory state by producing cytokines and through phagocytosis of ox-
LDL, which together promote formation of foam cells that accumulate to form plaques.  
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Inflammation and disease risk 
Inflammation is a characteristic held in common by a variety of diseases including lupus, 
rheumatoid arthritis, Crohn disease, ulcerative colitis, dermatomyositis and 
polymyositis56. The majority of these disorders can increase a patient’s risk for 
myocardial infarction or coronary artery disease related events when compared to 
control or the general population; for this analysis, only disorders associated with 
inflammatory bowel disease did not increase vascular disease risk56. The heightened 
inflammatory state increased lipoprotein oxidation and unresolved inflammation 
promoting the observed effect on cardiovascular outcomes. The pro-inflammatory 
cytokines, tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6) are risk factors for 
cardiovascular diseases and are increased in rheumatoid arthritis (RA) patients; further, 
coronary calcification is greater in RA patients with longer disease histories, which is 
associated with increased cardiovascular disease prevalence in this patient population57.  
Interestingly, many chronic inflammatory disease states are characterized by a 
dysregulated immune response in the epithelial and mesenchymal cell structures of the 
affected organ; in the case of atherosclerosis, the endothelium is activated by bacterial 
components, lipoproteins or other stimuli which induce vascular cell adhesion molecule 1 
(VCAM1) expression and the recruitment of immune cells that perpetuate the interstitial 
inflammatory response58. Coplanar PCBs and other environmental pollutants are 
potential activators of vascular inflammation.   
PCBs as a risk factor in diseases of inflammation 
Low grade inflammation is associated with many of chronic disorders including 
cardiovascular diseases, diabetes, metabolic syndrome and obesity. Tissue 
inflammation in the vascular system, adipose, and liver are all indicators and risk factors 
for the development of disease. PCBs have been associated with the development of 
multiple inflammation-associated medical conditions. For example, diabetes and 
metabolic syndrome are increased relative to PCB levels in both the general population 
and in communities with increased PCB exposure59-61. In particular, a survey of the 
Japanese population indicated that PCB 126 was a key toxicant associated with the 
increased prevalence of metabolic syndrome61. In a study of the 2003-2004 NHANES 
data, elevated serum alanine aminotransferase (ALT), a biomarker associated with non-
alcoholic fatty liver disease (NAFLD) and other liver diseases, was increased in 
association with heavy metal and PCB exposure62, and NAFLD was increased in mice 
exposed to PCBs11. Toxicant induced liver diseases, which include toxicant-associated 
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fatty liver disease and toxicant-associated steatohepatitis, are associated with exposure 
to industrial chemicals including vinyl chloride and PCBs63. Further, cardiovascular 
disease risk was increased in an elderly population independent of lipid levels and other 
cardiovascular disease risk factors64, and in rats, PCB 126 was associated with 
heightened cardiovascular disease risk resulting from changes in cholesterol, blood 
pressure and heart weight65. Industrial workers with high levels of PCB exposure have 
significantly increased levels of cardiovascular disease-related death66. These data 
support of the role of PCBs in the propagation of inflammatory diseases. 
PCBs, as lipophilic compounds, accumulate in the adipose and are recirculated through 
the body by enterohepatic circulation, a process which exposes both the vascular 
system and the liver to these toxicants. Given this environment, PCBs induce a stress 
response that promotes chronic, low grade inflammation and thus predispose the 
vasculature, specifically the endothelium, to heightened response to lifestyle and 
pathogenic stressors, like bacterial lipopolysaccharide (LPS)67. A recent study of the 
Framingham heart study cohort has concluded that the traditional risk factors are 
insufficient to explain the level of inflammation observed in the study68; this would 
suggest that genetic factors and environmental factors like PCBs could be the 
“unobserved” risk factors. Vascular biomarkers like soluble VCAM1 provide a critical 
observational link between metabolic syndrome and insulin resistance and the 
development of CVD and diabetes69. Studies have suggested that certain PCBs 
contribute to the development of metabolic syndromes like Type II Diabetes and 
atherosclerosis64, 70-72. Coplanar PCBs initiate an inflammatory signaling cascade that 
increases oxidative stress and promotes endothelial dysfunction in vascular endothelial 
cells73. To better understand the inflammatory potential of PCBs, chapter two assesses 
endothelial cell response to PCB 77 and PCB 77 remediation products which are the 
byproducts of PCB 77 dechlorination. To establish a dosing model and further our 
understanding of environmentally persistent coplanar PCBs, chapter three determines 
which of five increasing concentration of PCB 126 are effective in producing a moderate 
inflammatory response without causing toxic wasting syndrome. Using the dosing model 
developed in chapter three, we were able to test nutritional interventions of PCB 126-
induced inflammation in chapter four.  
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1.3 Nutrition and inflammation  
Fatty acids and inflammation 
A fatty acid is a long carbon chain with four to twenty-four carbons that is capped by a 
methyl group containing the omega carbon and a carboxyl group74. There are multiple 
structural classes of fatty acids that are defined by the number and location of double 
bonds within the carbon chain and include saturated, monounsaturated, 
polyunsaturated, and trans fatty acids. Diets high in saturated fat have been associated 
with cardiovascular disease and are known to promote inflammation75, 76. Saturated fatty 
acids, which are not essential for a complete human diet, are long carbon chains that are 
fully substituted with hydrogen atoms and do not contain double bonds; examples 
include palmitate, laurate, myristate and stearate, which are found in red meat and 
dairy74.  The amount of saturated fat consumed determines the inflammatory effects. In a 
study in mice, mice consuming 12% saturated fat, which is equivalent to the average 
American diet, had greater adipose inflammation and macrophage activity than mice fed 
diets with 6% and 24% saturated fat77. One of the mechanism by which saturated fatty 
acids cause inflammation is through the toll-like receptors (TLRs)76, including TLR4 
which has increased expression in atherosclerotic lesions78. Saturated fatty acids 
modulate gene expression and increase TLR expression which increases sensitivity to 
inflammatory stimuli, such as lipopolysaccharide (LPS)79. In the Nurses’ Health Study, 
women who consumed 5% more saturated fat compared to those who consumed 5% 
more carbohydrate were 17% more likely to have a cardiac event80. Replacing dietary 
saturated fatty acids with polyunsaturated fatty acids reduces the number of coronary 
events81. Unlike saturated fatty acids, polyunsaturated fats (PUFA), e.g. omega-3 and 
omega-6 fatty acids, have two or more double bonds with the first double bond at the 
third or sixth carbon, respectively. PUFA are essential to the human diet74, yet 
differences exist between the omega-3 and omega-6 inflammatory potential.  
Omega-3 and omega-6 fatty acids and inflammation 
The ratio of omega-3/omega-6 fatty acids influences metabolism of fatty acid substrates 
and the generation of inflammatory mediators. For example, the elongation of the parent 
omega-3 fatty acid α-linolenic acid to the longer chain docosahexaenoic acid (DHA) 
molecules can be inhibited by competition with high levels of the omega-6 linoleic acid 
for the same desaturase enzymes82. Linoleic acid is elongated to form arachidonic acid, 
which is the primary substrate for prostaglandin, leukotriene and thromboxane formation; 
higher substrate availability increases the baseline levels of these inflammatory 
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eicosanoids82. Long-chain omega-3 fatty acids, eicosapentanoic acid (EPA) and DHA 
are also metabolized by cyclooxygenases (COX) and lipoxygenases.(LOX) to form 
eicosanoid and docosanoid metabolites, which are either less inflammatory than their 
omega-6 derived counterparts or have anti-inflammatory properties83, 84 (Figure 1.285-88). 
Arachidonic acid is a major component of the plasma membrane and is the precursor of 
prostaglandin E2 (PGE2) and leukotriene B4 (LTB4); diets containing omega-3 fatty acid 
rich-flaxseed oil or fish oil competitively reduced the production of arachidonic acid-
derived eicosanoids and other inflammatory cytokines89.  F2-isoprostanes (F2-IsoPs), 
which are similar in structure to the COX-derived prostaglandins, are formed by non-
enzymatic peroxidation of arachidonate and are an indication of oxidative stress90. 
Elevated levels of F2-IsoPs are associated with chronic disease states including 
atherosclerosis, hypercholesterolemia, diabetes, obesity, Alzheimer’s, pulmonary 
disorders, and allergen-aggravated asthma90.   All of these disorders are associated with 
elevated levels of inflammation and oxidative stress.  
Different fatty acids modulate PCB-induced inflammation.  In a feeding study using LDL-
R-/- (low-density lipoprotein receptor deficient) mice, we observed VCAM1 tissue 
expression in the endothelium of mice fed omega-6-rich corn oil, and PCB treatment 
promoted more extensive VCAM1 expression extending to the smooth muscle portions 
of the vessel wall91. In contrast, dietary feeding of monounsaturated-rich olive oil did not 
promote vascular inflammation, and though PCBs induced inflammation in olive oil fed 
mice, the high oleic acid diet supported compensatory metabolic changes in the livers of 
PCB-treated mice. In vitro work using primary vascular endothelial cells enabled us to 
modulate PCB-induced inflammation by changing the omega-3/omega-6 fatty acid ratio. 
Increasing levels of α-linolenic acid (omega-3) to linoleic acid (omega-6) reduced 
VCAM1 and COX-2 mRNA and protein expression and attenuated PGE2 production. 
With the same model, we demonstrated that oxidized DHA-derived A4/J4-neuroprostanes 
reduced coplanar PCB-induced oxidative stress, NFкB activation, and MCP-1 protein 
and mRNA expression92. When compared, DHA-derived neuroprostanes were more 
effective at attenuating PCB-induced inflammation than those derived from EPA. From 
these data, we concluded that future in vivo nutritional intervention studies, as presented 
in chapter four, would use a DHA-enriched diet.  
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Omega-3 fatty acids and implications in inflammation resolution 
Fish oil presents the richest source of DHA and EPA, and the precursor fatty acid, α-
linolenic acid, is available from multiple plant sources including walnuts, flax seed, and 
canola oil74. A human trial comparing the effect of DHA-EPA, α-linolenic acid (ALA), 
DHA-EPA/ALA combination or placebo treatment on major cardiovascular events found 
that ALA was most beneficial to women and that the DHA-EPA treatment was most 
beneficial to patients with a diabetic comorbidity93. A meta-analysis of eleven studies that 
provided DHA/EPA supplementation for one year or longer determined that 
supplementation significantly reduced the risk of sudden cardiac death and all-cause 
mortality for high risk patients and reduced the risk of nonfatal cardiovascular events in 
patients with moderate risk94. In culture, omega-6 fatty acid-exposed endothelial cells 
had more monocyte adhesion, a pre-cursor to atherosclerotic plaque formation, than 
those treated with omega-3 fatty acids; these changes were attributed to an alteration in 
the function of COX-295. Omega-3 fatty acids alter inflammatory response through many 
potential mechanisms including (a) modification of the membrane through disruption of 
lipid rafts, (b) propagation of bioactive metabolites, and/or (c) alteration of nuclear 
transcription factor signaling96. Omega-3 enriched diet disrupts the microenvironment of 
caveolae lipid domains in colonocytes initiating changes in signaling by displacing 
caveolin-1 (Cav-1) and other raft specific signaling molecules97. Endothelial cells treated 
with DHA have similar disruption in lipid raft composition that displaces the Cav-1 protein 
and releases endothelial nitric oxide (eNOS), which is critical to vascular homeostasis98. 
In a model of allergic lung inflammation, omega-3 fatty acid supplementation reduced 
arachidonic acid-derived F2-isoprostane production presumably through displacement of 
arachidonic acid and competition for COX and LOX enzymes99. E-series and D-series 
resolvins are derived from EPA and DHA, respectively. Research into the functional 
roles of resolvins and other EPA- and DHA-derived metabolites demonstrate changes to 
leukocyte response including the inhibition of dendritic cell and T-cell maturation and 
activation, reduction of leukocyte chemotaxis, and changes in the cytokine response by 
immune cells100-102. Understanding the molecular signaling pathways by which omega-3 
fatty acid-derived metabolites promote these actions is an area of active research. 
Peroxisome proliferator-activated receptors (PPARs) are of particular interest. An 
increase in PPARγ activity is associated improved outcomes in many inflammatory 
disease states; unfortunately, rosiglitazone, pioglitazone and other PPARγ agonists have 
undesirable side effects103. Oxidized-DHA metabolites are possible ligands of PPARγ 
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Chapter One: Introduction  
1.1 Environmental pollution – PCB 
The unprecedented boom in chemical manufacturing had produced a legacy of chemical 
wastes and byproducts that flowed into streams and piled up in landfills. Scientists and 
the public began to awaken to the horror of a polluted world. Rachel Carson, a leader in 
the environmental movement, raised public awareness through her book Silent Spring; 
she writes,  
“The most alarming of all man’s assaults upon the environment is the 
contamination of air, earth, rivers, and sea with dangerous and even lethal 
materials. This pollution is for the most part irrecoverable; the chain of evil it 
initiates not only in the world that must support life but in living tissues is for the 
most part irreversible1.”   
In response to the public outcry and mounting scientific evidence about environmental 
and human health effects, Congress passed a series of environmental legislation, and 
the President established the Environmental Protection Agency (EPA)2.  Within this 
legislation, certain environmental pollutants were banned from manufacturing including 
polychlorinated biphenyls (PCBs). PCBs like many other contaminants from that era are 
distinguished by their stable chemical structure which includes a biphenyl and many 
configurations of chlorine substitutions that account for up to 209 possible congeners3 
(Figure 1.1). Produced in mixtures, called Aroclors, PCBs were widely marketed and 
used in applications in which their stability and low electrical conductivity were prized; 
these applications included dielectric fluid in capacitors and light ballasts and building 
materials such as paint and sealants4.  
The two major classes of PCBs are defined by the stereochemistry of the biphenyl bond 
(Figure 1.1)3, 5. The coplanar PCBs do not contain ortho-substitutions and exhibit dioxin-
like properties. The presence of coplanar PCBs in human and animal tissues are orders 
of magnitude lower than other congeners, but as a class of compounds they exhibit 
greater potential for toxicity, especially PCB 1266, 7. They are dioxin-like and bind the aryl 
hydrocarbon receptor (AhR) which activates cytochrome P450 (CYP) metabolizing 
enzymes, the expression of which are associated with increased cellular oxidative stress 
and inflammation8. Chlorine substitutions in the ortho- position cause steric hindrance for 
noncoplanar PCBs, which have different biological activity than the coplanar PCBs. 
Noncoplanar PCBs have an affinity for the constitutive androstane receptor (CAR)9, 
which activates CYP metabolizing enzymes, and are known to disrupt Ca2+ signaling in 
2 
 
the brain through the ryanodine receptors3, 10.  In addition, noncoplanar PCBs have been 
associated with certain metabolic disorders. For example, PCB 153 is a noncoplanar 
PCB that is present in high levels in human serum; it is associated with increased risk for 
nonalcoholic fatty liver disease and Type 2 diabetes11, 12. Congeners which are mono-
ortho-substituted, such as PCB 118, have reduced AhR activity and have molecular 
similarities to noncoplanar PCBs3, 5, 13. Our research has demonstrated that in 
comparison to noncoplanar PCBs, coplanar PCBs and mixed inducers promote oxidative 
stress and decrease endothelial barrier function, which is critical to inflammatory process 
that causes endothelial dysfunction and promotes the vascular inflammation that leads 
to atherosclerosis14. We have also demonstrated that certain nutrients either promote or 
inhibit coplanar PCB-induced endothelial cell dysfunction. For example, the omega-6 
fatty acid linoleic acid promotes coplanar PCB-induced inflammation, but when the ratio 
of omega-3 to omega-6 fatty acids is increased, the omega-3 fatty acids protect against 
PCB-induced oxidative stress and nuclear factor kappa B (NFкB) activation15, 16. As a 
result, the work in our laboratory has focused on the dioxin-like, coplanar PCBs. 
Pollutant toxicity is compared using toxic equivalency factors (TEFs) which designate a 
toxicity value based on a comparison to the toxicity of  2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD, dioxin). For PCBs, only coplanar PCBs (non-ortho substituted) exhibit 
dioxin-like qualities and are ligands had arylhydrocarbon receptor (AhR).  The major 
congeners in this class are PCB 77, PCB 126, and PCB 169 with TEFs in humans of 
0.0001, 0.1 and 0.01, respectively17. In addition, PCB 170 and PCB 180 have 
ethoxyresorufin-O-deethylase (EROD) activity that is sufficient for a TEF equivalency to 
be assigned. Based on the median TEF values of PCB 105, PCB 118, and PCB 156, the 
TEF for mono-ortho PCBs, containing one ortho substitution or a mixed congener, is 
0.0000318. Together, TEFs can be combined to develop toxic equivalents (TEQ) that 
may be applied when assessing limits in food sources, sediments, waterways, etc. 
However, the TEFs are based primarily on studies of oral exposure, which is often the 
source of exposure for both animals and humans18. As such, human exposure risk and 
risk attenuation continue to be primary concerns in environmental health research. 
PCB distribution in the body 
The concept of persistence and biomagnification in humans and animals is based on the 
ability of adipose tissue to act as a storage facility for persistent organic pollutants 
(POPs)19, 20. The degree of lipophilicity for a particular toxicant is determined by a log10 
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value of >6.0 for the solubility ratio of octanol to water21. POPs that exceed the 6.0 
lipophilicity threshold are soluble in dietary fat sources and are absorbed in the intestinal 
lumen with triacylglycerols into the lymphatic circulation22. After entry into the lymphatic 
system, they are incorporated into chylomicrons which transport the toxicants to other 
tissues including the primary storage depot, the adipose. PCBs display a range of 
affinities and distribute among LDL, HDL, and albumin fractions23, 24. Fortunately, the 
body has a mechanism for reducing its burden of PCBs and other POPs by utilizing 
enterohepatic circulation21. Through this cycle, POPs may be returned to circulation in 
the blood, be acquired by the liver which packages them with bile for excretion into the 
intestine. Once in the intestine, the pollutants will either be reabsorbed with the bile salts 
or be excreted in the feces. Through a similar pattern of circulation, POPs are also 
incorporated into mother’s breast milk, which serves as one of the first and most 
concentrated exposures for humans25, 26.  The circulation of these compounds is not an 
innocuous process, and PCBs or other compounds are able to interact with the tissues 
that are exposed during circulation including the vascular endothelium and the liver.  
PCBs and other dioxin-like compounds are associated with a wide range of human 
health outcomes, the mechanisms of which are still being explored. The immune, 
hepatic, neural, endocrine, vascular and reproductive systems are all affected in by PCB 
exposure27-29. 
Molecular interactions of coplanar PCBs with target receptors 
As dioxin-like compounds, coplanar PCBs are ligands for the AhR.  The transcription 
factor, AhR, is a member of the PER-ARNT-SIM (PAS) superfamily that has a helix-loop-
helix structure. This highly conserved protein requires ligand binding for activity and is a 
cellular sensor that has a critical function in development, especially of the liver and 
vascular systems, circadian rhythms, hypoxia, hormonal signaling, inflammation and 
other biological processes30. The AhR and its chaperone proteins including two HSP90 
units reside in the cytosol until ligand binding which causes the release of one HSP90 
and translocation into the nucleus where AhR dimerizes with ARNT (AhR nuclear 
translocator), releases the second HSP90, binds to a xenobiotic response element 
(XRE, also called the dioxin response element, DRE) and facilitates transcription29. The 
transcriptional changes directed by XRE binding facilitate cellular responses to 
environmental stimuli; however, when these signals are prolonged by strong ligand 
affinity, such as is the case of AhR binding with TCDD, disease processes are activated. 
AhR activity promotes expression of Phase I and Phase II metabolism and anti-oxidant 
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response enzymes, such as the Phase I enzyme cytochrome P450 1A1 (CYP1A1)31, 32. 
Ligands of the AhR require a degree of hydrophobicity, e.g. be lipophilic in nature, and 
exhibit certain electronegative and hydrogen bonding properties, and as follows, this 
includes a varied set of xenobiotic, endogenous and dietary compounds33. The 
xenobiotic ligands that meet the physical requirements of the AhR binding pocket 
represent a large number of environmental pollutants examples of which include the 
following: PCBs, dioxins, naphthalenes and PAHs (polycyclic aromatic hydrocarbons), 
such as benzo[a]pyrene. An equally extensive list of possible endogenous ligands have 
also been identified for the AhR; these include the following: indigoids (indigo and 
indirubin), 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE), 
equilenin (equine estrogen), metabolites of arachidonic acid, of heme and of tryptophan. 
From food sources, derivatives of indole-3-carbinol, found in cruciferous vegetables, and 
flavonoids, such as quercetin are potential ligands. The diversity of AhR ligands has led 
scientists to appreciate a number of functional roles for this transcription factor. Through 
endogenous ligand activation, the AhR is responsible for a number of developmental 
and cellular processes including cardiovascular, immune and neuronal systems34; for 
example, AhR deficient mice have incomplete liver vascularization33. Dietary 
polyphenols, like flavonoids, have been linked to the protective anti-oxidant response 
and initiate binding to alternative XRE binding sites. In contrast, xenobiotics, such as 
PCBs, hijack the endogenous functions of the AhR to produce an inflammatory 
response34. The AhR-induced inflammatory response is linked to the upregulation of 
detoxifying enzymes, such as CYP1A1, and cross-talk with the nuclear nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2) mediated anti-oxidant response35.    
The AhR induces CYP1A1 expression in response to coplanar PCBs and other ligands36, 
37. CYP1A1 activity includes the hydroxylation or epoxidation of the offending xenobiotic. 
When the reaction is unsuccessful and the enzyme “slips” or becomes uncoupled, a 
superoxide ion is released into the cell rather than being added to the compound38. 
Xenobiotics, such as PCBs, are not well metabolized, and their interaction with Phase I 
enzymes, like CYP1A1, leads to a greater release of reactive oxygen species (ROS), 
which significantly shift the redox balance of the cell39. Nrf2 regulated anti-oxidant 
enzymes, such as glutathione-S-transferase (GST) and NAD(P)H:quinine 
oxidoreductase (NQO1), serve to mitigate the increase in ROS, but when the oxidant 
capacity has been exceeded the cell initiates NFĸB and other redox sensitive 
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transcription factors to produce a heightened inflammatory cascade40, 41. NFĸB promotes 
the transcription of the chemokine monocyte chemoattractant protein 1 (MCP-1)42, 43, 
also called CCL2, and vascular cell adhesion molecule 1 (VCAM1)44, 45, which are key 
markers of endothelial cell dysfunction and the initiation of macrophage recruitment. The 
cytochrome P450 enzymes are part of Phase I metabolism during which the substrates 
are attacked at the site of a good leaving group which is replaced by hydroxyl, epoxide 
or carboxyl functional groups 46, 47.  This conversion is the first step in the transformation 
of the liphophilic molecule into a water soluble substrate that can be excreted through 
the kidneys. Phase II metabolizing enzymes that are upregulated through AhR activation 
include glutathione transferases, UDP-glucuronyltransferases and sulfotransferases48, 
which utilize the nucleophilic functional group to add a water soluble moiety such as a 
glucuronic acid, amino acid (glutathione, GSH) or sulfuric acid47. CYP metabolism of 
PCBs results in epoxide and hydroxylated products that are processed by the Phase II 
enzymes to generate all these metabolites3.  
1.2 PCBs and predisposition to inflammatory response  
Endothelial dysfunction 
As sensitive modulators of vascular homeostasis, endothelial cells both respond to the 
changing climate within the blood and regulate the vascular environment49. For the 
average American, this “climate” includes the following: dietary factors such as high 
levels of fatty acids, sodium, and glucose; lifestyle factors such as minimal physical 
activity; and exposure environmental pollutants from food, air, and built environments50, 
51. The endothelium responds to each of these factors by modulating the physiological 
environment including vasorelaxation through endothelial nitric oxide synthase (eNOS) 
signaling or inflammation through cytokine and adhesion molecule expression52, 53. The 
endothelial inflammatory response culminates in a change in function termed endothelial 
dysfunction in which cytokines like the chemokine monocyte chemoattractant protein-1 
(MCP-1) are secreted to recruit macrophages that are captured via adhesion molecules 
like VCAM1, and decreases in cell:cell junction integrity allow the macrophages to 
penetrate the endothelial cell barrier42, 54, 55.  Once in the intimal space, macrophages 
promote the inflammatory state by producing cytokines and through phagocytosis of ox-
LDL, which together promote formation of foam cells that accumulate to form plaques.  
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Inflammation and disease risk 
Inflammation is a characteristic held in common by a variety of diseases including lupus, 
rheumatoid arthritis, Crohn disease, ulcerative colitis, dermatomyositis and 
polymyositis56. The majority of these disorders can increase a patient’s risk for 
myocardial infarction or coronary artery disease related events when compared to 
control or the general population; for this analysis, only disorders associated with 
inflammatory bowel disease did not increase vascular disease risk56. The heightened 
inflammatory state increased lipoprotein oxidation and unresolved inflammation 
promoting the observed effect on cardiovascular outcomes. The pro-inflammatory 
cytokines, tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6) are risk factors for 
cardiovascular diseases and are increased in rheumatoid arthritis (RA) patients; further, 
coronary calcification is greater in RA patients with longer disease histories, which is 
associated with increased cardiovascular disease prevalence in this patient population57.  
Interestingly, many chronic inflammatory disease states are characterized by a 
dysregulated immune response in the epithelial and mesenchymal cell structures of the 
affected organ; in the case of atherosclerosis, the endothelium is activated by bacterial 
components, lipoproteins or other stimuli which induce vascular cell adhesion molecule 1 
(VCAM1) expression and the recruitment of immune cells that perpetuate the interstitial 
inflammatory response58. Coplanar PCBs and other environmental pollutants are 
potential activators of vascular inflammation.   
PCBs as a risk factor in diseases of inflammation 
Low grade inflammation is associated with many of chronic disorders including 
cardiovascular diseases, diabetes, metabolic syndrome and obesity. Tissue 
inflammation in the vascular system, adipose, and liver are all indicators and risk factors 
for the development of disease. PCBs have been associated with the development of 
multiple inflammation-associated medical conditions. For example, diabetes and 
metabolic syndrome are increased relative to PCB levels in both the general population 
and in communities with increased PCB exposure59-61. In particular, a survey of the 
Japanese population indicated that PCB 126 was a key toxicant associated with the 
increased prevalence of metabolic syndrome61. In a study of the 2003-2004 NHANES 
data, elevated serum alanine aminotransferase (ALT), a biomarker associated with non-
alcoholic fatty liver disease (NAFLD) and other liver diseases, was increased in 
association with heavy metal and PCB exposure62, and NAFLD was increased in mice 
exposed to PCBs11. Toxicant induced liver diseases, which include toxicant-associated 
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fatty liver disease and toxicant-associated steatohepatitis, are associated with exposure 
to industrial chemicals including vinyl chloride and PCBs63. Further, cardiovascular 
disease risk was increased in an elderly population independent of lipid levels and other 
cardiovascular disease risk factors64, and in rats, PCB 126 was associated with 
heightened cardiovascular disease risk resulting from changes in cholesterol, blood 
pressure and heart weight65. Industrial workers with high levels of PCB exposure have 
significantly increased levels of cardiovascular disease-related death66. These data 
support of the role of PCBs in the propagation of inflammatory diseases. 
PCBs, as lipophilic compounds, accumulate in the adipose and are recirculated through 
the body by enterohepatic circulation, a process which exposes both the vascular 
system and the liver to these toxicants. Given this environment, PCBs induce a stress 
response that promotes chronic, low grade inflammation and thus predispose the 
vasculature, specifically the endothelium, to heightened response to lifestyle and 
pathogenic stressors, like bacterial lipopolysaccharide (LPS)67. A recent study of the 
Framingham heart study cohort has concluded that the traditional risk factors are 
insufficient to explain the level of inflammation observed in the study68; this would 
suggest that genetic factors and environmental factors like PCBs could be the 
“unobserved” risk factors. Vascular biomarkers like soluble VCAM1 provide a critical 
observational link between metabolic syndrome and insulin resistance and the 
development of CVD and diabetes69. Studies have suggested that certain PCBs 
contribute to the development of metabolic syndromes like Type II Diabetes and 
atherosclerosis64, 70-72. Coplanar PCBs initiate an inflammatory signaling cascade that 
increases oxidative stress and promotes endothelial dysfunction in vascular endothelial 
cells73. To better understand the inflammatory potential of PCBs, chapter two assesses 
endothelial cell response to PCB 77 and PCB 77 remediation products which are the 
byproducts of PCB 77 dechlorination. To establish a dosing model and further our 
understanding of environmentally persistent coplanar PCBs, chapter three determines 
which of five increasing concentration of PCB 126 are effective in producing a moderate 
inflammatory response without causing toxic wasting syndrome. Using the dosing model 
developed in chapter three, we were able to test nutritional interventions of PCB 126-
induced inflammation in chapter four.  
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1.3 Nutrition and inflammation  
Fatty acids and inflammation 
A fatty acid is a long carbon chain with four to twenty-four carbons that is capped by a 
methyl group containing the omega carbon and a carboxyl group74. There are multiple 
structural classes of fatty acids that are defined by the number and location of double 
bonds within the carbon chain and include saturated, monounsaturated, 
polyunsaturated, and trans fatty acids. Diets high in saturated fat have been associated 
with cardiovascular disease and are known to promote inflammation75, 76. Saturated fatty 
acids, which are not essential for a complete human diet, are long carbon chains that are 
fully substituted with hydrogen atoms and do not contain double bonds; examples 
include palmitate, laurate, myristate and stearate, which are found in red meat and 
dairy74.  The amount of saturated fat consumed determines the inflammatory effects. In a 
study in mice, mice consuming 12% saturated fat, which is equivalent to the average 
American diet, had greater adipose inflammation and macrophage activity than mice fed 
diets with 6% and 24% saturated fat77. One of the mechanism by which saturated fatty 
acids cause inflammation is through the toll-like receptors (TLRs)76, including TLR4 
which has increased expression in atherosclerotic lesions78. Saturated fatty acids 
modulate gene expression and increase TLR expression which increases sensitivity to 
inflammatory stimuli, such as lipopolysaccharide (LPS)79. In the Nurses’ Health Study, 
women who consumed 5% more saturated fat compared to those who consumed 5% 
more carbohydrate were 17% more likely to have a cardiac event80. Replacing dietary 
saturated fatty acids with polyunsaturated fatty acids reduces the number of coronary 
events81. Unlike saturated fatty acids, polyunsaturated fats (PUFA), e.g. omega-3 and 
omega-6 fatty acids, have two or more double bonds with the first double bond at the 
third or sixth carbon, respectively. PUFA are essential to the human diet74, yet 
differences exist between the omega-3 and omega-6 inflammatory potential.  
Omega-3 and omega-6 fatty acids and inflammation 
The ratio of omega-3/omega-6 fatty acids influences metabolism of fatty acid substrates 
and the generation of inflammatory mediators. For example, the elongation of the parent 
omega-3 fatty acid α-linolenic acid to the longer chain docosahexaenoic acid (DHA) 
molecules can be inhibited by competition with high levels of the omega-6 linoleic acid 
for the same desaturase enzymes82. Linoleic acid is elongated to form arachidonic acid, 
which is the primary substrate for prostaglandin, leukotriene and thromboxane formation; 
higher substrate availability increases the baseline levels of these inflammatory 
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eicosanoids82. Long-chain omega-3 fatty acids, eicosapentanoic acid (EPA) and DHA 
are also metabolized by cyclooxygenases (COX) and lipoxygenases.(LOX) to form 
eicosanoid and docosanoid metabolites, which are either less inflammatory than their 
omega-6 derived counterparts or have anti-inflammatory properties83, 84 (Figure 1.285-88). 
Arachidonic acid is a major component of the plasma membrane and is the precursor of 
prostaglandin E2 (PGE2) and leukotriene B4 (LTB4); diets containing omega-3 fatty acid 
rich-flaxseed oil or fish oil competitively reduced the production of arachidonic acid-
derived eicosanoids and other inflammatory cytokines89.  F2-isoprostanes (F2-IsoPs), 
which are similar in structure to the COX-derived prostaglandins, are formed by non-
enzymatic peroxidation of arachidonate and are an indication of oxidative stress90. 
Elevated levels of F2-IsoPs are associated with chronic disease states including 
atherosclerosis, hypercholesterolemia, diabetes, obesity, Alzheimer’s, pulmonary 
disorders, and allergen-aggravated asthma90.   All of these disorders are associated with 
elevated levels of inflammation and oxidative stress.  
Different fatty acids modulate PCB-induced inflammation.  In a feeding study using LDL-
R-/- (low-density lipoprotein receptor deficient) mice, we observed VCAM1 tissue 
expression in the endothelium of mice fed omega-6-rich corn oil, and PCB treatment 
promoted more extensive VCAM1 expression extending to the smooth muscle portions 
of the vessel wall91. In contrast, dietary feeding of monounsaturated-rich olive oil did not 
promote vascular inflammation, and though PCBs induced inflammation in olive oil fed 
mice, the high oleic acid diet supported compensatory metabolic changes in the livers of 
PCB-treated mice. In vitro work using primary vascular endothelial cells enabled us to 
modulate PCB-induced inflammation by changing the omega-3/omega-6 fatty acid ratio. 
Increasing levels of α-linolenic acid (omega-3) to linoleic acid (omega-6) reduced 
VCAM1 and COX-2 mRNA and protein expression and attenuated PGE2 production. 
With the same model, we demonstrated that oxidized DHA-derived A4/J4-neuroprostanes 
reduced coplanar PCB-induced oxidative stress, NFкB activation, and MCP-1 protein 
and mRNA expression92. When compared, DHA-derived neuroprostanes were more 
effective at attenuating PCB-induced inflammation than those derived from EPA. From 
these data, we concluded that future in vivo nutritional intervention studies, as presented 
in chapter four, would use a DHA-enriched diet.  
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Omega-3 fatty acids and implications in inflammation resolution 
Fish oil presents the richest source of DHA and EPA, and the precursor fatty acid, α-
linolenic acid, is available from multiple plant sources including walnuts, flax seed, and 
canola oil74. A human trial comparing the effect of DHA-EPA, α-linolenic acid (ALA), 
DHA-EPA/ALA combination or placebo treatment on major cardiovascular events found 
that ALA was most beneficial to women and that the DHA-EPA treatment was most 
beneficial to patients with a diabetic comorbidity93. A meta-analysis of eleven studies that 
provided DHA/EPA supplementation for one year or longer determined that 
supplementation significantly reduced the risk of sudden cardiac death and all-cause 
mortality for high risk patients and reduced the risk of nonfatal cardiovascular events in 
patients with moderate risk94. In culture, omega-6 fatty acid-exposed endothelial cells 
had more monocyte adhesion, a pre-cursor to atherosclerotic plaque formation, than 
those treated with omega-3 fatty acids; these changes were attributed to an alteration in 
the function of COX-295. Omega-3 fatty acids alter inflammatory response through many 
potential mechanisms including (a) modification of the membrane through disruption of 
lipid rafts, (b) propagation of bioactive metabolites, and/or (c) alteration of nuclear 
transcription factor signaling96. Omega-3 enriched diet disrupts the microenvironment of 
caveolae lipid domains in colonocytes initiating changes in signaling by displacing 
caveolin-1 (Cav-1) and other raft specific signaling molecules97. Endothelial cells treated 
with DHA have similar disruption in lipid raft composition that displaces the Cav-1 protein 
and releases endothelial nitric oxide (eNOS), which is critical to vascular homeostasis98. 
In a model of allergic lung inflammation, omega-3 fatty acid supplementation reduced 
arachidonic acid-derived F2-isoprostane production presumably through displacement of 
arachidonic acid and competition for COX and LOX enzymes99. E-series and D-series 
resolvins are derived from EPA and DHA, respectively. Research into the functional 
roles of resolvins and other EPA- and DHA-derived metabolites demonstrate changes to 
leukocyte response including the inhibition of dendritic cell and T-cell maturation and 
activation, reduction of leukocyte chemotaxis, and changes in the cytokine response by 
immune cells100-102. Understanding the molecular signaling pathways by which omega-3 
fatty acid-derived metabolites promote these actions is an area of active research. 
Peroxisome proliferator-activated receptors (PPARs) are of particular interest. An 
increase in PPARγ activity is associated improved outcomes in many inflammatory 
disease states; unfortunately, rosiglitazone, pioglitazone and other PPARγ agonists have 
undesirable side effects103. Oxidized-DHA metabolites are possible ligands of PPARγ 
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Chapter One: Introduction  
1.1 Environmental pollution – PCB 
The unprecedented boom in chemical manufacturing had produced a legacy of chemical 
wastes and byproducts that flowed into streams and piled up in landfills. Scientists and 
the public began to awaken to the horror of a polluted world. Rachel Carson, a leader in 
the environmental movement, raised public awareness through her book Silent Spring; 
she writes,  
“The most alarming of all man’s assaults upon the environment is the 
contamination of air, earth, rivers, and sea with dangerous and even lethal 
materials. This pollution is for the most part irrecoverable; the chain of evil it 
initiates not only in the world that must support life but in living tissues is for the 
most part irreversible1.”   
In response to the public outcry and mounting scientific evidence about environmental 
and human health effects, Congress passed a series of environmental legislation, and 
the President established the Environmental Protection Agency (EPA)2.  Within this 
legislation, certain environmental pollutants were banned from manufacturing including 
polychlorinated biphenyls (PCBs). PCBs like many other contaminants from that era are 
distinguished by their stable chemical structure which includes a biphenyl and many 
configurations of chlorine substitutions that account for up to 209 possible congeners3 
(Figure 1.1). Produced in mixtures, called Aroclors, PCBs were widely marketed and 
used in applications in which their stability and low electrical conductivity were prized; 
these applications included dielectric fluid in capacitors and light ballasts and building 
materials such as paint and sealants4.  
The two major classes of PCBs are defined by the stereochemistry of the biphenyl bond 
(Figure 1.1)3, 5. The coplanar PCBs do not contain ortho-substitutions and exhibit dioxin-
like properties. The presence of coplanar PCBs in human and animal tissues are orders 
of magnitude lower than other congeners, but as a class of compounds they exhibit 
greater potential for toxicity, especially PCB 1266, 7. They are dioxin-like and bind the aryl 
hydrocarbon receptor (AhR) which activates cytochrome P450 (CYP) metabolizing 
enzymes, the expression of which are associated with increased cellular oxidative stress 
and inflammation8. Chlorine substitutions in the ortho- position cause steric hindrance for 
noncoplanar PCBs, which have different biological activity than the coplanar PCBs. 
Noncoplanar PCBs have an affinity for the constitutive androstane receptor (CAR)9, 
which activates CYP metabolizing enzymes, and are known to disrupt Ca2+ signaling in 
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the brain through the ryanodine receptors3, 10.  In addition, noncoplanar PCBs have been 
associated with certain metabolic disorders. For example, PCB 153 is a noncoplanar 
PCB that is present in high levels in human serum; it is associated with increased risk for 
nonalcoholic fatty liver disease and Type 2 diabetes11, 12. Congeners which are mono-
ortho-substituted, such as PCB 118, have reduced AhR activity and have molecular 
similarities to noncoplanar PCBs3, 5, 13. Our research has demonstrated that in 
comparison to noncoplanar PCBs, coplanar PCBs and mixed inducers promote oxidative 
stress and decrease endothelial barrier function, which is critical to inflammatory process 
that causes endothelial dysfunction and promotes the vascular inflammation that leads 
to atherosclerosis14. We have also demonstrated that certain nutrients either promote or 
inhibit coplanar PCB-induced endothelial cell dysfunction. For example, the omega-6 
fatty acid linoleic acid promotes coplanar PCB-induced inflammation, but when the ratio 
of omega-3 to omega-6 fatty acids is increased, the omega-3 fatty acids protect against 
PCB-induced oxidative stress and nuclear factor kappa B (NFкB) activation15, 16. As a 
result, the work in our laboratory has focused on the dioxin-like, coplanar PCBs. 
Pollutant toxicity is compared using toxic equivalency factors (TEFs) which designate a 
toxicity value based on a comparison to the toxicity of  2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD, dioxin). For PCBs, only coplanar PCBs (non-ortho substituted) exhibit 
dioxin-like qualities and are ligands had arylhydrocarbon receptor (AhR).  The major 
congeners in this class are PCB 77, PCB 126, and PCB 169 with TEFs in humans of 
0.0001, 0.1 and 0.01, respectively17. In addition, PCB 170 and PCB 180 have 
ethoxyresorufin-O-deethylase (EROD) activity that is sufficient for a TEF equivalency to 
be assigned. Based on the median TEF values of PCB 105, PCB 118, and PCB 156, the 
TEF for mono-ortho PCBs, containing one ortho substitution or a mixed congener, is 
0.0000318. Together, TEFs can be combined to develop toxic equivalents (TEQ) that 
may be applied when assessing limits in food sources, sediments, waterways, etc. 
However, the TEFs are based primarily on studies of oral exposure, which is often the 
source of exposure for both animals and humans18. As such, human exposure risk and 
risk attenuation continue to be primary concerns in environmental health research. 
PCB distribution in the body 
The concept of persistence and biomagnification in humans and animals is based on the 
ability of adipose tissue to act as a storage facility for persistent organic pollutants 
(POPs)19, 20. The degree of lipophilicity for a particular toxicant is determined by a log10 
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value of >6.0 for the solubility ratio of octanol to water21. POPs that exceed the 6.0 
lipophilicity threshold are soluble in dietary fat sources and are absorbed in the intestinal 
lumen with triacylglycerols into the lymphatic circulation22. After entry into the lymphatic 
system, they are incorporated into chylomicrons which transport the toxicants to other 
tissues including the primary storage depot, the adipose. PCBs display a range of 
affinities and distribute among LDL, HDL, and albumin fractions23, 24. Fortunately, the 
body has a mechanism for reducing its burden of PCBs and other POPs by utilizing 
enterohepatic circulation21. Through this cycle, POPs may be returned to circulation in 
the blood, be acquired by the liver which packages them with bile for excretion into the 
intestine. Once in the intestine, the pollutants will either be reabsorbed with the bile salts 
or be excreted in the feces. Through a similar pattern of circulation, POPs are also 
incorporated into mother’s breast milk, which serves as one of the first and most 
concentrated exposures for humans25, 26.  The circulation of these compounds is not an 
innocuous process, and PCBs or other compounds are able to interact with the tissues 
that are exposed during circulation including the vascular endothelium and the liver.  
PCBs and other dioxin-like compounds are associated with a wide range of human 
health outcomes, the mechanisms of which are still being explored. The immune, 
hepatic, neural, endocrine, vascular and reproductive systems are all affected in by PCB 
exposure27-29. 
Molecular interactions of coplanar PCBs with target receptors 
As dioxin-like compounds, coplanar PCBs are ligands for the AhR.  The transcription 
factor, AhR, is a member of the PER-ARNT-SIM (PAS) superfamily that has a helix-loop-
helix structure. This highly conserved protein requires ligand binding for activity and is a 
cellular sensor that has a critical function in development, especially of the liver and 
vascular systems, circadian rhythms, hypoxia, hormonal signaling, inflammation and 
other biological processes30. The AhR and its chaperone proteins including two HSP90 
units reside in the cytosol until ligand binding which causes the release of one HSP90 
and translocation into the nucleus where AhR dimerizes with ARNT (AhR nuclear 
translocator), releases the second HSP90, binds to a xenobiotic response element 
(XRE, also called the dioxin response element, DRE) and facilitates transcription29. The 
transcriptional changes directed by XRE binding facilitate cellular responses to 
environmental stimuli; however, when these signals are prolonged by strong ligand 
affinity, such as is the case of AhR binding with TCDD, disease processes are activated. 
AhR activity promotes expression of Phase I and Phase II metabolism and anti-oxidant 
4 
 
response enzymes, such as the Phase I enzyme cytochrome P450 1A1 (CYP1A1)31, 32. 
Ligands of the AhR require a degree of hydrophobicity, e.g. be lipophilic in nature, and 
exhibit certain electronegative and hydrogen bonding properties, and as follows, this 
includes a varied set of xenobiotic, endogenous and dietary compounds33. The 
xenobiotic ligands that meet the physical requirements of the AhR binding pocket 
represent a large number of environmental pollutants examples of which include the 
following: PCBs, dioxins, naphthalenes and PAHs (polycyclic aromatic hydrocarbons), 
such as benzo[a]pyrene. An equally extensive list of possible endogenous ligands have 
also been identified for the AhR; these include the following: indigoids (indigo and 
indirubin), 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE), 
equilenin (equine estrogen), metabolites of arachidonic acid, of heme and of tryptophan. 
From food sources, derivatives of indole-3-carbinol, found in cruciferous vegetables, and 
flavonoids, such as quercetin are potential ligands. The diversity of AhR ligands has led 
scientists to appreciate a number of functional roles for this transcription factor. Through 
endogenous ligand activation, the AhR is responsible for a number of developmental 
and cellular processes including cardiovascular, immune and neuronal systems34; for 
example, AhR deficient mice have incomplete liver vascularization33. Dietary 
polyphenols, like flavonoids, have been linked to the protective anti-oxidant response 
and initiate binding to alternative XRE binding sites. In contrast, xenobiotics, such as 
PCBs, hijack the endogenous functions of the AhR to produce an inflammatory 
response34. The AhR-induced inflammatory response is linked to the upregulation of 
detoxifying enzymes, such as CYP1A1, and cross-talk with the nuclear nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2) mediated anti-oxidant response35.    
The AhR induces CYP1A1 expression in response to coplanar PCBs and other ligands36, 
37. CYP1A1 activity includes the hydroxylation or epoxidation of the offending xenobiotic. 
When the reaction is unsuccessful and the enzyme “slips” or becomes uncoupled, a 
superoxide ion is released into the cell rather than being added to the compound38. 
Xenobiotics, such as PCBs, are not well metabolized, and their interaction with Phase I 
enzymes, like CYP1A1, leads to a greater release of reactive oxygen species (ROS), 
which significantly shift the redox balance of the cell39. Nrf2 regulated anti-oxidant 
enzymes, such as glutathione-S-transferase (GST) and NAD(P)H:quinine 
oxidoreductase (NQO1), serve to mitigate the increase in ROS, but when the oxidant 
capacity has been exceeded the cell initiates NFĸB and other redox sensitive 
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transcription factors to produce a heightened inflammatory cascade40, 41. NFĸB promotes 
the transcription of the chemokine monocyte chemoattractant protein 1 (MCP-1)42, 43, 
also called CCL2, and vascular cell adhesion molecule 1 (VCAM1)44, 45, which are key 
markers of endothelial cell dysfunction and the initiation of macrophage recruitment. The 
cytochrome P450 enzymes are part of Phase I metabolism during which the substrates 
are attacked at the site of a good leaving group which is replaced by hydroxyl, epoxide 
or carboxyl functional groups 46, 47.  This conversion is the first step in the transformation 
of the liphophilic molecule into a water soluble substrate that can be excreted through 
the kidneys. Phase II metabolizing enzymes that are upregulated through AhR activation 
include glutathione transferases, UDP-glucuronyltransferases and sulfotransferases48, 
which utilize the nucleophilic functional group to add a water soluble moiety such as a 
glucuronic acid, amino acid (glutathione, GSH) or sulfuric acid47. CYP metabolism of 
PCBs results in epoxide and hydroxylated products that are processed by the Phase II 
enzymes to generate all these metabolites3.  
1.2 PCBs and predisposition to inflammatory response 
Endothelial dysfunction 
As sensitive modulators of vascular homeostasis, endothelial cells both respond to the 
changing climate within the blood and regulate the vascular environment49. For the 
average American, this “climate” includes the following: dietary factors such as high 
levels of fatty acids, sodium, and glucose; lifestyle factors such as minimal physical 
activity; and exposure environmental pollutants from food, air, and built environments50, 
51. The endothelium responds to each of these factors by modulating the physiological
environment including vasorelaxation through endothelial nitric oxide synthase (eNOS) 
signaling or inflammation through cytokine and adhesion molecule expression52, 53. The 
endothelial inflammatory response culminates in a change in function termed endothelial 
dysfunction in which cytokines like the chemokine monocyte chemoattractant protein-1 
(MCP-1) are secreted to recruit macrophages that are captured via adhesion molecules 
like VCAM1, and decreases in cell:cell junction integrity allow the macrophages to 
penetrate the endothelial cell barrier42, 54, 55.  Once in the intimal space, macrophages 
promote the inflammatory state by producing cytokines and through phagocytosis of ox-
LDL, which together promote formation of foam cells that accumulate to form plaques.  
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Inflammation and disease risk 
Inflammation is a characteristic held in common by a variety of diseases including lupus, 
rheumatoid arthritis, Crohn disease, ulcerative colitis, dermatomyositis and 
polymyositis56. The majority of these disorders can increase a patient’s risk for 
myocardial infarction or coronary artery disease related events when compared to 
control or the general population; for this analysis, only disorders associated with 
inflammatory bowel disease did not increase vascular disease risk56. The heightened 
inflammatory state increased lipoprotein oxidation and unresolved inflammation 
promoting the observed effect on cardiovascular outcomes. The pro-inflammatory 
cytokines, tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6) are risk factors for 
cardiovascular diseases and are increased in rheumatoid arthritis (RA) patients; further, 
coronary calcification is greater in RA patients with longer disease histories, which is 
associated with increased cardiovascular disease prevalence in this patient population57.  
Interestingly, many chronic inflammatory disease states are characterized by a 
dysregulated immune response in the epithelial and mesenchymal cell structures of the 
affected organ; in the case of atherosclerosis, the endothelium is activated by bacterial 
components, lipoproteins or other stimuli which induce vascular cell adhesion molecule 1 
(VCAM1) expression and the recruitment of immune cells that perpetuate the interstitial 
inflammatory response58. Coplanar PCBs and other environmental pollutants are 
potential activators of vascular inflammation.   
PCBs as a risk factor in diseases of inflammation 
Low grade inflammation is associated with many of chronic disorders including 
cardiovascular diseases, diabetes, metabolic syndrome and obesity. Tissue 
inflammation in the vascular system, adipose, and liver are all indicators and risk factors 
for the development of disease. PCBs have been associated with the development of 
multiple inflammation-associated medical conditions. For example, diabetes and 
metabolic syndrome are increased relative to PCB levels in both the general population 
and in communities with increased PCB exposure59-61. In particular, a survey of the 
Japanese population indicated that PCB 126 was a key toxicant associated with the 
increased prevalence of metabolic syndrome61. In a study of the 2003-2004 NHANES 
data, elevated serum alanine aminotransferase (ALT), a biomarker associated with non-
alcoholic fatty liver disease (NAFLD) and other liver diseases, was increased in 
association with heavy metal and PCB exposure62, and NAFLD was increased in mice 
exposed to PCBs11. Toxicant induced liver diseases, which include toxicant-associated 
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fatty liver disease and toxicant-associated steatohepatitis, are associated with exposure 
to industrial chemicals including vinyl chloride and PCBs63. Further, cardiovascular 
disease risk was increased in an elderly population independent of lipid levels and other 
cardiovascular disease risk factors64, and in rats, PCB 126 was associated with 
heightened cardiovascular disease risk resulting from changes in cholesterol, blood 
pressure and heart weight65. Industrial workers with high levels of PCB exposure have 
significantly increased levels of cardiovascular disease-related death66. These data 
support of the role of PCBs in the propagation of inflammatory diseases. 
PCBs, as lipophilic compounds, accumulate in the adipose and are recirculated through 
the body by enterohepatic circulation, a process which exposes both the vascular 
system and the liver to these toxicants. Given this environment, PCBs induce a stress 
response that promotes chronic, low grade inflammation and thus predispose the 
vasculature, specifically the endothelium, to heightened response to lifestyle and 
pathogenic stressors, like bacterial lipopolysaccharide (LPS)67. A recent study of the 
Framingham heart study cohort has concluded that the traditional risk factors are 
insufficient to explain the level of inflammation observed in the study68; this would 
suggest that genetic factors and environmental factors like PCBs could be the 
“unobserved” risk factors. Vascular biomarkers like soluble VCAM1 provide a critical 
observational link between metabolic syndrome and insulin resistance and the 
development of CVD and diabetes69. Studies have suggested that certain PCBs 
contribute to the development of metabolic syndromes like Type II Diabetes and 
atherosclerosis64, 70-72. Coplanar PCBs initiate an inflammatory signaling cascade that 
increases oxidative stress and promotes endothelial dysfunction in vascular endothelial 
cells73. To better understand the inflammatory potential of PCBs, chapter two assesses 
endothelial cell response to PCB 77 and PCB 77 remediation products which are the 
byproducts of PCB 77 dechlorination. To establish a dosing model and further our 
understanding of environmentally persistent coplanar PCBs, chapter three determines 
which of five increasing concentration of PCB 126 are effective in producing a moderate 
inflammatory response without causing toxic wasting syndrome. Using the dosing model 
developed in chapter three, we were able to test nutritional interventions of PCB 126-
induced inflammation in chapter four.  
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1.3 Nutrition and inflammation  
Fatty acids and inflammation 
A fatty acid is a long carbon chain with four to twenty-four carbons that is capped by a 
methyl group containing the omega carbon and a carboxyl group74. There are multiple 
structural classes of fatty acids that are defined by the number and location of double 
bonds within the carbon chain and include saturated, monounsaturated, 
polyunsaturated, and trans fatty acids. Diets high in saturated fat have been associated 
with cardiovascular disease and are known to promote inflammation75, 76. Saturated fatty 
acids, which are not essential for a complete human diet, are long carbon chains that are 
fully substituted with hydrogen atoms and do not contain double bonds; examples 
include palmitate, laurate, myristate and stearate, which are found in red meat and 
dairy74.  The amount of saturated fat consumed determines the inflammatory effects. In a 
study in mice, mice consuming 12% saturated fat, which is equivalent to the average 
American diet, had greater adipose inflammation and macrophage activity than mice fed 
diets with 6% and 24% saturated fat77. One of the mechanism by which saturated fatty 
acids cause inflammation is through the toll-like receptors (TLRs)76, including TLR4 
which has increased expression in atherosclerotic lesions78. Saturated fatty acids 
modulate gene expression and increase TLR expression which increases sensitivity to 
inflammatory stimuli, such as lipopolysaccharide (LPS)79. In the Nurses’ Health Study, 
women who consumed 5% more saturated fat compared to those who consumed 5% 
more carbohydrate were 17% more likely to have a cardiac event80. Replacing dietary 
saturated fatty acids with polyunsaturated fatty acids reduces the number of coronary 
events81. Unlike saturated fatty acids, polyunsaturated fats (PUFA), e.g. omega-3 and 
omega-6 fatty acids, have two or more double bonds with the first double bond at the 
third or sixth carbon, respectively. PUFA are essential to the human diet74, yet 
differences exist between the omega-3 and omega-6 inflammatory potential.  
Omega-3 and omega-6 fatty acids and inflammation 
The ratio of omega-3/omega-6 fatty acids influences metabolism of fatty acid substrates 
and the generation of inflammatory mediators. For example, the elongation of the parent 
omega-3 fatty acid α-linolenic acid to the longer chain docosahexaenoic acid (DHA) 
molecules can be inhibited by competition with high levels of the omega-6 linoleic acid 
for the same desaturase enzymes82. Linoleic acid is elongated to form arachidonic acid, 
which is the primary substrate for prostaglandin, leukotriene and thromboxane formation; 
higher substrate availability increases the baseline levels of these inflammatory 
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eicosanoids82. Long-chain omega-3 fatty acids, eicosapentanoic acid (EPA) and DHA 
are also metabolized by cyclooxygenases (COX) and lipoxygenases.(LOX) to form 
eicosanoid and docosanoid metabolites, which are either less inflammatory than their 
omega-6 derived counterparts or have anti-inflammatory properties83, 84 (Figure 1.285-88). 
Arachidonic acid is a major component of the plasma membrane and is the precursor of 
prostaglandin E2 (PGE2) and leukotriene B4 (LTB4); diets containing omega-3 fatty acid 
rich-flaxseed oil or fish oil competitively reduced the production of arachidonic acid-
derived eicosanoids and other inflammatory cytokines89.  F2-isoprostanes (F2-IsoPs), 
which are similar in structure to the COX-derived prostaglandins, are formed by non-
enzymatic peroxidation of arachidonate and are an indication of oxidative stress90. 
Elevated levels of F2-IsoPs are associated with chronic disease states including 
atherosclerosis, hypercholesterolemia, diabetes, obesity, Alzheimer’s, pulmonary 
disorders, and allergen-aggravated asthma90.   All of these disorders are associated with 
elevated levels of inflammation and oxidative stress.  
Different fatty acids modulate PCB-induced inflammation.  In a feeding study using LDL-
R-/- (low-density lipoprotein receptor deficient) mice, we observed VCAM1 tissue 
expression in the endothelium of mice fed omega-6-rich corn oil, and PCB treatment 
promoted more extensive VCAM1 expression extending to the smooth muscle portions 
of the vessel wall91. In contrast, dietary feeding of monounsaturated-rich olive oil did not 
promote vascular inflammation, and though PCBs induced inflammation in olive oil fed 
mice, the high oleic acid diet supported compensatory metabolic changes in the livers of 
PCB-treated mice. In vitro work using primary vascular endothelial cells enabled us to 
modulate PCB-induced inflammation by changing the omega-3/omega-6 fatty acid ratio. 
Increasing levels of α-linolenic acid (omega-3) to linoleic acid (omega-6) reduced 
VCAM1 and COX-2 mRNA and protein expression and attenuated PGE2 production. 
With the same model, we demonstrated that oxidized DHA-derived A4/J4-neuroprostanes 
reduced coplanar PCB-induced oxidative stress, NFкB activation, and MCP-1 protein 
and mRNA expression92. When compared, DHA-derived neuroprostanes were more 
effective at attenuating PCB-induced inflammation than those derived from EPA. From 
these data, we concluded that future in vivo nutritional intervention studies, as presented 
in chapter four, would use a DHA-enriched diet.    
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Omega-3 fatty acids and implications in inflammation resolution 
Fish oil presents the richest source of DHA and EPA, and the precursor fatty acid, α-
linolenic acid, is available from multiple plant sources including walnuts, flax seed, and 
canola oil74. A human trial comparing the effect of DHA-EPA, α-linolenic acid (ALA), 
DHA-EPA/ALA combination or placebo treatment on major cardiovascular events found 
that ALA was most beneficial to women and that the DHA-EPA treatment was most 
beneficial to patients with a diabetic comorbidity93. A meta-analysis of eleven studies that 
provided DHA/EPA supplementation for one year or longer determined that 
supplementation significantly reduced the risk of sudden cardiac death and all-cause 
mortality for high risk patients and reduced the risk of nonfatal cardiovascular events in 
patients with moderate risk94. In culture, omega-6 fatty acid-exposed endothelial cells 
had more monocyte adhesion, a pre-cursor to atherosclerotic plaque formation, than 
those treated with omega-3 fatty acids; these changes were attributed to an alteration in 
the function of COX-295. Omega-3 fatty acids alter inflammatory response through many 
potential mechanisms including (a) modification of the membrane through disruption of 
lipid rafts, (b) propagation of bioactive metabolites, and/or (c) alteration of nuclear 
transcription factor signaling96. Omega-3 enriched diet disrupts the microenvironment of 
caveolae lipid domains in colonocytes initiating changes in signaling by displacing 
caveolin-1 (Cav-1) and other raft specific signaling molecules97. Endothelial cells treated 
with DHA have similar disruption in lipid raft composition that displaces the Cav-1 protein 
and releases endothelial nitric oxide (eNOS), which is critical to vascular homeostasis98. 
In a model of allergic lung inflammation, omega-3 fatty acid supplementation reduced 
arachidonic acid-derived F2-isoprostane production presumably through displacement of 
arachidonic acid and competition for COX and LOX enzymes99. E-series and D-series 
resolvins are derived from EPA and DHA, respectively. Research into the functional 
roles of resolvins and other EPA- and DHA-derived metabolites demonstrate changes to 
leukocyte response including the inhibition of dendritic cell and T-cell maturation and 
activation, reduction of leukocyte chemotaxis, and changes in the cytokine response by 
immune cells100-102. Understanding the molecular signaling pathways by which omega-3 
fatty acid-derived metabolites promote these actions is an area of active research. 
Peroxisome proliferator-activated receptors (PPARs) are of particular interest. An 
increase in PPARγ activity is associated improved outcomes in many inflammatory 
disease states; unfortunately, rosiglitazone, pioglitazone and other PPARγ agonists have 
undesirable side effects103. Oxidized-DHA metabolites are possible ligands of PPARγ 
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with natural metabolism pathways that would limit potential side effects103. Others have 
demonstrated an Nrf2-dependent anti-oxidant effect in adipocytes following EPA and 
DHA treatment104. Our work suggests that caveolae are critical to PCB-induced 
inflammation making lipid rafts a target for omega-3 fatty acid nutritional intervention105, 
and our study of oxidized DHA neuroprostane metabolites indicates molecular 
modulation of Nrf2 signaling92. Thus, omega-3 fatty acid-derived protection is most likely 
an integration of multiple mechanisms. We recognize that the inflammatory signaling of 
TLR4 is sensitive to DHA modulation of caveolae-based signaling molecules106, 107. In 
chapter five, we propose TLR4 as a model caveolae-based signaling pathway that could 
be developed for future study of omega-3 nutritional intervention of PCB-induced 
inflammation. 
1.4 Targets for nutritional modulation of inflammation  
Caveolae – the interface of innate immunity and nutritional intervention 
Lipid or membrane rafts are 10-200 nm structures that are typified by sphingolipid and 
cholesterol enrichment and are characterized dynamic protein interactions as these 
domains play a critical though often transient role in protein scaffolding and signaling108. 
Caveolae are some of the larger raft structures included in this classification. The major 
structural proteins are the caveolins. Caveolin-1 (Cav-1) and caveolin-2 (Cav-2) are 
ubiquitously expressed and are particularly enriched in endothelial cells and 
adipocytes109. Muscle specific caveolin-3 (Cav-3) is structurally similar to Cav-1, and 
both Cav-1 and Cav-3 are critical to caveolae formation in their respective tissues 
whereas Cav-2 is not essential for the formation of the raft structure110. Caveolae play a 
crucial role in cellular and tissue nutrition having the ability to capture and endocytose 
albumin and fatty acids111, 112. Fatty acid binding by Cav-1 facilitates fatty acid distribution 
within cellular membranes as Cav-1 migrates between the plasma membrane and the 
Golgi apparatus24, which makes Cav-1 a likely modulator of lipophilic environmental 
pollutant trafficking.  Further, caveolae provide a signaling hub, in which endogenous 
molecules, like fatty acids, and xenobiotics, such as PCBs, may modulate the cellular 
response, which make them of particular interest in the study of lipophilic environmental 
pollutants and nutrients105.  
The development of Cav-1/ApoE double knockout (KO) mice substantiated the role of 
caveolae in vascular disease in part by altering protein expression of CD36 and VCAM1 
in the plasma membrane113. In addition, Cav-1 deficient mice are more resistant to LPS 
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challenge with reduced mortality from 90% to 30%114. LPS is the primary ligand of TLR4, 
which initiates an inflammatory signaling cascade115. TLR4 signaling requires 
dimerization of the TLR4 monomer and membrane translocation to lipid rich domains, 
such as caveolae, in the plasma membrane116, 117. Cholesterol and saturated fat 
enrichment promote TLR4 trafficking to Cav-1-rich membrane fractions76, 118.  TLR 
activity is inhibited by omega-3 fatty acids including the inflammatory response 
modulated by TLR4, TLR2/1 and TLR2/6106, 119, and this inhibition has been attributed to 
disruption of TLR4 activated COX-2 expression and mitigation of ROS107, 120, 121. Nrf2 
regulates anti-oxidant enzyme expression that is critical to cell survival; this includes 
hemeoxygenase 1 (HO-1), an anti-oxidant enzyme that interacts with caveolae122. 
Interestingly, in LPS stimulated cells, carbon monoxide CO production by HO-1 inhibits 
NADPH oxidase generated ROS and alters the Cav-1/TLR4 interaction to prevent 
myeloid differentiation primary response 88 (MyD88) scaffolding with TLR4121, 123. 
Similarly, DHA inhibits TLR4 dimerization and trafficking into lipid rafts by altering the raft 
microdomain composition and inhibiting NADPH oxidase ROS production107. It is clear 
that caveolae provide a critical structural interface for membrane signaling and protein 
scaffolding108, and Cav-1 is also integral to both PCB-induced inflammation and 
modulation of inflammation.  
Coplanar PCB induction of the AhR-mediated inflammatory response including up-
regulation of CYP1A1, MCP1, and VCAM1 expression require the presence of Cav-1124-
126. Further Cav-1 is a key regulator of nutritional interventions including both fatty acids 
and flavonoids. For example, we have demonstrated that α-linolenic acid, an omega-3 
fatty acid, reduces Cav-1 expression and overall inflammatory response to TNFα 
stimulation127. Similarily, quercetin, a flavanol found in fruit and vegetables, decreases 
PCB-mediated CYP1A1 expression by reducing the levels of phosphorylated Cav-1128. 
Epigallocatechin gallate (EGCG), a green tea catechin, accumulates in the caveolae rich 
cellular fractions, displaces Cav-1,  promotes Nrf2-dependent anti-oxidant gene 
expression, and reduces the NFкB-mediated inflammatory response129, 130. EGCG and α-
linolenic acid both attenuate the linoleic acid and PCB-induced inflammatory response16, 
130, 131. Caveolae are critical mediators of both pro- and anti-inflammatory stimuli and 
present an ideal platform in which to study the interface of innate immune and toxicant-
induced inflammatory signaling as a potential target for nutritional modulation. 
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1.5 Summary 
The major aim of this dissertation is to better understand the molecular 
consequences of coplanar PCB-induced inflammation and examine omega-3 fatty 
acids as potential nutritional modulators of environmental toxicant-induced 
inflammation. From the environmental to the molecular level, the human body is a 
staging ground for the many environmental factors that we encounter. Whether the 
stimuli are PCBs or remediation mixtures, the nuances of the physiological response 
include oxidative stress and the induction of inflammatory cytokines. We propose that 
omega-3 fatty acids are protective dietary components against inflammation. Thus, the 
activation of anti-oxidant enzymes and the fine tuning of the immunological response by 
fatty acid metabolites are fields ready for continued investigation.  
The following dissertation provides a discussion which begins with an 
environmental problem, tests a nutritional intervention using omega-3 fatty acids, 
and explores a mechanistic target for studies of nutritional interventions (Figure 
1.3):  
In chapter two, endothelial cell culture provides an in vitro model for the study of the 
inflammatory response to coplanar PCBs, such as PCB 77. Remediation products of 
PCB 77 were used to demonstrate the sensitivity of the biological response to low levels 
of the parent compound and its dechlorination products. As long as remediation 
technologies such as the dechlorination process that was assessed in chapter two are 
not a hundred percent efficient, there will be a continued risk of human exposures and 
disease outcomes associated with PCBs and other environmental pollutants.  
In response, we need to develop means of attenuating health risks using lifestyle 
changes such as diet/nutrition and exercise. The subsequent chapters develop a 
toxicant exposure model and test a nutritional intervention. In chapter three, we 
characterize the use of PCB 126 as a model toxicant and define the toxicological 
response to acute exposure in C57BL/6 mice. After defining the PCB 126 exposure level 
in chapter three, we assess in vivo the role of the omega-3 fatty acid, DHA, in the 
modulation of the PCB 126-induced inflammatory response in chapter four.  
In chapter five, we complement the in vivo work by investigating in vitro mechanisms of 
the toxicant inflammatory responses. Others have shown that omega-3 fatty acids 
attenuate LPS stimulated inflammation; thus, LPS was used as a positive control. The 
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research in this chapter was focused on caveolae-based signaling in the response to 
PCB 126 and LPS-induced inflammation, which could broaden our ability to apply fatty 
acids as a nutritional intervention. Together these studies provide insight into the 
regulation of coplanar PCB-induced inflammation and possible protection by omega-3 
lipids. 
 
  
15 
 
  
Figure 1.1 Polychlorinated biphenyl (PCB) structure, nomenclature and 
classifications. PCBs consist of chlorine-substituted biphenyl rings. The chemical 
name of each PCB congener includes the position and number of the chlorine 
substituted carbons.  The two major classifications of PCBs include the coplanar 
PCBs, which do not have ortho- substitutions, and the noncoplanar or ortho- 
substituted congeners. For example, PCB 126 is a coplanar PCB named 3,3’,4,4’,5-
pentachlorobiphenyl. The ortho-substituted PCB 153 is noncoplanar and is named 
2,2’,4,4’,5,5’-hexachlorobiphenyl.  
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Figure 1.2 Summary of the eicosanoid and docosanoid metabolites formed 
following stressed-induced phospholipase A2 fatty acid release. The 
arachidonic acid (AA)-derived metabolites contribute to inflammation and oxidative 
stress while eicosapentaenoic acid (EPA)-derived metabolites exhibit either 
moderately inflammatory effects or anti-inflammatory effects. Docosahexaenoic acid 
(DHA) metabolites are anti-inflammatory and pro-resolving. The metabolite class 
names are as follows: prostaglandin (PG), thromboxane (TX), leukotriene (LT), 
hydroxydocosahexaenoic acid (HDHA), hydroperoxy eicosatetraenoic acids 
(HPETE), hydroxyeicosatetraenoic acid (HETE),  hydroxyeicosapentaenoic acid 
(HEPE),  epoxyeicosatrienoic acids (EET), epoxyeicosatetraenoic acid (EETeTr), 
epoxydocosapentaenoic acid (EDP), hydroxydocosahexaenoic acid (HDHE). 
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Figure 1.3 Overview of dissertation objectives and placement of chapters 
within these goals.  
 
Copyright © Katryn Elizabeth Eske 2013 
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Chapter Two: PCB 77 dechlorination products modulate pro-inflammatory events 
in vascular endothelial cells 
 
Springer and Environmental Science and Pollution Research International, DOI 
10.1007/s11356-013-1591-3, 2013, PCB 77 dechlorination products modulate pro-
inflammatory events in vascular endothelial cells, Eske K, Newsome B, Han SG, Murphy 
M, Bhattacharyya D, Hennig B is given to the publication in which the material was 
originally published; with kind permission from Springer Science and Business Media. 
2.1 Synopsis 
Persistent organic pollutants such as polychlorinated biphenyls (PCBs) are associated 
with detrimental health outcomes including cardiovascular diseases. Remediation of 
these compounds is a critical component of environmental policy. Although remediation 
efforts aim to completely remove toxicants, little is known about the effects of potential 
remediation byproducts. We previously published that Fe/Pd nanoparticles effectively 
dechlorinate PCB 77 to biphenyl, thus eliminating PCB-induced endothelial dysfunction 
using primary vascular endothelial cells. Herein, we analyzed the toxic effects of PCB 
congener mixtures (representative mixtures of commercial PCBs based on previous 
dechlorination data) produced at multiple time points during the dechlorination of PCB 77 
to biphenyl. Compared to pure PCB 77, exposing endothelial cells to lower chlorinated 
PCB byproducts led to improved cellular viability, decreased superoxide production, and 
decreased nuclear factor kappa B (NFкB) activation based on duration of remediation. 
Presence of the parent compound, PCB 77, led to significant increases in mRNA and 
protein inflammatory marker expression. These data implicate that PCB dechlorination 
reduces biological toxicity to vascular endothelial cells. 
2.2 Introduction 
Polychlorinated biphenyls (PCBs) are a class of organic pollutants that were used 
heavily as dielectric fluids in industrial and electrical applications until evidence surfaced 
linking PCBs to cancer and cardiovascular disease.  Remediation efforts for these highly 
persistent pollutants have proven difficult, expensive and slow.  Our laboratories have 
developed new fast, low-cost techniques that employ Pd/Fe nanoparticles for reductive 
PCB dechlorination, which systematically dechlorinate higher congener PCBs to 
biphenyl, with lower chlorinated congeners produced as byproducts prior to complete 
degradation.  The goal of this work is to better understand the toxicological effects of 
these byproducts and to further validate the importance of PCB dechlorination for 
reducing cardiovascular risk factors and for improving overall public health.  
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Even though PCB production has been banned in the US since the late 1970s, PCBs 
remain concentrated in many waterways and Superfund sites, as well as in electrical 
devices such as transformers and light ballasts.  Additionally, recent research has 
indicated that a variety of PCB congeners are still being generated as industrial 
byproducts from pigment production and certain paper manufacturing 132, 133.  PCBs 
exhibit unique properties, such as high environmental persistence and resistance to 
metabolism in organisms, which lead to difficulties for remediation.  Additionally, the 
costs associated with large-scale clean-up and removal of these and other chemical 
pollutants is great, and thus the development of more efficient, cost effective 
technologies continues to be important. Current remediation techniques rely on 
expensive dredging followed by incineration or bioremediation techniques. Although 
PCBs can be degraded through some natural processes such as bacterial degradation 
134, 135 and photolysis 136-138, these processes are prohibitively slow for remediation of 
larger scale contaminations. Our research group recently developed a Pd/Fe 
nanoparticle system that catalyzes the dechlorination of PCBs to form biphenyl in order 
to address this need for low cost, high throughput chlorinated aromatic degradation (139, 
140.  During chlorinated aromatic degradation, hydrogen ions are used to displace 
chlorine on biphenyl rings in stages, resulting in the production of lower chlorinated PCB 
congeners prior to complete degradation to biphenyl. It is generally believed that less-
chlorinated congeners are more water soluble, more volatile, and more likely to 
biodegrade further 141.  In a previous study, we compared the biological activity of the 
parent compound (PCB 77) with the dechlorination end product (biphenyl), and found 
that complete dechlorination markedly reduced the pro-inflammatory activity of PCB 77 
140. 
 
Many environmental contaminants, and especially persistent organic pollutants, are risk 
factors for cardiovascular diseases such as atherosclerosis because they can initiate or 
exacerbate the underlying disease by altering gene expression patterns and subsequent 
vascular inflammation 142, 143.  Because the endothelium is in immediate contact with the 
blood, endothelial cells are particularly susceptible to the effect of environmental 
contaminants.  The lining of blood vessels is protected by the endothelium, and 
endothelial cells play an active role in physiological processes such as regulation of 
vessel tone, blood coagulation, and vascular permeability.  In turn, endothelial cell 
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activation or dysfunction is a critical marker of the pathology of cardiovascular diseases 
such as atherosclerosis. 
 
Activated endothelial cells produce chemokines such as monocyte chemoattractant 
protein 1 (MCP-1) and inflammatory cytokines, which attract monocytes from the blood 
stream to the site of injury.  Part of the resulting inflammatory process includes the 
endothelial cell expression of adhesion molecules, like vascular adhesion molecule 1 
(VCAM1), which allow the monocytes to attach to the endothelial layer and infiltrate this 
barrier into the intimal space.  We have demonstrated previously that coplanar PCBs 
(e.g., PCB 77) can induce DNA-binding activity of the oxidative stress-sensitive 
transcription factor nuclear factor kappa B (NFкB) and expression of VCAM1, which is 
dependent on functional aryl hydrocarbon receptor (AhR) activity 73.  Recently, we have 
reported the mechanisms of PCB 77-mediated upregulation of MCP-1 125.  
 
Little is known about vascular toxicity of PCBs, and especially about the toxicity of 
dechlorination or remediation products.  There is a clear need to evaluate products of 
remediation (e.g., dechlorination products) for biological activity in mammalian systems 
144.  It is important to know to what degree remediation processes of persistent organic 
pollutants have to occur before toxicity and any vascular injury becomes negligible.  
Thus, the present study was designed to test the effects of PCB 77 dechlorination 
products on pro-inflammatory parameters in a vascular endothelial cell model system.  
Data from this study suggest that the presence of the parent compound (e.g., PCB 77) is 
necessary for maximal endothelial cell dysfunction and inflammation.  These data also 
suggest that dechlorination is a successful method for decreasing biological toxicity, with 
overall toxicity linked to the level of degradation of the parent compound.  Herein, 
dechlorination is demonstrated to be an effective platform for addressing public health 
concerns associated with these persistent chlorinated pollutants. 
2.3 Materials and Methods 
Biphenyl, 3-chlorobiphenyl (PCB 2), 4-chlorobiphenyl (PCB 3), 3,3’-dichlorobiphenyl 
(PCB 11),  3,4-dichlorobiphenyl (PCB 12), 3,4’-dichlorobiphenyl (PCB 13), 4,4’-
dichlorobiphenyl (PCB 15),  3, 3’,4-trichlorobiphenyl (PCB 35),  3,4,4’-trichlorobiphenyl 
(PCB 37) and  3, 3’, 4, 4’-tetrachlorobiphenyl (PCB 77) were purchased from 
AccuStandard, Inc. (New Haven, CT).  Experiments that included hazardous materials 
such as PCBs were performed in accordance with institutional and federal guidelines 
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(11). All cell culture reagents, including ProLong Gold antifade reagent with 4',6-
diamidino-2-phenylindole (DAPI), were purchased from Life Technologies (Carlsbad, 
CA).  All other chemicals were purchased from Sigma-Aldrich Corporation (St. Louis, 
MO), unless otherwise specified. 
Description of PCB 77 dechlorination treatment mixtures 
Treatment mixtures were based on the composition of PCB 77 and its dechlorination 
products at 0, 10, 24, and 48 hours of remediation as derived from GC-MS data 
comparing the reductive efficiencies of 0.1 mg mL-1 400 nm Pd/Fe nanotubes and 1 mg 
mL-1 Pd/Fe nanoparticles 139, 140. Dechlorination product compositions were determined 
from these data (Table 2.1); treatments from each stage of the dechlorination are 
described as percent by weight and as molarity. Stocks of individual PCB commercial 
congeners were solubilized in fresh dimethyl sulfoxide (DMSO) at a concentration of 10 
mM. Treatment mixtures were developed to delineate between the effects of the parent 
compound and dechlorination products including treatments representing product 
mixtures without PCB 77 (mixtures 4 and 6), treatments representing only the 
concentration of PCB 77 at a particular stage of dechlorination (mixtures 9 and 10), and 
a treatment representing the 24 h dechlorination products with the higher PCB 77 
concentration found following 10 h dechlorination (mixture 7), to emphasize the role of 
PCB 77 in overall toxicity (Table 2). Stock treatment mixtures were prepared in DMSO at 
a 5 mM total concentration and diluted 1:1000 in cell culture medium for 5 µM final cell 
culture treatments. PCB mixtures were kindly composed by Bradley Newsome.  
Cell culture 
Primary endothelial cells (ECs) were isolated from porcine pulmonary arteries as 
described previously 145. Cell culture media consisted of medium 199 (M199) containing 
10% fetal bovine serum (FBS).  At 70-80% confluence, cells were incubated overnight 
with treatment media (M199 with 1% FBS), followed by exposure to PCB 77 or 
respective treatment mixtures for 24 h.  Treatment mixtures were added to cell culture at 
a final concentration of 5 µM, which represented a maximum concentration of 0.1% v/v 
DMSO/media (see Tables 1 and 2 for PCB treatment concentrations). Cell viability was 
tested in the presence of dechlorination products using the Vybrant MTT Cell 
Proliferation Assay Kit (Invitrogen, Eugene, OR) according to manufacturer guidelines 
and was kindly performed by Bradley Newsome.  
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Assessment of superoxide (O2.-) levels 
Superoxide levels were assessed as recently reported 92.  Cells were grown to 
confluence in 4-chamber culture slides (BD Biosciences, Bedford, MA). After 4 h 
exposure to PCB treatments (5 µM total concentrations; Table 1), the cells were rinsed 
2x with Krebs-Ringer buffer (KRB) and incubated with 5 µM dihydroethidium (DHE) or 
KRB (blank) at 37oC for 30 min. Cells were rinsed with KRB, fixed with 10% buffered 
formalin, and washed with PBS. Slides were mounted with ProLong Gold antifade 
reagent with DAPI for nuclei staining. Slides were evaluated with an Olympus BX61W1 
fluorescence microscope. Mean fluorescence intensity was quantified using ImageJ 
1.42q (NIH, Bethesda, MD). 
Assessment of NFкB activation 
Nuclear extracts were prepared from endothelial cells cultured as described above in 10 
cm dishes and treated with PCB 77 or dechlorination mixtures for 4 h.  The nuclear 
extraction was performed as described previously 146.  EMSA (electrophoretic mobility 
shift assay) of nuclear factor kappa B (NFкB) binding was kindly performed by Dr. 
Seong-Su Han of the University of Iowa College of Medicine using the DNA-protein 
binding detection kit (Gibco-BRL, Grand Island, NY) with radio-labeled oligonucleotides 
130, 147. 
Measurement of CYP1A1, MCP-1 or VCAM1 mRNA  
CYP1A1, MCP-1 and VCAM1 mRNA expression was assessed using real-time PCR 
(RT-PCR), as described previously 125, 126.  Briefly, mRNA was isolated using TRIzol 
Reagent (Life Technologies, Carlsbad, CA) and quantified using a SmartSpec Plus 
Spectrophotometer (BIO-RAD, Philadelphia, PA). cDNA was then generated using 
Promega AMV reverse transcriptase (Fisher Scientific, Waltham, MA) and  RT-PCR was 
performed using Power SYBR Green PCR Master Mix (Life Technologies, Carlsbad, CA) 
and the following porcine primer sequences: β-actin sense 5′-TCA TCA CCA TCG GCA 
ACG-3′ and antisense, 5′-TTC CTG ATG TCC ACG TCG-3′; CYP1A1 sense 5’- TGG 
AGA GGC AAG AGT AGT TGG-3’and anti-sense 5’-GGC ACA ACG GAG TAG CTC 
ATA-3’; MCP-1 sense 5′-CGG CTG ATG AGC TAC AGA AGA GT-3′and antisense, 5′-
GCT TGG GTT CTG CAC AGA TCT-3′; and VCAM1 sense 5′-TGG AAA GAC ATG GCT 
GCC TAT-3′ and antisense, 5′-ACA CCA CCC CAG TCA CCA TAT-3′.  Assays were run 
using the Applied Biosystems 7300 Real time PCR System (Life Technologies, 
Carlsbad, CA) using absolute quantification. The raw data were quantified using a 
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standard curve and analyzed with a manual CT threshold of 0.200. Sample data were 
normalized to individual β-actin values.  
Measurement of CYP1A1, MCP-1 and VCAM1 protein 
CYP1A1 and VCAM1 protein levels were assessed by Western blotting, as described 
previously 140.  After semi-dry transfer, nitrocellulose membranes were incubated for 2 h 
in blocking buffer (5% non-fat milk in Tris-buffered saline containing 0.05% Tween 20).  
Rabbit polyclonal CYP1A1 (H-70) and VCAM1 (C-19)-R (Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA) primary antibodies were diluted 1:1000 in blocking buffer and 
incubated overnight at 4 °C, and the secondary antibody was diluted 1:4000.  β-actin 
primary and secondary antibodies were diluted 1:10,000 125. MCP-1 protein levels were 
measured in cell culture media diluted 1:7 using an OptEIA Human MCP-1 ELISA Kit 
(BD Biosciences, San Diego, CA) according to manufacturer guidelines.   
Statistical analysis 
Values are reported as means ± SEM obtained from a representative sample set of a 
minimum of three independent experiments, unless otherwise stated. Comparisons were 
made by one-way analysis of variance (ANOVA) with Tukeys test for post-hoc analysis, 
using SigmaPlot 12.0 software (Systat Software, San Jose, CA). Statistical probability of 
pvalue < 0.05 was considered significant. Different statistical marker letters indicate 
statistical differences. 
2.4 Results 
Dechlorination alters cellular oxidative stress and viability  
PCB-induced cellular dysfunction is characterized by increased oxidative stress and 
subsequent activation of inflammatory pathways including NFкB.  The uncoupling of 
CYP1A1 leads to the generation of reactive oxygen species (ROS), such as superoxide.  
Endothelial cell monolayers were exposed to representative dechlorination product 
mixtures (Table 2.1) for 4 h before ROS were visualized with DHE fluorescence (Figure 
2.1a).  Strong staining was observed in cells exposed to 0 h (pure PCB 77) and 10 h 
dechlorination products, whereas mixtures representing longer periods of dechlorination 
showed decreased superoxide production. When DHE fluorescence was quantified and 
normalized to DAPI nuclear staining, fluorescence from initial dechlorination mixtures (0 
and 10 h of dechlorination) indicated higher ROS production which decreased to control 
levels with further dechlorination (differences between groups approached significance, 
p=0.052; See Figure 2.1b).  A similar trend was observed with regard to viability, where 
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no changes were observed in cells treated with PCB vehicle (DMSO) and the 48 h 
dechlorination product, although cell viability was decreased in 0 h (parent compound, 
PCB 77), 10 h and 24 h dechlorination product treatments to 69±1%, 61±3%, 87±2% of 
control, respectively.  
NFкB activation is attenuated by dechlorination   
Data from an NFкB EMSA showed that cells treated for 4 h with the dechlorination 
products exhibited a prominent increase in NFкB activation when treated with the 0 h 
product, or pure PCB 77. Intermediate activation by the 10 and 24 h products was 
observed; NFĸB:DNA binding for these treatments was significantly decreased 
compared to exposure to the 0 h product but remained increased relative to the vehicle 
control and biphenyl (48 h product; see Figure 2.2).  Biphenyl was consistently within 
control expression levels for superoxide fluorescence, viability, and NFкB:DNA binding. 
The 10 and 24 h dechlorination products were increased from control but did not exhibit 
a consistent linear change from parent PCB 77, 0 h of dechlorination, expression levels. 
We, therefore, tested a series of treatment mixtures to delineate between the effects of 
the dechlorination products and the residual PCB 77.  
 
Dechlorination products alter CYP1A1, MCP-1 and VCAM1 mRNA expression  
CYP1A1, VCAM1 and MCP-1 levels were assessed in mRNA using treatment groups 1-
10 (Figure 2.3, Table 2.2).  CYP1A1 expression is a sensitive marker of coplanar PCB-
mediated cellular activation and toxicity.  Thus, significant response from all treatments 
containing PCB 77 was expected (Figure 2.3a).  Indeed, all treatments that contained 
pure or some PCB 77 (treatments 2, 3, 5, 7, 9 and 10) exhibited almost maximal 
CYP1A1 expression.  There was no difference in CYP1A1 expression among the pure 
PCB 77 (treatment 2) and both 10 h (treatment 3) and 24 h (treatment 5) dechlorination 
mixtures.  Interestingly, when 10 h and 24 h dechlorination treatments lacked PCB 77 
(treatments 4 and 6, respectively), induction of CYP1A1 was reduced linearly.  Both 
MCP-1 and VCAM1 mRNA expression patterns (Figures 2.3b and 2.3c, respectively) 
followed approximately the CYP1A1 treatment patterns, suggesting some correlation 
between CYP1A1 induction and inflammatory markers in these dechlorination 
experiments.   As with CYP1A1 expression, MCP-1 and VCAM1 expression exhibited a 
linear decrease to control levels when treated with mixtures representing 10, 24 and 48 
h dechlorination products without PCB 77 (treatments 4, 6 and 8), indicating that any 
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byproduct contribution to the inflammatory response was eliminated by further 
dechlorination. Total dechlorination to biphenyl (48 h product) showed no statistical 
difference from control, indicating that it was relatively benign in our EC model.  The 
presence of residual parent PCB dominated the inflammatory response in product 
mixtures, but mRNA expression levels of PCB 77 alone were moderately attenuated at 
the lower concentrations.  
Degree of dechlorination affects CYP1A1, MCP-1 and VCAM1 protein expression 
Endothelial cells were treated with the dechlorination mixtures mentioned above (Table 
2.2) in order to determine the effects of PCB 77 dechlorination on endothelial cell 
inflammatory response expressed in protein markers (Figure 2.4).  Treatments 
containing the parent compound showed strong correlations in both mRNA and protein. 
Similar to the mRNA expression levels, CYP1A1 protein levels were highest for 
treatments containing PCB 77 (Figure 2.4a).  However, treatments that did not contain 
PCB 77 showed a marked decrease in CYP1A1 and MCP-1 protein expression, 
correlated to the degree of dechlorination. Significant increases in MCP-1 expression 
were observed with the 0 h product (PCB 77, treatment 2) and, to a lesser degree, with 
dechlorination products containing decreasing concentrations of PCB 77 (treatments 3, 
5, and 8). VCAM1 protein expression of dechlorination product mixtures without PCB 77 
(treatments 4 and 6) and biphenyl (treatment 8) were not significantly different from 
control. The presence of PCB 77 in all treatment groups corresponded to significant 
increases in VCAM1 protein expression above control levels.  These data suggest a 
complicated interplay between inflammatory parameters in response to PCB 77 
dechlorination product exposure.  Nevertheless, the presence of PCB 77 in the individual 
treatments markedly induced vascular inflammation.     
2.5 Discussion 
PCBs are man-made chemicals that were used in hundreds of industrial and commercial 
applications 148 and are byproducts of certain industries today 133. Even though their 
mass production has been banned, PCBs are chemically stable, persistent 
environmental toxicants that can cause harmful health effects.  Remediation or 
detoxification of contaminated sites is difficult and expensive, and it is not clear to what 
extent these remediation processes have to occur before their disease potential is 
mitigated.  The present study was designed to test the hypothesis that dechlorination of 
coplanar PCB 77 diminishes its pro-inflammatory potential in vascular endothelial cells.  
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This is an important issue because PCBs can damage vascular tissues and thus 
contribute to cardiovascular diseases such as atherosclerosis.  In fact, a recent study 
reported increased hospitalization rates for acute myocardial infarction and diabetes 
mellitus in populations residing near areas contaminated with persistent organic 
pollutants 149, 150.  Furthermore, the administration of PCB 77 to male apolipoprotein E 
(ApoE) -/- mice has been shown to promote atherosclerosis 151.   
 
The lining of blood vessels is protected by the endothelium, and endothelial cells play an 
active role in physiological processes such as regulation of vessel tone, blood 
coagulation, and vascular permeability.  Dysfunction of endothelial cells is a critical 
underlying cause of the initiation of cardiovascular diseases such as atherosclerosis. 
Coplanar PCBs are initiators of endothelial dysfunction and exert their toxicity through 
binding to the AhR. AhR target genes, including CYP1A1, are considered a source of 
oxidative stress in endothelial cells and subsequent vascular dysfunction 152, 153.  We 
confirmed in the present study the oxidative stress potential of coplanar PCBs.  In fact, 
CYP1A1 induction was maximal in cells exposed to pure PCB 77 and remained elevated 
in all dechlorination mixtures that contained PCB 77, independent of its relative 
concentration.  When residual amounts of PCB 77 were excluded from the 
dechlorination mixtures, CYP1A1 induction was markedly reduced, suggesting that the 
presence of the parent coplanar PCB is necessary for maximal CYP1A1 expression.  
Furthermore, we have previously shown that coplanar PCBs 77, 126 and 169 increased 
expression of the CYP1A1 gene, oxidative stress (DCF fluorescence), and the DNA-
binding activity of NF-кB 73.  In the current study, oxidative stress and DNA-binding of 
NF-кB decreased with increasing dechlorination.  In fact, when PCB 77 was completely 
dechlorinated to biphenyl, oxidative stress and NF-кB levels approached control levels. 
This suggests that effective dechlorination should be as complete as possible to avoid 
oxidative stress-mediated tissue toxicity.   
 
Oxidative stress-induced transcription factors such as NF-кB, which regulate 
inflammatory cytokine and adhesion molecule production, play critical roles in the 
induction of inflammatory responses and subsequent atherosclerotic lesion formation.  
We have demonstrated previously that coplanar PCBs can cause endothelial cell 
dysfunction as determined by inflammatory markers, such as expression of inflammatory 
cytokines and adhesion molecules, i.e. MCP-1 and VCAM1, respectively 91, 125, 154. In our 
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analysis of the dechlorination product mixtures, we found that inflammatory patterns of 
MCP-1 and VCAM1 were similar to CYP1A1 patterns induced by pure PCB 77 and the 
dechlorination mixtures that contained residual PCB 77, suggesting that the parent 
compound is necessary for an endothelial inflammatory response.  The 10 h 
dechlorination byproducts also induced an MCP-1 and VCAM1 response that was 
alleviated by further dechlorination. Again, as was found with CYP1A1, total 
dechlorination to biphenyl did not induce MCP-1 and VCAM1 inflammatory parameters 
in our endothelial cell model system. 
 
The dechlorination process decreased the parent PCB 77 but contributed to various 
lower-chlorinated PCBs.  Furthermore, the ratio and proportion of these lower-
chlorinated PCBs changes with degree of dechlorination.  Even though their level of 
interaction with the AhR is not well characterized, lower-chlorinated PCBs may 
contribute to cellular dysfunction.  PCB cogeners with substitutions in both para positions 
(4,4’) are reported to exhibit a level of AhR activity; this includes PCBs 15 and 37 in 
addition to the parent compound PCB 775. For example, PCB 15, which was found in 
relatively high concentrations in the dechlorination mixtures, can contribute to liver 
carcinogenesis 155.  PCB 11, another common PCB in our dechlorination mixtures, 
recently has been discovered in relatively large amounts in commercial paint pigments 
133.  Furthermore, other lower chlorinated PCBs generated during dechlorination have 
been shown to be metabolically activated by electrophilic quinoid species, which can 
bind to DNA, including PCBs 2, 3, 12 and 15156-158.  Our data suggest that the temporary 
formation of lower chlorinated PCBs during dechlorination can contribute in part to 
induction of inflammatory parameters.  
 
In addition, the lipophilic nature of PCBs enables them to perturb membrane structures. 
We have evidence that membrane domains like caveolae are critically involved in 
endothelial inflammation induced by exposure to PCBs.  For example, PCB 77 can 
accumulate in caveolae-rich fractions of endothelial cells 124, and upregulation of 
endothelial MCP-1 by PCB 77 is caveolin-1-dependent 125.  Evidence from our laboratory 
implicates caveolae as a regulatory platform involved in endothelial activation and 
inflammation by environmental contaminants (Figure 2.5). As a regulatory platform, 
caveolae facilitate the interaction of PCBs with the AhR, which in turn promotes the 
upregulation of CYP1A1, a phase I detoxifying enzyme. CYP1A1 metabolism of coplanar 
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PCBs, like PCB 77, is inefficient, leading to protein uncoupling and release of 
superoxide, which promotes the formation of reactive oxygen species (ROS) in the cell 
38.  The cell responds to this change in redox status by activating the transcription factor 
NFкB, which regulates enzymes and inflammatory parameters associated with 
endothelial dysfunction and cell injury such as MCP1 and VCAM1 159.  Further studies 
are needed to understand whether caveolae have differential selectivity for various PCB 
species such as those present in dechlorination mixtures and to determine if the 
interaction of these congeners with caveolae has potential to induce endothelial cell 
dysfunction.   
 
In summary, our study provides evidence that dechlorination of highly chlorinated PCBs 
is beneficial for protecting the vasculature from oxidative stress-induced inflammation 
and subsequent pathologies like atherosclerosis. Highly chlorinated PCBs are persistent 
and cytotoxic and a significant risk factor to endothelial injury and associated vasculature 
pathologies.  The pro-inflammatory potential of the dechlorination mixtures that we 
observed appears to depend largely on the presence of the parent compound (e.g., PCB 
77).  Clearly, cytotoxicity decreased relative to degree of dechlorination, and the final 
dechlorination product, biphenyl, was nontoxic in our endothelial cell model system.  
More studies are needed to understand threshold concentrations of dechlorination 
mixtures that are required to prevent or mitigate compromised health associated with 
exposure to environmentally toxic chlorinated biphenyls. 
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Table 2.1 Treatment mixtures representing PCB 77 dechlorination byproducts at 
various time points during dechlorination.  
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Figure 2.1 Dechlorination of PCB 77 alters cellular oxidative stress.  Cells 
grown on chamber slides were treated with DMSO (vehicle control) or dechlorination 
products with a total concentration of 5 µM total concentrations and were incubated 
for 4 h. Cells were then treated with N,N'-(1,2-dihydroxyethylene) bisacrylamide, 
(DHE, in red) for superoxide detection. Slides were fixed with DAPI (in blue) for 
nuclear staining, (a) fluorescent images were recorded at 40X and (b) DHE 
fluorescence was quantified and normalized to DAPI. 
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Figure 2.2 Dechlorination of PCB 77 attenuates NFкB activation.  Cells were 
treated with vehicle control (DMSO), 0 h (PCB 77, 5 µM) 10 h, 24 h and 48 h 
dechlorination mixtures (5 µM), and incubated for 4 h. Both PCB 77 and 
dechlorination products (10 and 24 h product treatments) significantly increased 
DNA binding of NFкB over DMSO and biphenyl (48 h treatment). Results are given 
as mean ± SEM. Different statistical marker letters represent significant differences 
among treatment groups (determined by pvalue ≤ 0.05).  
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Figure 2.3 
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Figure 2.3 Dechlorination products alter CYP1A1 (A), MCP-1 (B) and VCAM1 
(C) mRNA expression. The presence of PCB 77 significantly upregulated mRNA 
inflammatory markers in ECs; inflammation decreased with further dechlorination of 
the parent compound. Please see Table 2.2 for detailed treatment descriptions.  The 
vehicle, DMSO (treatment 1), was applied at 0.1% v/v for all treatments.  Treatments 
representing the dechlorination products at 0 h (treatment 2), 10 h (treatment 3), 24 
h (treatment 5), and 48 h (treatment 8) are the same as those tested previously for 
NFкB, superoxide production and viability. Treatments 4 and 6 excluded PCB 77 
while maintaining the representative concentrations of the dechlorination products 
found at 10 h and 24 h, respectively.  In contrast, treatments 9 and 10 contained only 
PCB 77 at the concentrations found in the 10 h and 24 h mixtures, respectively.  
Treatment 7 consisted of the 24 h dechlorination mixture with the level of PCB 77 
found in the 10 h mixture.  Different statistical marker letters represent significant 
differences among treatment groups (determined by Pvalue ≤ 0.05 using one-way 
ANOVA with Tukey’s post hoc).  For example, in CYP1A1, treatment 2 (statistical 
marker “b”) is significantly different from treatment 1 (“a”) and treatment 4 (“c”).  
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Figure 2.4 
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Figure 2.4 Dechlorination mixtures alter CYP1A1 (A), MCP-1 (B) and VCAM1 (C) 
protein expression. The presence of PCB 77 significantly upregulated protein 
inflammatory markers in ECs; inflammation decreased with further dechlorination of 
the parent compound.  Treatments are the same as described in Figure 3 (please 
see Table 2.2 for detailed treatment descriptions). Statistical differences among 
treatment groups (determined by pvalue ≤ 0.05) are represented by marker letters, as 
stated previously.  
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Figure 2.5 PCB 77 increases ROS production and downstream cellular 
dysfunction. PCB 77 interacts with caveolae in the plasma membrane, is 
endocytosed into the cell, and interacts with the AhR and its chaperone ARNT (aryl 
hydrocarbon receptor nuclear translocater), leading to nuclear translocation, XRE 
(xenobiotic response element) binding and CYP1A1 upregulation. CYP1A1 protein 
uncoupling occurs during PCB 77 metabolism and leads to an increase in cellular 
ROS. NFкB is activated in response to the change in cellular redox status and 
translocates to the nucleus where it acts as a transcription factor to upregulate 
adhesion molecules and cytokines.  
Copyright © Katryn Elizabeth Eske 2013 
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Chapter Three: Assessment of toxicological and inflammatory endpoints following 
acute exposure to increasing concentrations of PCB 126 
3.1 Synopsis  
Polychlorinated biphenyls (PCBs) are persistent organic pollutants. The dioxin-like 
coplanar PCBs, such as PCB 77 and PCB 126, interact with the aryl hydrocarbon 
receptor (AhR), and previous work has demonstrated that coplanar PCBs initiate 
endothelial dysfunction which leads to inflammation, that can lead to diseases such as 
atherosclerosis. Many of these animal studies utilized PCB 77; however, use of PCB 
126, a coplanar PCB with a higher affinity for the AhR, has not been well characterized. 
In order to determine the appropriate dose of PCB 126 in mice, a concentration range 
was selected including 0.0, 0.5, 5.0, 50, and 150 μmol/kg, also expressed as 0.0, 0.16, 
1.63, 16.3, and 49.0 mg/kg (ppm).  Each group of C57BL/6 mice was gavaged twice with 
the same concentration of PCB126 within a seven day period. After this acute exposure, 
the mice were sacrificed and assessed for toxicological and inflammatory endpoints of 
PCB 126 exposure.  The goal of this study was to identify PCB 126 concentrations which 
do not lead to wasting syndrome.  Mice receiving the highest doses (50 and 150 
μmol/kg) of PCB 126 exhibited a significant decrease in body weight, indicative of broad 
toxicity. The lowest concentrations of 0.0 and 0.5 μmol/kg did not contribute to weight 
loss or changes in inflammatory markers. All mice which received PCB 126 had 
significant increases in cytochrome P4501A1 (CYP1A1) mRNA expression, while those 
mice which received 5.0 μmol/kg of PCB 126 had significant increases in liver to body 
weight ratio and the inflammatory marker monocyte chemoattractant protein-1 (MCP- 1).  
Exposure to 5.0 μmol/kg PCB 126 did not contribute to weight loss.  These data indicate 
that a concentration of 5.0 μmol/kg PCB 126 may be used to study inflammation in 
C57BL/6 mice without causing overt toxicity.  
3.2 Introduction 
General Overview 
Persistent organic pollutants (POPs) present a chronic disease risk and are linked to a 
range of vascular, neurological, and teratogenic outcomes65, 160-163. Our work with 
coplanar PCBs addresses both dioxin-like toxicity and the toxicity of PCBs as a class of 
compounds. We have demonstrated the role of PCB 77 in inducing vascular 
inflammation, modulating molecular aspects of vascular tone and responding to 
nutritional interventions73, 92, 164, 165. The literature suggests that PCB 77 is metabolized, 
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and methodology to detect the hydroxylated products confirms the generation of these 
metabolites which has led us and other researchers to question the persistent nature of 
PCB 77166. Clearly, PCB 77 has been an effective tool for the study dioxin-like 
inflammation and general knowledge of coplanar PCB activity, but PCB 126 presents a 
more useful model for the study of POPs because of its persistence and resistance to 
metabolism.  
Chemical problem 
Co-planar PCBs are model toxicants, but each PCB congener evokes a unique 
biological response.  PCB 77, for example, contains an open meta and two open ortho 
positions on each phenol which facilitate metabolism by Phase I metabolizing enzymes, 
such as CYP1A1, which form epoxides and cause hydroxyl substitution. In contrast, 
PCB 126 contains only one open meta position making it less vulnerable to electrophilic 
substitution and, therefore, more resistant to metabolism and more environmentally 
persistent, a characteristic which better represents the nature of PCBs as a class of 
compounds. When compared to dioxin, PCB 77 has a TEF of 0.0005 in contrast to the 
more toxic PCB 126 with a TEF of 0.1167. Though both compounds are AhR ligands, the 
theoretical potential of PCB 126 to induce oxidative stress and cellular damage is much 
greater.  
PCB 126 in health and disease 
The National Toxicology Program (NTP) comparative study of PCB 126 and 2,3,7,8- 
Tetrachlorodibenzo-p-dioxin (TCDD) concluded that vascular disease was a critical risk 
factor following exposure to dioxin-like compounds168. The liver, as a highly vascularized 
organ that is critically involved in toxicant metabolism, is also affected by exposure to 
coplanar PCBs including PCB 126169. NHANES data suggests a statistical link between 
elevated amino L transferase (ALT) and aspartate aminotransferase (AST) levels and 
plasma levels of persistent organic pollutants, such as coplanar PCBs62.  
Hypothesis and Rationale 
We hypothesize that acute exposure to high doses of PCB 126 will cause wasting 
syndrome and that low to median doses will induce inflammation and associated 
toxicological endpoints without wasting symptoms. To establish the use of PCB 126 as a 
model toxicant, we utilized a dose-response study that assessed basic toxicity and 
inflammatory endpoints including PCB tissue distribution, liver to body weight ratio 
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changes, and mRNA levels of inflammatory markers, such as CYP1A1 and MCP-1, in 
liver.   
3.3 Methods 
Reagents and Materials  
PCB 126 was obtained from AccuStandard (New Haven, CT). The Jackson Laboratory 
provided the C57BL/6 mice (Bar Harbor, MN).  Tocopherol-stripped safflower oil 
(vehicle) was obtained from Dyets (Bethlehem, PA). Reverse transcriptase reagents 
were purchased from Fisher Scientific (Waltham, MA). Western blotting reagents were 
obtained from BioExpress (Kaysville, UT).  Reagents used for mRNA isolation and 
qPCR were purchased from Life Technologies (Grand Island, NY). 
Animal Care  
Male C57BL/6 mice were housed and handled according to a protocol approved by the 
University of Kentucky IACUC. After acclimation, animals were treated with an initial 
dose of 0.0, 0.5, 5.0, 50, or 150 μmol/kg PCB 126 in safflower oil (vehicle, Table 3.1) on 
Day 1 and received a second gavage of the same dose on Day 7. Animals were 
sacrificed 24 hours after the final dose and tissues were collected for analysis. For the 
dose response study, C57BL/6 mice were maintained on standard chow.  
PCB 126 Tissue Analysis 
Analysis of tissues for PCB 126 was kindly performed by the lab of Dr. Yinan Wei in the 
University of Kentucky Department of Chemistry70. Frozen tissue samples, including 
liver, adipose, lung, muscle, and kidney, and sera were weighed and processed with an 
internal standard (100 µL 0.35 ng/µL PCB 166 in isooctane). Samples were combined 
with diatomaceous earth and extracted with hexane. The dry hexane extract was 
combined with 10 µL of 0.1 ng/µL PCB 209, internal standard. Analysis was performed 
using GC/MS with the Agilent 6890N GC, G2913A auto sampler, and 5975 MS detector 
(Agilent Technologies, Santa Clara, CA) using an HP-5MS 5% phenyl methyl siloxane 
column (30 m length, 0.25 mm internal diameter, 0.25 µm film thickness). Retention 
times were used to identify standards and PCB 126. Internal standard values were used 
to calculate recovery efficiency, and tissue amounts were normalized to sample weight 
for µg of PCB 126/g of tissue.  
Alanine Aminotransferase (ALT) ELISA 
 Serum was collected by cardiac puncture, incubated on ice to allow clotting and 
centrifuged for 15 min at 12,000 rpm and 4°C. Serum was collected and stored at -80°C.  
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Mouse alanine aminotransferase (ALT) ELISA kit (TSZ ELISA, Framingham, MA) was 
used to measure serum ALT levels. Serum was diluted 1:5 in assay Sample Solution, 
and the ELISA was performed according to manufacturer’s instructions.  Sample 
absorbances were measured at 450 nm using a SpectraMax M2 spectrophotometer 
(Molecular Devices, Sunnyvale, CA), and sample values were calculated from the 
standard curve using the SoftMax Pro 4.8 software (Molecular Devices, Sunnyvale, CA).  
Western Blot 
 Protein was collected from liver tissue homogenates, was quantified using the Bradford 
method, and run on 10% SDS-PAGE gels.  Bax was detected using primary antibody 
from Cell Signaling170. 
Real time – PCR  
RNA was isolated from homogenized liver tissues using the TRIzol® method. Isolated 
mRNA was resuspended in RN/DNAse free water and quantified using UV-vis 
spectroscopy at 260 nM.  cDNA was made using Promega AMV reverse transcriptase. 
CYP1A1, MCP-1, IL-6, VCAM1, HO-1, NQO1 and β-actin were analyzed with using 
SYBR® Green reagent and assessed using the qPCR on the 7300 Real Time PCR 
Systems (Life Technologies, Grand Island, NY ) 125, 126.  
Statistical Analysis 
 Comparisons between treatments were made by one-way analysis of variance followed 
by Tukey’s post-hoc test. Statistical probability of P0.05 was considered significant. 
Statistical tests were performed using SigmaPlot©12.0. 
3.4 Results 
Gross Physiological Changes  
PCB 126 was distributed throughout the animal, but as was consistent with current 
literature, liver and adipose were the primary storage depots (Table 3.2).  A very low 
level of PCB was detected in animals that did not receive PCB 126 treatment, which is 
consistent with the ubiquitous nature of PCB environmental contamination. As expected, 
this baseline level of PCB 126 was found predominantly in adipose.   
Significant changes in body weight following toxicant exposure are associated with toxic 
wasting syndrome. The total body weights of animals receiving 0.0, 0.5 or 5.0 µmol/kg 
PCB 126 were not changed due to treatment. The higher concentrations of PCB 126, 50 
and 150 µmol/kg, caused significant decreases in total body weight when compared to 
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vehicle treated animals (Table 3.3, Figure 3.1).  Interestingly, the liver to body weight 
ratio, another indicator of toxicant exposure, was only significantly changed in the 5.0 
µmol/kg treatment when compared to both the 0.0 and 0.5 µmol/kg treatment groups 
(Figure 3.2). The liver to body weight ratios of the 50 and 150 µmol/kg PCB 126 treated 
mice were not different from vehicle and low dose treated animals. This unexpected 
result led us to investigate Bcl-2-associated X protein (Bax) a key marker of apoptosis 
and liver damage171. Bax protein expression was low in the 0.0, 0.5, and 5.0 µmol/kg 
PCB 126 treated animals; in contrast significant increases were observed in 50 and 150 
µmol/kg treated animals, an indicator of liver cell apoptosis (Figure 3.3). Interestingly, 
when the serum samples were assessed by alanine aminotransferase (ALT) ELISA, an 
indicator of liver damage, no significant increases were detected (Figure 3.4). Further 
analysis was performed on liver mRNA to assess the PCB 126-induced inflammatory 
response.  
Markers of AhR activation and inflammatory response  
CYP1A1 expression is a hallmark of AhR activation.  As expected, all mice exposed to 
PCB 126 had increased CYP1A1 mRNA expression regardless of treatment 
concentration (Figure 3.5a).  MCP-1, a down-stream target of CYP1A1 mediated 
oxidative stress and NFĸB activation, was significantly increased only in the mRNA of 5 
µmol/kg treated mice when compared to both the 0.0 and 0.5 µmol/kg groups (Figure 
3.5b).  IL-6 expression was similar to MCP-1 with a significant increase in the 5.0 
µmol/kg group over all other treatment groups (Figure 3.5c).  Interestingly, VCAM1 
expression in the 50 and 150 µmol/kg groups was highly increased compared to 0.0 
µmol/kg and the lower PCB 126 doses. This observation correlates with the indications 
of cell death. Using the macrophage marker F4/80, the presence of macrophages was 
assessed and correlated with the increase in VCAM1 expression reaching significance in 
the 150 µmol/kg treatment group (Figure 3.6). In response to the cellular stress 
associated with these inflammatory markers, the anti-oxidant response, as indicated by 
hemeoxygenase 1 (HO-1) and NADPH:quinone oxidoreductase 1 (NQO1) enzyme 
mRNA, was significantly increased with the highest doses of PCB 126 (Figure 3.7). 
NQO1 was increased in the 5 µmol/kg group relative to the 0.0 and 0.5 µmol/kg doses 
but was significantly lower than the highest doses.  Together these data suggest that 5.0 
µmol/kg was sufficient to produce moderate inflammation. 
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3.5 Discussion 
Differences exist between model species and their response to PCBs and other 
environmental toxicants172, and the literature does not provide sufficient mouse data to 
determine an inflammatory but not overtly toxic dose of PCB 126.  For this reason, we 
performed this dose-response assessment in C57BL/6 mice. The National Toxicology 
Program (NTP) assessment of PCB 126 in rats corroborates our tissue distributions 
data173. They and other investigators found the liver and the adipose to be the primary 
depots for PCB 126 deposition. In our animals, the higher doses of PCB 126 resulted in 
an increase in the percentage of PCB distributed to the adipose (Table 3.2). During a 
study which included a 22-day observation period, liver levels of PCB 126 were reported 
to remain stable174. These findings indicate that the PCB tissue levels are in keeping with 
dose and duration of exposure. As is consistent with our results in mice, peripheral 
tissues, i.e. lung, and serum contained detectable but much lower levels of PCB 126173. 
When compared to TCDD, PCB 126 has greater tissue retention175. The PCB 126 tissue 
retention levels in our mice were dose dependent with 150 µmol/kg mice having 
estimated total body levels (µg) correlating to dose amount. The lower PCB 126 doses 
did not correlate as well implicating metabolism and excretion through feces174, 176. 
Concentrations of 50 µmol/kg PCB 126 and above induced wasting in C57BL/6 mice, 
which is associated with metabolic and hormonal changes that affect the metabolism of 
glucose and decrease appetite177, 178. A change in liver to body weight ratio was 
observed in mice receiving two doses of 5 µmol/kg PCB 126. The hepatic response to 
toxicants promotes an increase in liver fatty acid and protein content, which is supported 
by both the increase in liver weight and gene expression179.  
All treatment doses of PCB 126 upregulated Phase I enzyme CYP1A1.  Previous work 
from our laboratory has established CYP1A1 as a key response enzyme to PCB 77-
induced inflammation via critical interaction between AhR and Cav-1124. CYP1A1 is 
responsible for the oxidative stress induced by PCB 126 and other aromatic 
hydrocarbons which cause the release of hydroxyl radicals and uncoupling of the 
enzyme38. In response to the cellular stress, multiple indicators of inflammation were 
increased. The liver mRNA expression of the chemokine MCP-1 and the cytokine IL-6 
were increased in the 5 µmol/kg PCB 126 exposure group.  IL-6 is an acute phase 
cytokine that stimulates protein synthesis and promotes tissue healing and is expressed 
by hepatocytes, leukocytes, and endothelial cells180, 181.  Mice deficient in IL-6 were 
unable to induce normal protein synthesis in response to turpentine tissue damage or 
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Gram-positive bacterial infection, though systemic response to LPS stimulation was near 
normal182. The role of IL-6 in protein synthesis and tissue healing supports the 
observation that 5 µmol/kg treated mice had higher liver to body weight ratios. Some 
literature indicates that AhR agonists moderate the IL-6 response183, 184, which provides 
a limited explanation for the low induction of IL-6 in higher PCB 126 doses. In vascular 
disease, IL-6 is a marker of plaque instability185 and has been noted as a common risk 
factor associated with low-grade inflammation and CVD risk186. Similarly, VCAM1 is a 
common marker for vascular disease that is critical to lesion formation and the 
recruitment of monocytes to regions of tissue damage and endothelial dysfunction44, 45, 
69. Coplanar PCBs promote VCAM1 expression and endothelial dysfunction126, as is 
supported by the increase in VCAM1 in the 50 and 150 µmol/kg PCB 126 treatment 
groups. PCB 126-induced VCAM1 expression in the 50 and 150 µmol/kg treatment 
groups indicates a dose and tissue-dependent effect that promotes macrophage 
accumulation with the highest exposure. Further the oxidative stress resulting from the 
50 and 150 µmol/kg exposure levels were sufficient to induce HO-1 and NQO1 
expression, which is associated with the cellular ant-oxidant response. Oxidative stress 
induces Nrf2 regulated anti-oxidant genes187, 188. This critical protective response is 
positively regulated by lifestyle factors such as diet through phytochemicals including 
flavonoids found in green tea, fruit and vegetables and through long-chain omega-3 
polyunsaturated fatty acids including docosahexaenoic acid (DHA)189, 190. Our in vitro 
work with epigallocatechin 3-gallate (EGCG), a green tea catechin, and oxidized DHA 
neuroprostanes has implicated Nrf2 as a critical protective mechanism in response to 
coplanar PCB-induced oxidative stress92, 129, 130. The protective nature of these dietary 
factors warrants further exploration in vivo.   
Previous work assessing different concentrations of PCB 126 have reported similar 
dose-dependent expression patterns of CYP and anti-oxidant response genes175, 191. 
PCB 126 exhibits a lower TEQ than TCDD, which induces more genes and exhibits 
greater toxicity18. However, low levels of exposure and the persistent nature of PCB 126 
is sufficient to alter the inflammatory and metabolic homeostasis, which promotes the 
development of atherosclerosis and other diseases associated with inflammation192. 
Together these changes indicate that acute exposure to 5 µmol PCB 126/kg body weight 
is sufficient to produce a moderate inflammatory response without overt toxicity and 
could be utilized for experimental designs that include, for example, nutritional 
modulation of PCB 126-induced metabolic insults. 
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PCB 126 Treatments
µmol/kg mg/kg
0.00 0.00
0.50 0.16
5.00 1.63
50.0 16.3
150 49.0
Table 3.1 Treatment doses 
shown in µmol/kg and mg/kg 
(ppm). Mice were treated via 
oral gavage. Each group of mice 
(n=6) received two doses of 
PCB 126 in tocopherol stripped 
safflower oil (vehicle, Dyets®) at 
the respective concentrations.  
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Serum Liver Adipose Muscle Kidney Lung
0.00 1.03 0.00 (0.00) 27.0 (0.28) 69.4 (0.71) 0.00 (0.00) 3.65 (0.04) 0.00 (0.00)
0.50 31.4 0.00 (0.00) 37.9 (11.9) 4.28 (1.34) 56.7 (17.8) 0.82 (0.26) 0.27 (0.08)
5.00 143 0.07 (0.09) 55.7 (79.9) 15.0 (21.6) 25.6 (36.7) 2.84 (4.08) 0.80 (1.15)
50.0 937 0.18 (1.67) 29.0 (272) 54.5 (510) 7.24 (67.8) 7.09 (66.4) 2.00 (18.8)
150 2148 0.40 (8.67) 22.0 (473) 56.0 (1200) 11.9 (256) 5.57 (119) 4.07 (87.4)
Group 
(μmol/kg)
Total 
Average 
Recovery 
(μg/g tissue)
Percentage of  Total PCB 126 by Treatment and Tissue                     
(average µg PCB 126/g tissue)
Table 3.2 PCB 126 tissue concentration and distributions represented by dose. 
Each group of mice received two doses of PCB 126 at the respective concentrations. 
Total average tissue concentration is represented in µg of PCB 126 per g of tissue 
and is the summation of the tissue averages from each group as a representation of 
body burden. The distribution of PCB 126 within the representative tissues was 
calculated as a percentage of the total for the respective concentrations. 
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PCB126 
Dose 
(µmol/kg)
PCB126 
Dose in 
ppm 
(mg/kg) 
Average 
Pre-
treament 
Weight (g)
Average 
Post-
treatment 
Weight (g)
Average 
Change 
in Weight 
(g)
Standard 
Deviation SEM P value
0.00 0.00 23.00 24.13 1.15 1.13 0.128 -
0.50 0.16 23.58 24.73 1.13 0.62 0.251 1.000
5.00 1.63 22.97 23.62 0.65 0.82 0.334 0.897
50.0 16.3 23.92 22.37 -1.55 1.71 0.700 <0.001
150 49.0 23.97 22.00 -1.97 0.55 0.226 <0.001
Table 3.3 Body weight was decreased by treatment with high-doses of PCB 
126. Average pre- and post-treatment whole body weights were calculated. The 
changes in body weight were calculated and were compared to vehicle treated 
animals (0.0 µmol/kg).  
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Figure 3.1 PCB 126 treatment causes a decrease in body weight at higher 
concentrations.  Mice were orally gavaged twice with PCB 126. Weights were 
recorded before and after treatment with PCB 126. The average weight change is 
expressed as a positive or negative change from baseline weight. Results are the 
mean ± SEM, n=6. Significantly different compared with 0.0 µmol/kg at *P < 0.001. 
(See also Table 3.3) 
49 
 
  
Figure 3.2 PCB 126 treatment at 5 µmol PCB 126/kg mouse causes a 
significant increase in liver wet weight compared to body weight. Liver weights 
were recorded after sacrifice and set over the final body weight to determine the 
ratio. Results are the mean ± SEM, n=6. Significantly different compared with 0.0 
µmol/kg at * P<0.001 and compared with 0.5 µmol/kg at + P < 0.05. 
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Figure 3.3 PCB 126 induced dose-dependent increases in 
Bax protein expression. Bax results are the mean ± SEM, n=6. 
Significantly different compared with 0.0 µmol/kg at *P<0.05 and 
0.5 µmol/kg at + P<0.05. 
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Figure 3.4 PCB 126 did not significantly increase the serum ALT 
levels. Alanine aminotransferase (ALT) results are the mean ± SEM 
P<0.05, n=6. 
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Figure 3.5 Expression of inflammatory markers increased following PCB 126 
exposure. (A) CYP1A1 mRNA results are significantly different compared with 0.0 
µmol/kg (Oil) at * P<0.005 and significantly different from 50 µmol/kg + P < 0.02. (B) 
For MCP-1, the 5.0 µmol/kg group was significantly different from 0.0 and 0.5 
µmol/kg treatments at * P<0.02. (C) VCAM-1 expression was significantly increased 
in the 50 and 150 µmol/kg treatments P≤0.001. (D) 5.0 µmol/kg PCB 126 treatment 
caused a significant increase in IL-6 expression, * P<0.05. 
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Figure 3.6 The highest dose, 150 µmol PCB 126/kg mouse, initiated infiltration 
of macrophages after acute exposure. F4/80 mRNA expression was significantly 
increased in the 150 µmol/kg treatment group, * P<0.03. 
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Figure 3.7 Anti-oxidant enzyme mRNA expression increased with higher 
concentrations of PCB 126. (A) HO-1 expression was significantly increased in the 
50 and 150 µmol/kg treatments, * P≤0.007. (B) NQO1 mRNA increased significantly 
over vehicle (0.0 µmol/kg) and 0.5 µmol/kg at * P<0.05. The 5.0 µmol/kg expression 
level was significantly less than 50 and 150 µmol/kg levels, + P < 0.001. 
Copyright © Katryn Elizabeth Eske 2013 
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Chapter Four: DHA feeding modulates the inflammatory profile of C57BL/6 mice 
exposed to coplanar PCB 126 
4.1 Synopsis 
Consumption of fish oil is associated with improved coronary health outcomes, but the 
mechanism of protection is not fully understood.  Environmental stressors, such as 
polychlorinated biphenyls (PCBs), contribute to the development of cardiovascular 
diseases like atherosclerosis.  We study the protective benefits of nutrients such as the 
polyunsaturated omega-3 fatty acids found in fish oil in reducing the inflammatory 
response to PCBs.  Higher consumption of fatty fish or fish oil supplementation has been 
associated with improved cardiac outcomes in high-risk patients193, 194.  To further our 
understanding of the mechanism by which the omega-3 fatty acid, docosahexaenoic 
acid (DHA), is protective, we fed C57BL/6 mice diets enriched in DHA (3% DHA/22% 
safflower oil in % kcal) or a safflower control diet for four weeks before administration of 
the coplanar PCB 126 via oral gavage at week five.  DHA feeding moderately attenuated 
serum expression of pro-inflammatory cytokines following PCB 126 gavage. CYP1A1 
mRNA expression was reduced in DHA-fed/PCB 126-treated mice. CYP1A1 activity 
promotes oxidative stress, yet 8-iso-prostaglandin 2 alpha (8-iso-PGF2α), a measure of 
tissue oxidative stress, was not changed by PCB 126. DHA monohydroxy lipoxygenase 
(LOX) metabolites were increased with DHA-enriched diet and compensatory decreases 
in omega-6 fatty acids and metabolites were observed. In DHA-fed mice, peroxisome 
proliferator-activated receptor gamma (PPARγ), a positive co-activator of Nrf2, had 
increased mRNA expression which indicate priming of the anti-oxidant response even in 
the absence of oxidative stress.  Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) mRNA 
was increased following DHA/PCB 126 treatment. Real time- PCR analysis revealed 
increased expression levels of Nrf2 activated anti-oxidant enzymes NAD(P)H 
dehydrogenase (quinone 1) (NQO1) and hemeoxygenase 1 (HO-1) in PCB treated mice 
on a DHA diet.  Liver samples were analyzed by microarray to examine the interactive 
effects of PCBs and DHA and identify potential pathways for future investigation. 
Together these data suggest that DHA promotes an anti-oxidant response in mice 
exposed to environmental pollutants such as PCBs. 
4.2 Introduction 
Inflammation is a key characteristic of many disorders including atherosclerosis, Type 2 
diabetes mellitus and obesity58, 195, 196.  Patients who suffer from a chronic inflammatory 
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disease state, such rheumatoid arthritis and diabetes, have an accelerated risk for 
vascular disease development56, 57, 197. Inflammation is a response to a range of stimuli 
which includes the oxidative stress caused by environmental pollutants and is linked by 
the nuclear factor kappa B (NFкB) signaling pathway which drives the expression of an 
array of genes including cytokines and adhesion molecules198. Coplanar PCBs, such as 
PCB 77 and PCB 126, initiate an oxidative stress response in the vascular endothelium, 
which disrupts barrier function and promotes the expression of adhesion molecules like 
vascular cell adhesion molecule 1 (VCAM1) and chemokines such as monocyte 
chemoattractant protein 1 (MCP-1)14, 125, 126. The inflammatory response that is initiated 
by coplanar PCBs is sensitive to fatty acid exposure. For example, the omega-6 fatty 
acid linoleic acid promotes endothelial inflammation199, 200, and increasing the ratio of 
omega-3 fatty acids attenuates this response16. Further, oxidized docosahexaenoic acid 
(DHA) neuroprostanes promote an anti-oxidant response to coplanar PCB-induced 
inflammation through activation of the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) 
pathway92.  Others have reported that the disruption of lipid rafts, called caveolae, by 
DHA prevents an oxidative stress response by displacing lipid raft-based signaling 
proteins201. Omega-3 fatty acids, especially those found in fish oil, are of interest in the 
treatment of inflammation based diseases, such as atherosclerosis.  
Fish oil supplementation has been a subject of much study as epidemiological data 
reveal lower rates of heart disease in populations such as the Japanese who have diets 
high in omega-3 fatty acids202. Many clinical trials have tested fish oil supplementation in 
cardiac patients, and some have concluded that supplementation following a cardiac 
event reduces secondary events94, 193.  A Finnish study compared the effects of fish 
consumption and exposure to pollutants on low-grade inflammation and indicators of 
vascular and metabolic health; insulin sensitivity was decreased in association with 
pollutant exposure while high omega-3 consumption was associated with lower serum 
interleukin-6 (IL-6), a marker of inflammation203. Though not conclusive, higher fish 
intake in the presence of higher pollutant exposure produced a null effect on plaque 
formation, indicating a compensatory effect203.  The long-chain omega-3 fatty acids, such 
as EPA and DHA which are found in fish oil, are reported to be more efficacious than α-
linolenic acid in the prevention of primary and secondary cardiac events194.  
The beneficial nature of long-chain, omega-3 fatty acids may be due in part to the 
generation of oxidized and enzymatically derived metabolites. Our observations of 
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oxidized-DHA A4/J4-neuroprostane support their role in the anti-oxidant response92. The 
research of the Morrow laboratory has demonstrated neuroprostane-derived protection 
from the LPS-induced NFкB signaling response and that oxidized long-chain omega-3 
fatty acids disrupt the Kelch-like ECH-associated protein 1 (Keap1) inhibition of Nrf2204, 
205. Further, their laboratory has detected the presence of oxidized long-chain fatty acids 
in vivo in brain, cerebrospinal fluid and small amounts in plasma204, 206. The 
enzymatically derived long-chain, omega-3 fatty acid metabolites include the resolvins 
and protectins, which promote macrophage clearance of the inflammatory 
polymorphonuclear neutrophils (PMNs), which is a critical step in the resolution of local 
inflammation207, 208. Protectins and resolvins are the products of lipoxygenase (LOX) and 
cycloxygenase (COX) metabolism of EPA and DHA, and the activity of these enzymes is 
part of the response to the inflammatory states associated with allergies, obesity, 
diabetes and cardiovascular disease102. In epithelial cells, resolvin E1 promotes the 
expression of CD55, which disrupts neutrophil interaction with intercellular adhesion 
molecule 1 (ICAM1) and reduces transepithelial migration209. Human aortic endothelial 
cells (HAECs) activated by TNF-α and exposed to protectin D1 expressed lower levels of 
the inflammatory cytokines MCP-1 and interleukin 8 (IL-8)208. Taken together, a diet 
enriched in long-chain, omega-3 fatty acids provides substrate for the generation of 
these metabolites which have great potential as protective mediators that intervene in 
the development of the inflammatory pathology associated with disease states such as 
atherosclerosis. In addition, the metabolic actions of long-chain omega-3 fatty acids, 
such as DHA, promote an anti-oxidant response that is critical in the presence of 
oxidative stress caused by coplanar PCBs and other inflammatory stimuli.  
Hypothesis and Rationale 
We hypothesize that long-chain omega-3 fatty acids can be protective by modulating the 
inflammatory profile in mice following exposure to coplanar PCB 126.  The protective 
nature of omega-3 fatty acids common in fish oil was tested in mice supplemented with 
dietary DHA and exposed to PCB 126.  To characterize the role of DHA in response to 
PCB 126-induced inflammation in C57BL/6 mice, we monitored changes in body 
composition and metabolic endpoints, measured fatty acid incorporation into animal 
tissues, and reviewed the shift in cytokine expression, DHA metabolite levels, and anti-
oxidant enzyme expression following PCB 126 challenge. We anticipate that the 
inflammatory environment will be shifted toward a pro-resolving phenotype.  
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4.3 Methods 
Reagents and Materials  
PCB 126 was obtained from AccuStandard (New Haven, CT). The Jackson Laboratory 
provided the C57BL/6 mice (Bar Harbor, MN).  Tocopherol-stripped safflower oil 
(vehicle) and specialized diet were obtained from Dyets (Bethlehem, PA). Reverse 
transcriptase reagents were purchased from Fisher Scientific (Waltham, MA). Western 
blotting reagents were obtained from BioExpress (Kaysville, UT).  Reagents used for 
mRNA isolation and qPCR were purchased from Life Technologies (Grand Island, NY). 
Animal Work 
Male C57BL/6 mice were housed and handled according to a protocol approved by the 
University of Kentucky IACUC. A summary of the experimental design is provided in 
Table 4.1. After acclimation, baseline body compositions were assessed by ECHO MRI, 
and animals were trained in the Techniplast cages from which were taken baseline 
urine, feces, and food consumption data. Following the baseline measurements, animals 
were fed a semi-purified safflower oil control diet (25%kcal fat, Table 4.2) or a DHA-
enriched diet for 4 weeks (3%kcalDHA/22%kcal safflower, Table 4.2)99, 210-212. Body 
composition was assessed by ECHO MRI at the end of the third week and after the first 
gavage. During the fourth week, animals were individually housed in the Techniplast 
cages and underwent a glucose tolerance test (GTT). During the final week, animals 
were gavaged on the first and seventh day with 5.0 μmol/kg of PCB 126. Following the 
initial gavage, the animals were assessed by Techniplast cage observation, GTT, and 
ECHO MRI. The final gavage was performed 24 h before the animals were sacrificed. 
Liver and adipose were collected and divided between storage in RNALater for mRNA 
extraction or flash frozen in liquid nitrogen. All tissues were stored at -80°C. Serum was 
collected by cardiac puncture, kept on ice, centrifuged to separate serum from red blood 
cells, aliquoted and stored at -80°C. Unless otherwise stated, all animals from a group 
were used in the analysis, n= 9 or 10.  
The ECHO MRI for body composition analysis was available through the support of the 
Center of Obesity and Cardiovascular Disease (COCVD) Center for Biomedical 
Research Excellence (COBRE) grant from the National Institute of General Medical 
Sciences (8 P20 GM103527-05) of the National Institutes of Health. Techniplast solo 
mouse metabolic cages were used to collect urine and feces and monitor individual food 
consumption. Mice were placed in individual metabolic cages with free access to water 
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and food for 24 h. Animals and diet were weighed before and after placement into the 
cage, and the mice were returned to their normal social housing environment.  
For the glucose tolerance test (GTT), animals were fasted for 6 h. Blood was collected 
from the tail vein by use of a 0.5 inch 27 gauge sterile needle and measured using a 
glucometer to record fasting blood glucose levels.  Mice were intraperitoneally (i.p.) 
injected with 20% sterile glucose solution (2 g dextrose in 10 mL of 0.9% saline solution) 
at 2 mg glucose/g body weight. For example, a 20 g mouse would receive 200 µL of 
20% glucose solution. Blood glucose levels were measured by glucometer at 15, 30, 60, 
and 120 minutes after glucose i.p. injection.   
Real Time - PCR 
Messenger RNA (mRNA) was isolated from homogenized liver tissues using the Trizol® 
method. Isolated mRNA was resuspended in RNA/DNAse free water and quantified 
using UV-vis spectroscopy at 260 nM.  Complementary DNA (cDNA) was made using 
Promega AMV Reverse Transcriptase (Madison, WI) and followed a modified Promega 
protocol. For cDNA synthesis, 1 µg of mRNA per 10 µL reaction volume was used. 
Water volume was adjusted for volume of 1 µg mRNA to a total of 4.95 µl/10 µL reaction 
volume, and mRNA was heat denatured at 70°C for 10 min. Reverse transcription was 
run using the following thermocycler protocol: 25°C for 10 min, 42°C for 60 min, 95°C for 
5 min and 4°C hold. RT-PCR was performed using SYBR® Green reagent and run on 
the 7300 Real Time PCR System (Life Technologies, Grand Island, NY)126. Primer 
sequences are found in Table 4.3.  
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Measurements in Serum 
Alanine Aminotransferase (ALT) ELISA 
 Serum was collected by cardiac puncture, incubated on ice and centrifuged for 15 min 
at 12,000 rpm and 4°C. Serum was collected and stored at -80°C.  Mouse alanine 
aminotransferase (ALT) ELISA kit (TSZ ELISA, Framingham, MA) was used to measure 
serum ALT levels. Serum was diluted 1:5 in assay Sample Solution, and the ELISA was 
performed according to manufacturer’s instructions.  Sample absorbances were 
measured at 450 nm using a SpectraMax M2 spectrophotometer (Molecular Devices, 
Sunnyvale, CA), and sample values were calculated from the standard curve using the 
SoftMax Pro 4.8 software (Molecular Devices, Sunnyvale, CA).  
 
Total Serum Cholesterol and Fast Protein Liquid Chromatography (FPLC) Analysis 
Total serum cholesterol was measured using the Wako Cholesterol E colorimetric assay 
(Wako Chemicals USA, Inc., #439-17501, Richmond, VA) and serum samples were 
diluted 1:25 in H2O (n = 4 or 5).  Fast Protein Liquid Chromatography (FPLC) was 
performed in collaboration with the laboratory of Dr. Allen Daugherty, University of 
Kentucky, using the Bio-Rad Biological DuoFlow System with BioFrac Fraction Collector 
and a Superose 6 10/300GL Column (GE Healthcare, #17-5172-01)213. Serum samples 
(n= 4 or 5) were eluted with a 1.0 mM EDTA/0.15 M NaCl/0.02% wt/vol Azide buffer 
solution and a total of thirty-two fractions were collected in Fraction Collection Tubes in a 
96-well rack (BioRad, #233-9390). Fractions were stored at 4°C for less than a week and 
analyzed for cholesterol content using the Wako Cholesterol E colorimetric assay.  Area 
under the curves (AUCs) and elution times were assessed using PeakFit software 
(Systat Software, Inc., San Jose, CA). The Center parameter was used as a proxy for 
elution time and lipoprotein fractions were classified using the following parameters: 0-15 
were VLDL, 16-20 were LDL/IDL, and 21-28 were HDL. C57BL/6 mice are 
normolipidemic mice214.  
Serum Cytokine Measurements 
Serum cytokines were analyzed using a mouse cytokine/chemokine 16X custom 
multiplex assay from Millipore (Milliplex MAP Kit, Billerica, MA) and run on a Bioplex 200 
system from Biorad (Hercules, CA). Frozen serum aliquots were selected from each 
group (n=5) and diluted 1:1 in Assay Buffer. Standards and reagents were prepared 
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according to manufacturer’s directions, and the assay was performed as stated in the 
manufacture’s protocol.  
Lipid, DHA Metabolite and Isoprostane Extraction  
Lipids, DHA metabolites and isoprostanes were assessed in collaboration with the 
laboratory of  Dr. Morris, University of Kentucky using a Shimadzu UFLC coupled with 
an ABI 4000-Qtrap hybrid linearion trap triple quadrupole MS.  
Tissue Lipid Extraction 
Frozen liver and adipose (20-30 mg, n= 9 or 10) was homogenized in 1 mL of methanol 
using 4 mm stainless steel ball bearings and a Geno/Grinder homogenizer (SPEX 
SamplePrep, Metuchen, NJ). Homogenized samples were transferred to 8 mL 
borosilicate glass tubes with Teflon cap, and 1 mL of MeOH was added to the 
homogenate. The following were added to each tube in sequence: 1 mL chloroform, 500 
µL of 0.1 M HCL, 50 µL of 1 µM C17 internal standard. Samples were vortexed for 5 min 
and were stored at 4°C for a minimum of 1 hr. After incubation, 1 mL of chloroform and 
1.3 mL of 0.1 M HCl was added to separate the phases. The samples were vortexed for 
5 min and centrifuged for 10 min at 4000 rpm. The lower phase was transferred to 4 mL 
screw cap vials with a Pasteur pipette. Care was taken to avoid the upper phase and the 
protein interface. Using N2 in a N2-evaporation system, the lower phase was evaporated 
to dryness. Each sample was resuspended in 100 µL of methanol which was split for the 
respective experiments: 10 µL for phosphate assay and 90 µL for derivitization and 
further processing. Samples were evaporated to dryness and stored at -20°C. Samples 
were resuspended in 100 µL of methanol for liver and for adipose 100 µL 
methanol:chloroform 1:1, loaded to autosampler vials and run on the LC/MS according 
to protocols described previously215. Samples were normalized to C17 and phosphate.  
DHA Metabolite and Isoprostane Extraction 
For solid phase extraction, approximately 30 mg of liver or adipose tissue (n= 9 or 10) 
was ground in 1 mL of 0.5% acetic acid in ethyl acetate:methanol (5:1 v/v). Each sample 
received 100 µL 10 µM isoprostane standards and 50 µL 1 µM DHA/EPA standards, 
were vortexed to mix, and were centrifuged for 10 min at room temperature and 2500 x 
g. Supernatants were transferred to a glass tube and dried under nitrogen. Dried 
samples were reconstituted in 200 µL of methanol, vortexed, diluted in 3 mL of 0.5% 
acetic acid and vortexed. Solid phase extraction columns (Supelco Supel Select HLB 
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SPE, 60 mg/3 mL SPE tube, #54182-U, Sigma Aldrich, St. Louis, MO) were 
preconditioned with 3 mL of methanol and 3 mL of 0.5% acetic acid. The samples were 
applied to the columns and washed with 3 mL of 0.5% acetic acid and 3 mL of 0.5% 
acetic acid with 20% methanol. Columns were dried for 5 min and samples were eluted 
into glass vials with 3 mL of methanol. Samples were dried under nitrogen and stored at 
-20°C. Samples were resuspended in 100 µL of methanol, loaded to autosampler vials 
and run on the LC/MS according to protocols described previously216-218.  Samples were 
normalized to internal standard and/or tissue weight.  
 
Microarray 
Microarray was performed in conjunction with University of Kentucky Microarray Core 
Facility using Affymetrix Genechip Mouse  Exon 1.0 ST Arrays (Affymetrix Genechips, 
Santa Clara, CA). Liver mRNA was isolated from tissues frozen in RNALater via the 
TRIzol® method.  RNA integrity number (RIN) values were measured in isolated mRNA 
samples. Samples from 3 mice were pooled and applied to one microarray chip with a 
total of 3 chips per treatment group representing nine total samples.  
Statistical analyses 
 Comparisons of data were made by two-way analysis of variance (ANOVA) followed by 
Tukey’s post-hoc testing using SigmaPlot 12.0 software (Systat Software, Inc., San 
Jose, CA). Due to the nature of our study, animals which did not receive DHA-enriched 
diet or did not receive PCB 126 treatment did not necessarily express detectible levels of 
DHA metabolites, inflammatory cytokines, etc. For this reason, certain data sets 
contained zero values that proved problematic for statistical assumptions associated 
with normality and variance made by parametric tests and variance for non-parametric 
tests. For example, the data associated with the DHA metabolite 14-HDHA failed both 
normality and variance tests because the safflower/vehicle group did not have 
detectable levels of this metabolite (Supplemental Figure 4.1a). In contrast, 4-HDHA was 
produced by all groups and failed to reject the statistical assumption tests (Supplemental 
Figure 4.1b). In observing the data for 14-HDHA, the levels of 14-DHDA are increased 
for DHA-fed mice, and sufficient differences beteen the groups are present for both 
parametric and non-parametric analyses detected overall differences between diets. For 
the parametric two-way ANOVA, the overall difference between diets had p<0.001 with 
statistically significant differences between diets in the vehicle treatments (p<0.001) and 
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PCB treatments (p= 0.029). Following consultation with the University of Kentucky 
Department of Statistics, it was determined that the parametric two-way ANOVA was the 
most appropriate method for determining the statistical differences for these data. 
Statistical probability of p0.05 was considered significant.  
Microarray data were analyzed in collaboration with the University of Kentucky, 
Department of Statistics. Affymetrix MAS 5 was used to normalization the chip 
expression levels and to determine probe set expression measurements.  For quality 
control, distributions of gene expression for each chip and correlations between chips 
were confirmed.  Each probe set was fit to a 2 × 2 ANOVA model, and changes in gene 
expression were determined using overall significance of the model with a significant 
difference of p ≤ 0.01.  Increases and decreases in expression between treatment group 
pairs were determined by t-tests. The resulting gene list was sorted for overall 
significance and upregulated or downregulated gene expression between the 
safflower/PCB 126 treated and the DHA/PCB 126 treated groups. Supplemental data 
was generated by sorting for significant difference (p ≤ 0.01) in the safflower-fed groups.  
4.4 Results 
Food consumption and body composition 
Following baseline measurements, animals were placed on safflower control diet and 
DHA-enriched diet. Assessment of food consumption during 24 h isolation in the 
Techniplast cages at weeks four and five did not reveal statistical differences between 
diet or treatment (Figure 4.1). Animals fed diet enriched in DHA had significant increases 
in DHA and eicosapentaenoic acid (EPA) free fatty acid levels in both adipose and liver 
(Figure 4.2) but not in the serum of our DHA-fed animals. Arachidonic acid (AA) free 
fatty acid levels were decreased in DHA-fed animals compared to safflower-fed animals. 
PCB treatment significantly decreased tissue free fatty acid content AA levels in adipose 
(Figure 4.2a) and EPA levels in liver (Figure 4.2b). In addition, body weights were not 
different between groups prior to PCB gavage (Figure 4.3). Following treatment with 5 
µmol PCB 126/kg body weight, PCB 126 treated mice weighed significantly more than 
vehicle treated mice (Figure 4.3, Figure 4.4). The PCB 126 treated mice had diet 
independent increases in lean mass, but fat mass was not changed between groups 
(Figure 4.4). We attributed this increase in lean mass in part to the PCB 126-induced 
increase in liver weight to body weight ratio (Figure 4.5). The increase in liver size 
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demonstrated a clear response to the environmental toxicant; however, serum ALT 
levels were not increased by PCB 126 treatment (Figure 4.6). We concluded from this 
that there was no significant liver damage or cell death following this acute exposure to 
PCB 126.  
Metabolic assessment 
In order to gain a complete overview of the diet and toxicant interaction, we assessed 
basic metabolic parameters including glucose tolerance and serum cholesterol with 
lipoprotein profiles. Prior to treatment with PCB 126, glucose challenge did not result in 
significant changes in glucose clearance (Figure 4.7a&b). However, following a single 
gavage with 5 µmol/ kg of PCB 126, mice on a DHA-enriched diet had a significantly 
lower area under the curve (AUC) response to glucose challenge than both controls and 
safflower/PCB 126-treated mice (Figure4.7d). During the glucose tolerance test (GTT), 
DHA/PCB 126-treated animals had significantly lower glucose levels by 60 min, and at 
120 min, mice receiving PCB 126 had significantly lower glucose levels than dietary 
controls (Figure 4.7c). Similarly, total serum cholesterol was decreased in PCB 126-
treated mice (Figure 4.8).  DHA-enriched diet produced an overall decrease in the serum 
cholesterol levels (Figure 4.8). The FPLC data revealed major changes in the high 
density lipoprotein (HDL) fraction with overall cholesterol decreases in response to 
dietary DHA and PCB 126 treatment (Figure 4.9). The safflower/PCB 126 treated 
animals had lower very low density lipoprotein (VLDL) cholesterol compared to 
safflower/control mice (Figure 4.9b).  Similarly, all the VLDL, low density 
lipoprotein/intermediate density lipoprotein (LDL/IDL), and HDL fractions of the 
DHA/PCB 126 treated animals had lower levels of cholesterol compared to the 
DHA/control treated animals.  Liver metabolic function was clearly affected by the 
presence of both dietary DHA and coplanar PCB 126. To assess the inflammatory and 
anti-oxidant response, we tested serum and liver for changes in markers of inflammation 
and oxidative stress.   
Markers of inflammation and oxidative stress 
Serum levels of sixteen cytokines were measured using the Milleplex MAP Kit for mouse 
cytokines and chemokines.  Ten of the sixteen cytokines had detectable protein levels 
and were assessed for differences (Figure 4.10). Granulocyte colony-stimulating factor 
(G-CSF) and IL-6 were significantly increased only in the safflower/PCB 126 treated 
animals (Figure 4.10a&c). MCP-1 and MIG, mitokine induced by gamma-interferon or 
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CXCL9, were increased by PCB 126 in both diets (Figure 4.10f&h). Interleukin-12 (p70) 
(IL-12 p70) demonstrated an interactive effect between diet and treatment (Figure 
4.10d). The safflower/PCB 126 treated group was significantly increased; in comparison, 
the DHA/PCB 126 treated group was significantly decreased. The other cytokines were 
not significantly affected by diet or PCB 126 treatment including interleukin-1 alpha (IL-
1α), keratinocyte chemoattrant (KC), macrophage colony-stimulating factor (M-CSF), 
macrophage inflammatory protein 1 alpha (MIP-1α) and  macrophage inflammatory 
protein 1 beta (MIP-1β) (Figure 4.12b,e,g,i,&j, respectively). The cytokine protein 
expression changes implicate a moderate inflammatory response to PCB 126 treatment 
with a slightly higher response in safflower fed animals. With an exception for IL-12 
expression, dietary DHA did not alter the cytokine profile to the extent that we had 
hypothesized. The lack of significant data from the other cytokines may be attributed in 
part to the high variability between animals in each group.  There was moderate 
attenuation of the PCB 126-induced serum cytokine levels in mice fed a DHA-enriched 
diet when compared to the overall response of safflower/PCB 126 treated mice. 
 The liver is the primary site for toxicant metabolism and excretion. We expected a 
strong inflammatory response given the metabolic changes that we observed in glucose 
tolerance and lipoprotein cholesterol levels. Cytochrome P450 1A1 (CYP1A1) is an 
important Phase I metabolizing enzyme that responds to aryl hydrocarbon receptor 
(AhR) induction by PCB 126 and other dioxin-like molecules124.  CYP1A1 mRNA 
expression was significantly increased above dietary controls, but DHA-fed animals had 
lower CYP1A1 expression than their safflower-fed counterparts (Figure 4.11a). In 
contrast to the serum protein expression (Figure 4.10c), IL-6 had a significant mRNA 
increase only in the DHA/PCB 126-treated animals (Figure 4.11b). MCP-1 mRNA was 
increase following PCB treatment in both diets which is similar to the protein expression 
levels (Figures 4.11c and 4.10f, respectively); however, the fold change in the DHA/PCB 
126-treated animals was greater that the safflower/PCB 126-treated animals. In contrast, 
VCAM1 expression was not affected by either diet or treatment with PCB 126 (Figure 
4.11d). The overall expression patterns in Figure 4.11 resemble the moderate 
inflammatory profile of 5 µmol PCB 126/kg body weight that was observed in chapter 
three (Figure 3.5). Given the decrease in CYP1A1 mRNA expression in DHA-fed mice, 
we had expected to observe compensatory decreases in the inflammatory profile.  
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CYP1A1 is prone to enzyme uncoupling during the metabolism of coplanar PCBs; the 
consequence of the unsuccessful reaction is the release of superoxide which increases 
cellular oxidative stress38, 39, 73. 8-iso-prostaglandin 2 alpha (8-iso-PGF2α) is an 
arachidonic acid metabolite that serves as an in vivo marker of oxidative stress219-221. 
When measured in adipose and liver, PCB 126 did not induce significant increases in 
the relative levels of 8-iso-PGF2α, but in the DHA/PCB 126 treated animals, there was a 
significant decrease in adipose levels compared to DHA diet control (Figure 4.12).  The 
only change in the 8-iso-PGF2α levels implicated a baseline decrease in oxidative stress 
for animals exposed to both DHA and PCB 126.  
DHA Metabolism Products 
The literature indicates that metabolites of DHA, such as the protectins, promote the 
resolution of an inflammatory state222. Adipose and liver tissues were assessed for the 
presence of hydroxydocosahexaenoic acid (HDHA) lipoxygenanse (LOX) derived 
metabolites (see also Figure 1.2). Tissue levels of DHA and EPA were verified in these 
sample preparations with significant diet-dependent increases in both fatty acids (Figure 
4.13a and 4.14a). The levels of DHA and EPA were significantly decreased in adipose 
following treatment with PCB 126 (Figure 4.13a); a similar trend was observed in the 
liver (Figure 4.14a). 5-LOX generates leukotriene E4, an arachidonic acid metabolite and 
DHA-derived 4-HDHA and 7-HDHA222-224. The generation of these metabolites in both 
adipose and liver was not altered by either diet or PCB treatment (Figure 4.13b and 
4.14b, respectively). Tissue levels of 12-LOX and 15-LOX HDHA metabolites were 
significantly increased in response to administration of dietary DHA but not PCB 126 
(Figures 4.13c and 4.14c).  In particular, 14-HDHA is the monohydroxy marker from the 
12-LOX pathway that generates maresin 1222.  Protectin D1 (PD1) biosynthesis is 
indicated by the presence of 17-hydroxyl-docosa-4Z,7Z,10Z,13Z,15E,19Z-hexaenoic 
acid (17-HDHA)207, and 17S-HDHA is the product of DHA metabolism by 15-
lipoxygenase (15-LOX)102. In comparison to the overall trend observed in the DHA-
lipoxygenase metabolites, the 15-LOX products derived from the omega-6 fatty acid 
linoleic acid, 9-HODE and 13-HODE, were increased significantly only in the 
safflower/PCB 126 groups 225, and there was a significant difference in metabolite levels 
between diets (Figure 4.13d and 4.14d). The implication is that there is a compensatory 
shift from omega-6 to omega-3 fatty acid substrate following consumption of a DHA-
enriched diet.  
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Anti-oxidant response 
We would expect a minimal anti-oxidant response to PCB 126 given the unchanged 
oxidative stress levels of 8-iso-PGF2α following treatment (Figure 4.12).  Interestingly, the 
anti-oxidant profile would suggest that the underlying anti-oxidant phenotype is changed 
by dietary DHA. The anti-inflammatory arachidonic acid metabolite, 15-deoxy-∆12,14-PGJ2 
with an m/z of 315.2 to 217.1, was significantly increased only in the DHA-fed control 
group (Figure 4.15a). 15-deoxy-∆12,14-PGJ2 is the dehydration product of cyclooxygenase 
derived PGD2 and an activator of  PPAR and Nrf2 226, 227.  PPAR gamma isoform 2 
(PPARγ2) also had increased expression in the DHA control group (Figure 4.15b), which 
was attributed to the heightened levels of 15-deoxy-∆12,14-PGJ2228.  In contrast, exposure 
to PCB 126 significantly reduced the level of 15-deoxy-∆12,14-PGJ2 and PPARγ2 to levels 
equivalent to the safflower-fed groups (Figure 4.15a&b).  Nrf2, the nuclear transcription 
factor that regulates anti-oxidant response, was increased in mRNA of animals exposed 
to PCB 126 (Figure 4.15c). Further, the Nrf2 regulatory element Keap1 had reduced 
expression in the DHA-fed/PCB 126 treated animals (Figure 4.15d). In response to the 
changes in Nrf2 and Keap1, the anti-oxidant genes HO-1 and NQO1 were both 
significantly increased following PCB 126 exposure, but the DHA/PCB 126 group had 
higher NQO1 expression than the safflower/PCB 126 group (Figure 4.15e&f). Together, 
these data indicate that the presence of dietary DHA sensitizes the anti-oxidant 
response by dampening Nrf2 regulation to promote a heightened anti-oxidant response 
to moderate inflammation induced by PCB 126.    
Microarray overview  
Of the 35,000 probes assessed by the Agilent mouse chip, 624 probes had a significant 
interaction between PCB 126 treatment and dietary feeding, pvalue≤0.01. Of these genes, 
495 have known functions and were sorted for increased or decreased expression 
between the safflower/PCB 126 treated and the DHA/PCB 126 treated groups. The 
resulting genes sets were applied to the DAVID© software system and were sorted for 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway interactions229. The major 
metabolic pathways that were down-regulated in animals fed a DHA-enriched diet and 
exposed to PCB 126 when compared to the safflower/PCB 126 group include the 
glycine, serine, threonine metabolism pathway, the terpenoid backbone biosynthesis 
pathway, the proteasome pathway, and the porphyrin and chlorypyll metabolism 
pathway (Table 4.4).  These are indicators that the cell modified the rate of enzyme 
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metabolism to modulate the xenobiotic response which includes Phase I and II enzymes 
and the anti-oxidant response enzymes. The gene expression of control animals, e.g. 
safflower fed animals with or without 5 µmol/kg PCB 126 treatment, were compared; 
genes associated with biosynthesis of fatty acids and steroid hormones, insulin 
signaling, PPAR (peroxisome proliferator-activated receptor) signaling, and drug 
metabolism  were down-regulated (Supplemental Table 4.1) Major upregulated 
pathways in the DHA/PCB 126 group  include several pathways related to the cytotoxic 
response including cytokine/chemokine receptor interactions, chemokine and calcium 
signaling pathways, and adhesion molecule expression (Table 4.5). Increased 
expression was detected for genes associated with hematopoietic cell lineages and 
melanoma. For the direct comparison of safflower oil-fed animals with or without PCB 
126 treatment, expression of genes associated with xenobiotic metabolism, energy 
metabolism, and certain cancers were increased by PCB 126 treatment (Supplemental 
Table 4.2).  
4.5 Discussion 
Others have demonstrated the incorporation of omega-3 fatty acids into tissues after 
only three weeks of feeding and have observed relative decreases in arachidonic acid 
with increased dietary DHA or EPA, which are similar to our observations230. The DHA-
enriched algal oil, derived from Crypthecodinium cohnii , a microalga, that was used in 
our diet carried the fatty acids primarily in triglyceride form231. The DHASCO product 
contains minor constituents (5%) which are not triglycerides; these include tocopherols 
and other phenolic compounds, which promote the stability of the DHASCO product in 
various light and oxidizing conditions232.  In addition, fish bioaccummulate PCBs, which 
makes fish oil a potential source of pollutant exposure233. This is not a concern for the 
microalgal oil.  In a 72 h study of omega-3 fatty acid incorporation in plasma 
phospholipids, natural oils had the highest incorporation level followed by re-esterified 
triglycerides < ethyl esters234. The highest omega-3 plasma levels were achieved at 24 
hr post-supplementation and no differences were observed between EPA and DHA 
incorporation. In a study comparing healthy young and elderly subjects who consumed a 
meal containing 13C-DHA, the total omega-3 lipid profile increased at 24 h, but the 
triglyceride and free fatty acid profiles for 13C-DHA peaked at 4 h235. These data along 
with our observations indicate that long chain, omega-3 fatty acids have relatively short 
half-lives in plasma compared to tissues. The DHASCO product in our diet contained 
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negligible levels of EPA, <0.03% of the fat content, yet EPA tissue levels were increased 
following DHA feeding (Figure 4.2). Liver peroxisomes retroconvert DHA to EPA236. 
Retroconversion of DHA to EPA was observed at an average rate of 9.4% in human 
subjects receiving DHA supplementation for six weeks237. These findings were confirmed 
in a study of post-menopausal women, and interestingly, those who received hormone 
replacement therapy had lower rates of retroconversion, which was attributed to possible 
estrogen-mediated changes in both peroxisomal and mitochondrial  β-oxidation238.  As 
discussed in chapter three, coplanar PCB 126 toxicity mediates an increase in liver 
protein content179, which is supported both by our observations of total and lean body 
mass increases resulting in significant increases in liver to body weight ratio (Figures 
4.3-4.5). Further, as in chapter three, we did not detect toxicant-induced increases in 
serum ALT levels (Figure 4.6). 
The metabolic changes observed in this study present some interesting points for 
discussion. Our glucose tolerance data is in keeping with other reports of heightened 
insulin sensitivity in obese mice fed omega-3 fatty acids239 (Figure 4.7). Both PCBs and 
obesity promote a certain level of inflammatory stress240. DHA metabolites have been 
studied for their similar binding potentials to thiazolidinediones and may promote insulin 
sensitization through PPAR activation103, 241. Interestingly, changes to insulin sensitivity 
are only observed following the stress of PCB treatment indicating the formation of 
unidentified DHA oxidation products that activate PPAR103, 242.   In addition, IL-6 is a 
critical mediator in adiponectin induced insulin sensitivity243. IL-6 mRNA levels were 
significantly increased in the DHA/PCB 126 treatment group in which heightened 
sensitivity was observed (Figure 4.11b). Cholesterol levels are affected by both the 
presence of PCB 126 and DHA diet. In contrast to our data, significant increases in total 
and HDL cholesterol have been reported in rats65. In a PCB 126 dosing study, also in 
rats, investigators observed both increases in cholesterol and decreases in serum 
glucose levels following exposure to 0.1 ppm PCB 126 for thirteen weeks244. These 
studies used different exposure routes and dosing models but assessed the outcome of 
chronic PCB 126 exposure as opposed to the acute nature of this study. We previously 
reported that a high fat, omega-6 fatty acid-enriched diet increased genes involved in 
triglyceride synthesis, fatty acid metabolism and cholesterol catabolism which was 
reversed following coplanar PCB 77 exposure in C57BL/6 mice245. The contribution of 
dietary DHA to the observed reduction in cholesterol is supported by studies that 
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suggest that dietary omega-3 fatty acids are suppressors of sterol-regulatory element-
binding proteins (SREBPs) and 3-hydroxy-3-methylglutaryl-Coenzyme A reductase 
(HMGCR), which are both critical to cholesterol production246, 247 (Figures 4.8 and 4.9).  
Interestingly, the cytokine expression pattern reveals moderate attenuation by DHA diet 
(Figure 4.10). Of the ten cytokines, five were significantly increased in the safflower/PCB 
126 group when compared to diet control. In contrast, only two, MCP-1 and MIG, were 
significantly increased in the DHA/PCB 126 group compared to DHA diet control. Our 
data demonstrates increased MCP-1 expression in both the cytokine assay and mRNA 
(Figure 4.10f and 4.11c). This observation contrasts with our in vitro findings in which 
PCB 77-induced MCP-1 expression is attenuated by oxidized DHA neuroprostanes92. 
Other groups have demonstrated similar findings with DHA or EPA248 and oxidized 
EPA249 in which NFкB activation of MCP-1 expression was mitigated in a PPARγ- or 
PPARα -dependent manner, respectively. The omega-3 oxidation products have been 
implicated in PPAR activation63, and our findings indicate increases in enzymatically 
produced DHA metabolites in the plasma or liver which suggest an environment where 
oxidized metabolites may be formed.  IL-12 (p70) was the only cytokine in which the 
DHA/PCB 126 group levels were significantly less than the safflower/PCB 126 group 
levels (Figure 4.10d). IL-12 stimulates interferon gamma (INF-γ) secretion by natural 
killer and T helper cells and facilitates the transition from the innate immune response to 
the adaptive immune response250. In dendritic cells, DHA inhibits NFкB-induced 
expression of IL-12 by activating PPARγ100. In protein, IL-6 was increased only in the 
safflower/PCB 126 treatment group (Figure 4.10c); in contrast, the DHA/PCB 126 group 
had increased in IL-6 mRNA expression (Figure 4.11b).   Data from a study of allergic 
lung inflammation reported heterogeneity within the inflammatory endpoints as well. 
Following ovalbumin challenge, they observed that EPA and DHA-fed mice produced 
high IL-5 and IL-13 levels while suppressing F2-isoprostanes99.  
The formation of LTE4, 4-HDHA and 7-HDHA metabolites were not altered by either 
DHA-enriched diet or PCB 126, which implicates minimal activity of 5-LOX in both liver 
and adipose (Figures 4.13b and 4.14b). Phospholipids that contain DHA have been 
reported to inhibit 5-LOX activity251. As a result, we would have expected altered 
metabolite generation in DHA-fed animals. Others have found that the omega-3 to 
omega-6 ratio and the total amount of dietary fat alter the leukotriene levels252. High fat 
diet (20% fat) alone reduces leukotriene levels, and animals fed a high fat diet require a 
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high ratio of omega-3 to omega-6 fatty acids to observe a decrease in inflammation-
induced LTE4 levels252. We have reported that the ratio of omega-3 to omega-6 fatty 
acids influences the inflammatory response to coplanar PCB-induced inflammation16. 
Together these data suggest that at 25% kcal the fat content in our diet was sufficient to 
alter leukotriene and other eicosanoid levels and the 3% kcal DHA enrichment was not 
robust enough to mitigate the inflammatory response to PCB 126. We did not observe 
overall changes in eicosanoid metabolites as demonstrated by the 8-iso-PGF2α data, a 
phenomena which is supported by the insight that a high fat diet suppress the 
eicosanoid levels and a low omega-3 to omega-6 ratio with high fat diet is inefficacious 
in altering the inflammatory response Figure 4.12). Despite the impact of this 
observation on our findings, 3% kcal from DHA altered tissue fatty acid content and was 
sufficient for DHA monohydroxy metabolite formation (Figures 4.2, 4.13 and 4.14).  
The omega-6 metabolites 9-HODE, 13-HODE and 15-deoxy-∆12,14-PGJ2 are 
endogenous PPARγ ligands and as such contribute to PPAR-activated vascular 
remodeling, vasoprotection and anti-inflammatory potential253 (figures 4.13d, 4.13d and 
4.15a). 15-deoxy-∆12,14-PGJ2 promotes Nrf2 activation by binding to the intervening 
region of Keap1and facilitating the release of Nrf2227. Similarly, the oxidized DHA and 
EPA products have potential as nuclear receptor activators of both Nrf2 and PPAR92, 249. 
Resolvin E1 is also a potent PPARγ inducer102, 239. Our DHA control mRNA data 
supports increased expression of PPARγ2 (Figure 4.15b), and the changes in glucose 
clearance in the DHA/PCB 126 treated mice support PPARγ activity102, 239, 246.  PPARγ 
has had a controversial role in the field of DHA metabolite activity. Some have 
demonstrated that the oxidized DHA neuroprostanes exhibited anti-oxidant properties 
independent of the PPARs204. In contrast, the structural compatibility and the PPARγ 
transactivation potency of DHA oxidation products have been reported103. Our research 
supports the role of PPARs in the attenuation of PCB-induced inflammation254, 255. DHA 
metabolite interaction with Nrf2 has not been well characterized. In the DHA/PCB 126 
treated group, we observe a trend toward increased anti-oxidant response due to 
reduced Keap1 expression and heighted NQO1 expression, which cannot be correlated 
to an increase in the oxidative stress marker, 8-iso-PGF2α (Figures 4.15 and 4.12, 
respectively). Others have demonstrated in vitro with 3T3-L1 cells that EPA and DHA 
are protective against hydrogen peroxide-derived oxidative stress through Nrf2-
dependent anti-oxidant gene expression, an effect which is attenuated by Nrf2 
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silencing104. Of interest to us, the promoter regions of Nrf2 and PPARγ contain the 
alternate’s binding elements256. By extension, the heightened levels of PPARγ2 prior to 
PCB exposure would prime the hepatocytes for increased Nrf2 expression after PCB 
challenge (Figure 4.15).  
The microarray data support the idea that the enzymatic response is selectively 
regulated to sustain xenobiotic clearance and anti-oxidant enzyme activity when 
comparing safflower/PCB 126 and DHA/PCB 126 treatment groups. For example, 
porphyrins are intermediates in heme biosynthesis, and the genes included in this 
pathway, such as hydroxymethylbilane synthase (HMBS, also known as porphobilinogen 
deaminase) are essential to heme formation and the production of oxidative stress 
inducing cytochrome P450’s257. The attenuated level of CYP1A1 is supported by the 
suppression of the porphyrin metabolism pathway (Figure 4.11a).  Further, it is not 
surprising that proteasome pathway genes are decreased to regulate xenobiotic 
response. Oxidative stress conditions modify the efficacy of specific proteasomal 
activities which ensures the resolution of inflammation through inhibition of the NFкB 
response and the support of the anti-oxidant response through sustained Keap1 
degradation (Figure 4.15c&d)258.  The reduced expression of proteasome regulated 
genes supports the observed increase in liver protein content259, 260.  In addition, the 
inhibition of proteasomes has been attributed to a decrease in cholesterol261. Similarly, 
products of the terpenoid backbone biosynthesis pathway feed into cholesterol 
biosynthesis, which is reduced in this model262.  The suppression of these two pathways 
supports a mechanism that explains the reduction in total and specifically HDL 
cholesterol levels (Figures 4.8&4.9, respectively). The KEGG pathways associated with 
increased gene expression in the safflower/PCB 126 and DHA/PCB 126 treatment 
groups (Table 4.5) indicate subtle changes in the inflammatory response including 
higher expression of cytokine receptors and adhesion molecules including VCAM1 
expression, which was unchanged in the mRNA. For comparison, we assessed changes 
in the safflower diet response following PCB 126 exposure.   
Animals fed the safflower oil control diet and exposed to  5 µmol/kg PCB 126 exhibited 
dysregulation of a variety of metabolic processes (Supplemental Tables  4.1 and 4.2). 
For example, the microarray indicates suppression of acyl-CoA synthetase 1 (ACSL1) in 
control diet, PCB 126-treated animals (Supplemental Table 4.1). ACSL1 is associated 
with the PPAR signaling pathway and plays a role in both fatty acid efflux and insulin-
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mediated glucose uptake263, which supports the changes indicated by the microarray in 
the insulin signaling pathway and links the PPAR family with metabolic homeostasis264. 
Treatmen with PCB 126 decreases in the expression of  certain CYP enzymes including 
constitutively expressed CYP3A25265.  On the other hand, PCB 126 activation of the 
AhR induces the CYP1 family, including CYP1A1 and CYP1B1 (Supplemental Table 
4.2). Upregulated genes from the safflower diet groups indicates expression changes  in 
KEGG pathways associated with colorectal, pancreatic, and small cell lung cancer. 
Sustained activation of the AhR induces gene expression that potentiates the induction 
of cancer266. In a two-year chronic exposure study conducted by the National Toxicology 
Program (NTP), rats exposed to PCB 126 developed cancerous lesions173. Further, AhR 
activation promotes increased expression of Phase II metabolizing enzymes including  
glutathionine S- transferases and UDP- glucuronosyltransferases35. The gene 
expression changes in safflower-fed mice acutely exposed to PCB 126 are sufficient to 
disrupt a variety of cellular processes and initiate an inflammatory response. 
Omega-3 fatty acids may modulate the cellular response through several mechanisms 
including changing the membrane signaling capacity by alterations in the membrane 
structure, antagonizing signaling through key receptors, or activating critical cellular 
response mechanisms96. The data presented here demonstrate a shift in the 
inflammatory response and implicate activation of key anti-oxidant pathways which may 
be linked to the generation of DHA metabolites (Figure 4.16). Long-chain, omega-3 fatty 
acids also selectively alter the composition of membrane lipid rafts, by which they may 
reduce the pro-inflammatory potential of toxicants, such as coplanar PCBs267, 268. In 
chapter five, we will explore this third aspect of the inflammatory pathway by studying 
the activation of lipid raft-based signaling molecules.  
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Table 4.1 Experimental design.  
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Table 4.2 Control and DHA-enriched diet compositions. Semi-purified diets 
were manufactured by Dyets (Bethlehem, PA). Dietary compositions represent 
the composition for one kilogram of diet. The DHASCO product was generously 
provided by Martek Biosciences Corporation (Columbia, MD). The diets were 
matched for kilocalorie composition.  
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Table 4.3 Relative Real Time-PCR sequences. 
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Figure 4.1 Neither diet nor PCB 126 treatment caused significant 
differences in food consumption. (A) Pre-treatment food consumption 
averages based on animals individually housed in urine/feces collection 
cages for 24 hr, and (B) food consumption following initial gavage with 5 
µmol PCB 126/kg body weight from animals housed in urine/feces 
collection cages. 
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Figure 4.2 DHA-enriched dietary feeding promotes accumulation of 
DHA and EPA in both (A) adipose and (B) liver tissues.  Both tissues 
have a significant overall increase in free fatty acids between diets for 
EPA and DHA and an overall significant decrease in arachidonic acid 
(AA). There is an overall effect of PCB 126 treatment on adipose AA 
fatty acid levels and liver EPA fatty acid levels. A difference was 
detected between safflower/PCB 126 and DHA/PCB 126 treatments * 
pvalue <0.05, and a difference was detected between safflower/saline and 
DHA/saline treatments, + pvalue < 0.05. Significant differences between 
DHA/saline and DHA/PCB 126 are represented by $ pvalue<0.05. 
Significant differences between safflower/saline and safflower/PCB 126 
are represented by # pvalue<0.05. Overall difference between dietary 
feeding is represented by a bar.  
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Figure 4.3 Body weights were affected by treatment but not by diet. Control 
safflower oil diet is represented by black circles and a dashed line, and control 
safflower oil diet with PCB 126 treatment is represented by open circles with a 
dashed line. DHA diet only is represented by black squares and a solid line, and 
DHA-fed, PCB 126 treated animals are represented by open triangles and a solid 
line. Significant differences in body weight were observed following treatment with 
PCB 126 regardless of diet, *pvalue <0.05 significantly different from treatment 
controls of both diets. 
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Figure 4.4 Body compositions were affected by PCB 126 treatment 
but not by diet. (A) Total body mass was significantly increased 
following PCB 126 treatment. (B) Fat composition was not affected by 
PCB 126 treatment. (C) Lean body composition was significantly 
increased in the groups receiving PCB 126 treatment. Significantly 
difference found when compared to their respective treatment controls, 
*pvalue <0.05. 
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Figure 4.5 Liver weight to body weight ratio is increased with PCB 
126 treatment. Liver weight divided by total body weight in the PCB 126 
treated animals was significantly increased when compared to their 
respective treatment controls, *pvalue <0.05. 
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Figure 4.6 PCB 126 did not significantly increase the serum ALT 
levels. Alanine aminotransferase (ALT) results are the mean + SEM 
pvalue <0.05, n=5. 
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Figure 4.8 Treatment with PCB 126 decreases total serum 
cholesterol. Total serum cholesterol (mg/dL) in the PCB 126 treated 
animals was significantly decreased when compared to their respective 
treatment controls, * pvalue <0.001, and an overall difference was 
detected between diets, + pvalue = 0.032, with DHA/control being 
significantly less than Safflower/control, # pvalue = 0.01, n = 4 or 5.  
87 
 
  Figure 4.9 Acute exposure to PCB 126 reduces lipoprotein cholesterol 
content in C57BL/6 mice. (A) Average FPLC chromatograms representing 
cholesterol distribution within the lipoprotein fraction for normolipodemic 
C57BL/6 mice. (B) Significant overall differences were observed between 
PCB 126-treated and control animals. Differences between safflower/control 
and safflower/PCB 126 treatment were designated by # pvalue<0.05. 
Differences between in DHA/control and DHA/PCB 126 were designated by 
$ pvalue<0.05. HDL was significantly decreased when comparing 
safflower/control and DHA/control, + pvalue <0.05, and an overall difference 
was detected between diets in the HDL lipoprotein fraction, * pvalue< 0.05, n = 
4 or 5.  
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Figure 4.10 
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  Figure 4.10 Treatment with PCB 126 induces cytokine expression 
in serum with a trend toward increased expression in safflower fed 
mice. Overall differences between PCB 126 and vehicle treatment were 
found for (A) G-CSF, (C) IL-6, (F) MCP-1, and (H) MIG. (A) G-CSF and 
(C) IL-6 were significantly increased only in the safflower/PCB 126 
treated group. (D) IL-12 (p70) had an interactive effect between diet and 
treatment with significant differences between safflower/PCB 126 and 
both safflower/vehicle and DHA/PCB 126. (F) MCP-1 and (H) MIG were 
significantly increased for both PCB treated groups when compared to 
their respective dietary controls. There were no significant differences in 
cytokine expression for (B) IL-1α, (E) KC, (G) M-CSF, (I) MIP-1α, and 
(J) MIP-1β. Significant differences between safflower/saline and 
safflower/PCB 126 are represented by # pvalue<0.05. Differences 
detected between safflower/PCB 126 and DHA/PCB 126 treatments are 
represented by * pvalue <0.05, and significant differences between 
DHA/saline and DHA/PCB 126 are represented by $ pvalue<0.05, n=5.  
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Figure 4.11 PCB 126 promotes an inflammatory response in 
acutely exposed mice. Overall differences between PCB 126 and 
vehicle treatment were found for (A) CYP1A1, (B) IL-6 and (C) MCP-1. 
(A) CYP1A1 had overall differences between diets with reduced 
expression in the DHA-fed/PCB 126-treated animals. PCB 126 
significantly increased CYP1A1 expression over the control treated 
animals. (B) IL-6 had increased expression for DHA/PCB 126- treated 
mice in comparison to the untreated controls. PCB 126 signficantly 
increased (C) MCP-1 expression over controls, and DHA/PCB 126-
treated animals had higher MCP-1 expression than the safflower/PCB 
126 treated group. There were no significant differences in (D) VCAM1 
expression for treatment or diet. Significant differences between 
safflower/saline and safflower/PCB 126 are represented by # pvalue<0.05. 
Differences detected between safflower/PCB 126 and DHA/PCB 126 
treatments are represented by * pvalue <0.05, and significant differences 
between DHA/saline and DHA/PCB 126 are represented by $ 
pvalue<0.05.  
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Figure 4.12 Oxidative stress is not increased in the adipose and liver of 
mice acutely exposed to PCB 126. 8-iso-prostaglandin F2 alpha (8-iso-
PGF2α) is a marker of oxidative stress, and neither adipose nor liver tissues 
contained significant increases of 8-iso-PGF2α following PCB 126 exposure. 
DHA-fed mice had lower levels following PCB 126 exposure.  Significant 
differences between DHA/saline and DHA/PCB 126 are represented by $ 
pvalue<0.05.  
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Figure 4.13 Treatment with PCB 126 promotes DHA metabolite 
formation in the adipose of DHA fed mice. For DHA and EPA, there 
is an interactive effect between diet and treatment with a significant 
decrease in the DHA/PCB 126 treated group. LTE4, 4-HDHA and 7-
HDHA have no significant differences. For 9-HODE and 13-HODE, 
there are overall difference between diets and treatments with an 
increase in the safflower/PCB 126 treatment group. For 10-HDHA, 11-
HDHA, 13-HDHA, 14-HDHA, 16-HDHA, 17S-HDHA and 20-HDHA, 
there were overall differences between diets. Samples were normalized 
to tissue weight. A difference was detected between safflower/PCB 126 
and DHA/PCB 126 treatments * pvalue <0.05, and a difference was 
detected between safflower/saline and DHA/saline treatments, + pvalue < 
0.05. Significant differences between DHA/saline and DHA/PCB 126 are 
represented by $ pvalue<0.05. Significant differences between 
safflower/saline and safflower/PCB 126 are represented by # pvalue<0.05. 
Overall difference between dietary feeding is represented by a bar.  
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Figure 4.14 Treatment with PCB 126 promotes DHA metabolite 
formation in the livers of DHA fed mice. For DHA, there is a 
significant overall increase between diets. For EPA, there is an 
interactive effect between diet and treatment with a significant decrease 
in the DHA/PCB 126 treated group. LTE4, 4-HDHA and 7-HDHA have 
no significant differences. For 10-HDHA, 11-HDHA, 13-HDHA, 14-
HDHA, 16-HDHA, 17S-HDHA and 20-HDHA, there were overall 
differences between diets. For 9-HODE, there is almost an interactive 
effect with an overall difference between diets and an increase in the 
safflower/PCB 126 treatment group. 13-HODE had an interactive effect 
between diet and treatment. Samples were normalized to tissue weight. 
A difference was detected between safflower/PCB 126 and DHA/PCB 
126 treatments * pvalue <0.05, and a difference was detected between 
safflower/saline and DHA/saline treatments, + pvalue < 0.05. Significant 
differences between DHA/saline and DHA/PCB 126 are represented by 
$ pvalue<0.05. Significant differences between safflower/saline and 
safflower/PCB 126 are represented by # pvalue<0.05. Overall difference 
between dietary feeding is represented by a bar.  
94 
 
 
Figure 4.15 DHA-feeding promotes the formation of anti-
inflammatory 15-deoxy-∆12,14PGJ2 and anti-oxidant gene 
expression in response to PCB 126-induced inflammation. Overall 
differences between PCB 126 and vehicle treatment and diet were 
found for (A) arachidonic acid metabolite 15-deoxy-∆12,14PGJ2 and (B) 
PPARγ2, though PCB 126 treatment reduces this response. Overall 
differences between PCB 126 and vehicle treatment were found for (C) 
Nrf2, (D) Keap1, (E) HO-1, and (F) NQO1. (D) Keap1 mRNA expression 
is significantly decreased in the DHA/PCB 126 group when compared to 
control. (F) NQO1 is significantly increased in the DHA/PCB 126 treated 
group above both control and safflower/PCB 126 treated animals. 
Differences detected between safflower/control and DHA/control 
treatments are represented by + pvalue <0.05, and significant differences 
between DHA/saline and DHA/PCB 126 are represented by $ 
pvalue<0.05. Significant differences between safflower/saline and 
safflower/PCB 126 are represented by # pvalue<0.05. 
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Figure 4.16 DHA and DHA metabolites positively regulate anti-
inflammatory signaling pathways. The cell utilizes DHA to activate 
anti-oxidant enzyme systems through increased activity of the nuclear 
transcription factors, PPARγ and Nrf-2. PCB 126 binding with the AhR 
promotes an inflammatory response which is mitigated by increased 
anti-oxidant enzyme expression. 
 
 C
at
eg
or
y
Te
rm
C
ou
nt
%
PV
al
ue
G
en
es
Li
st
 T
ot
al
P
op
 H
its
P
op
 T
ot
al
Fo
ld
 E
nr
ic
hm
en
t
B
on
fe
rro
ni
B
en
ja
m
in
i
FD
R
K
E
G
G
_P
A
TH
W
A
Y
m
m
u0
09
83
:D
ru
g 
m
et
ab
ol
is
m
6
2.
39
0.
00
1
TY
M
P
, C
YP
3A
25
, C
YP
3A
41
A,
 
C
YP
3A
59
, D
P
YD
, E
S
31
, T
K
1
10
2
48
57
38
7.
03
2
0.
13
5
0.
13
5
1.
58
7
K
E
G
G
_P
A
TH
W
A
Y
m
m
u0
01
40
:S
te
ro
id
 h
or
m
on
e 
bi
os
yn
th
es
is
5
1.
99
2
0.
00
8
H
S
D
3B
2,
 C
YP
3A
25
, C
YP
3A
41
A
, 
H
S
D
3B
5,
 C
YP
3A
59
, S
R
D
5A
1
10
2
45
57
38
6.
25
1
0.
54
4
0.
32
5
8.
28
9
K
E
G
G
_P
A
TH
W
A
Y
m
m
u0
10
40
:B
io
sy
nt
he
si
s 
of
 u
ns
at
ur
at
ed
 fa
tty
 
ac
id
s
4
1.
59
4
0.
01
1
S
C
D
3,
 F
A
D
S
1,
 E
LO
V
L2
, A
C
A
A
1B
10
2
27
57
38
8.
33
4
0.
68
6
0.
32
0
12
.0
K
E
G
G
_P
A
TH
W
A
Y
m
m
u0
33
20
:P
P
A
R
 s
ig
na
lin
g 
pa
th
w
ay
6
2.
39
0.
01
2
S
C
D
3,
 A
C
SL
1,
 S
O
R
B
S
1,
 F
A
BP
2,
 
A
C
A
A
1B
, S
C
P
2
10
2
79
57
38
4.
27
3
0.
71
4
0.
26
9
12
.8
9
K
E
G
G
_P
A
TH
W
A
Y
m
m
u0
09
10
:N
itr
og
en
 m
et
ab
ol
is
m
3
1.
19
5
0.
06
1
C
A
R
14
, H
A
L,
 C
PS
1
10
2
23
57
38
7.
33
8
0.
99
8
0.
72
0
50
.3
8
K
E
G
G
_P
A
TH
W
A
Y
m
m
u0
49
10
:In
su
lin
 s
ig
na
lin
g 
pa
th
w
ay
6
2.
39
0.
09
5
S
R
E
B
F1
, S
O
R
B
S
1,
 G
C
K,
 P
YG
L,
 
P
K
LR
, G
YS
2
10
2
13
8
57
38
2.
44
6
1.
00
0
0.
81
5
67
.1
6
Su
pp
le
m
en
ta
l T
ab
le
 4
.1
 G
en
es
 d
ow
n-
re
gu
la
te
d 
by
 5
 µ
m
ol
/k
g 
PC
B
 1
26
 tr
ea
tm
en
t a
ffe
ct
 m
ul
tip
le
 m
et
ab
ol
ic
 p
at
hw
ay
s.
 
A
na
ly
si
s 
of
 1
02
 d
ow
n-
re
gu
la
te
d 
ge
ne
 tr
an
sc
rip
ts
 w
as
 g
en
er
at
ed
 u
si
ng
 th
e 
D
A
V
ID
©
 s
of
tw
ar
e 
sy
st
em
, w
hi
ch
 a
ss
es
se
d 
th
e 
ge
ne
s 
fo
r a
ct
iv
ity
 in
 s
ha
re
d 
m
et
ab
ol
ic
 p
at
hw
ay
s.
 
96
 C
at
eg
or
y
Te
rm
C
ou
nt
%
PV
al
ue
G
en
es
Li
st
 T
ot
al
Po
p 
H
its
P
op
 T
ot
al
Fo
ld
 E
nr
ic
hm
en
t
B
on
fe
rr
on
i
B
en
ja
m
in
i
FD
R
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
09
82
:D
ru
g 
m
et
ab
ol
is
m
13
3.
62
1
7.
81
E-
07
G
S
TA
1,
 G
S
TA
2,
 C
YP
1A
2,
 A
LD
H
3B
1,
 G
S
TM
7,
 G
ST
M
1,
G
S
TM
2,
 G
S
TM
3,
 U
G
T1
A
9,
 G
S
TM
4,
 F
M
O
2,
 A
O
X
1,
 F
M
O
3
16
0
75
57
38
6.
22
0.
00
0
0.
00
0
0.
00
1
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
09
80
:M
et
ab
ol
is
m
 o
f x
en
ob
io
tic
s 
by
 
cy
to
ch
ro
m
e 
P
45
0
12
3.
34
3
1.
51
E-
06
G
S
TM
1,
 G
S
TA
1,
 G
S
TA
2,
 G
S
TM
2,
 U
G
T1
A
9,
 G
S
TM
3,
 G
S
TM
4,
 
C
YP
1B
1,
 C
YP
1A
1,
 C
YP
1A
2,
 A
LD
H
3B
1,
 G
ST
M
7
16
0
66
57
38
6.
52
0.
00
0
0.
00
0
0.
00
2
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
04
80
:G
lu
ta
th
io
ne
 m
et
ab
ol
is
m
10
2.
78
6
1.
02
E-
05
G
S
TM
1,
 G
S
S
, G
S
TA
1,
 G
S
TA
2,
 G
S
TM
2,
 G
S
R
, G
ST
M
3,
 
G
S
TM
4,
 P
G
D
, G
S
TM
7
16
0
52
57
38
6.
90
0.
00
2
0.
00
1
0.
01
2
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
02
30
:P
ur
in
e 
m
et
ab
ol
is
m
12
3.
34
3
0.
00
4
X
D
H
, F
H
IT
, N
M
E
2,
 IT
PA
, P
O
LE
2,
 A
TI
C
, N
M
E
1,
 P
KM
2,
 
E
N
TP
D
5,
 P
O
LR
3A
, P
O
LR
2D
, E
N
TP
D
2
16
0
15
7
57
38
2.
74
0.
45
9
0.
14
2
4.
69
4
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
02
40
:P
yr
im
id
in
e 
m
et
ab
ol
is
m
9
2.
50
7
0.
00
5
U
M
P
S,
 N
M
E2
, I
TP
A,
 P
O
LE
2,
 U
P
R
T,
 N
M
E
1,
 E
N
TP
D
5,
 
P
O
LR
3A
, P
O
LR
2D
16
0
96
57
38
3.
36
0.
52
8
0.
13
9
5.
70
8
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
41
10
:C
el
l c
yc
le
9
2.
50
7
0.
02
5
C
C
N
D
1,
 T
G
FB
3,
 B
U
B1
, C
D
C
23
, M
C
M
2,
 M
C
M
3,
 M
YC
, M
C
M
5,
 
TG
FB
2
16
0
12
8
57
38
2.
52
0.
98
0
0.
47
8
26
.3
12
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
52
22
:S
m
al
l c
el
l l
un
g 
ca
nc
er
7
1.
95
0.
03
0
FH
IT
, C
C
N
D
1,
 R
XR
G
, P
IK
3R
3,
 T
R
A
F5
, M
YC
, T
R
A
F3
16
0
85
57
38
2.
95
0.
99
0
0.
48
4
30
.4
50
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
52
10
:C
ol
or
ec
ta
l c
an
ce
r
7
1.
95
0.
03
1
C
C
N
D
1,
 R
A
C
3,
 T
G
FB
3,
 P
IK
3R
3,
 M
YC
, F
ZD
7,
 T
G
FB
2
16
0
86
57
38
2.
92
0.
99
2
0.
45
7
31
.7
53
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
01
40
:S
te
ro
id
 h
or
m
on
e 
bi
os
yn
th
es
is
5
1.
39
3
0.
03
5
U
G
T1
A9
, C
YP
1B
1,
 C
YP
1A
1,
 H
SD
17
B
2,
 C
O
M
T1
16
0
45
57
38
3.
98
0.
99
6
0.
45
5
34
.8
09
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
30
10
:R
ib
os
om
e
7
1.
95
0.
03
6
R
PS
A,
 R
PS
28
, R
P
L1
3,
 R
PL
P
0,
 R
PL
P1
, R
P
LP
2,
 U
BB
16
0
89
57
38
2.
82
0.
99
6
0.
43
2
35
.7
74
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
00
10
:G
ly
co
ly
si
s 
/ G
lu
co
ne
og
en
es
is
6
1.
67
1
0.
03
9
A
KR
1A
4,
 H
K3
, P
K
M
2,
 F
B
P1
, P
G
AM
1,
 A
LD
H
3B
1
16
0
68
57
38
3.
16
0.
99
8
0.
42
9
38
.2
77
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
30
50
:P
ro
te
as
om
e
5
1.
39
3
0.
04
0
P
SM
F1
, P
S
M
C
3,
 P
SM
D
4,
 P
S
M
B
8,
 P
SM
B9
16
0
47
57
38
3.
82
0.
99
8
0.
40
8
38
.8
83
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
09
83
:D
ru
g 
m
et
ab
ol
is
m
5
1.
39
3
0.
04
3
X
D
H
, U
M
PS
, U
G
T1
A9
, I
TP
A,
 2
21
00
23
G
05
R
IK
16
0
48
57
38
3.
74
0.
99
9
0.
40
4
40
.9
46
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
52
12
:P
an
cr
ea
tic
 c
an
ce
r
6
1.
67
1
0.
04
9
C
C
N
D
1,
 R
A
C
3,
 T
G
FB
3,
 S
TA
T1
, P
IK
3R
3,
 T
G
FB
2
16
0
72
57
38
2.
99
1.
00
0
0.
42
0
44
.9
30
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
30
30
:D
N
A 
re
pl
ic
at
io
n
4
1.
11
4
0.
07
2
P
O
LE
2,
 M
C
M
2,
 M
C
M
3,
 M
C
M
5
16
0
35
57
38
4.
10
1.
00
0
0.
53
2
58
.9
76
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
00
40
:P
en
to
se
 a
nd
 g
lu
cu
ro
na
te
 
in
te
rc
on
ve
rs
io
ns
3
0.
83
6
0.
07
9
U
G
T1
A9
, A
K
R
1B
3,
 U
G
D
H
16
0
17
57
38
6.
33
1.
00
0
0.
54
5
62
.7
37
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
00
51
:F
ru
ct
os
e 
an
d 
m
an
no
se
 m
et
ab
ol
is
m
4
1.
11
4
0.
08
2
A
KR
1B
3,
 H
K3
, F
B
P1
, P
M
M
1
16
0
37
57
38
3.
88
1.
00
0
0.
53
6
64
.0
29
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
03
50
:T
yr
os
in
e 
m
et
ab
ol
is
m
4
1.
11
4
0.
09
2
A
O
X
1,
 W
B
S
C
R
22
, C
O
M
T1
, A
LD
H
3B
1
16
0
39
57
38
3.
68
1.
00
0
0.
56
2
68
.7
46
K
EG
G
_P
A
TH
W
A
Y
m
m
u0
03
80
:T
ry
pt
op
ha
n 
m
et
ab
ol
is
m
4
1.
11
4
0.
09
8
C
YP
1B
1,
 C
YP
1A
1,
 A
O
X1
, C
YP
1A
2
16
0
40
57
38
3.
59
1.
00
0
0.
56
4
70
.9
65
Su
pp
le
m
en
ta
l T
ab
le
 4
.2
 G
en
es
 u
p-
re
gu
la
te
d 
by
 5
 µ
m
ol
/k
g 
PC
B
 1
26
 tr
ea
tm
en
t a
ffe
ct
 m
ul
tip
le
 m
et
ab
ol
ic
 p
at
hw
ay
s.
 
A
na
ly
si
s 
of
 1
60
 u
p-
 re
gu
la
te
d 
ge
ne
 tr
an
sc
rip
ts
 w
as
 g
en
er
at
ed
 u
si
ng
 th
e 
D
A
V
ID
©
 s
of
tw
ar
e 
sy
st
em
, w
hi
ch
 a
ss
es
se
d 
th
e 
ge
ne
s 
fo
r 
ac
tiv
ity
 in
 s
ha
re
d 
m
et
ab
ol
ic
 p
at
hw
ay
s.
 
97
98 
Supplemental Figure 4.1 Data containing zero numbers do not meet all the 
assumptions of parametric and non-parametric tests. (A) 14-HDHA is not 
formed in safflower-fed, vehicle treated mice and the zero values are incompatible 
with assumptions of normality and equal variance. In contrast, 4-HDHA (B) is a 
metabolite found in all mice, and thus, the presence of non-zero data values 
satisfies both the normality and variance assumptions. Data are represented as 
averages ± SEM or as scatter plots of individual data points.  
Copyright © Katryn Elizabeth Eske 2013 
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Chapter Five: Mechanisms of PCB-induced Inflammation 
5.1 Synopsis 
Inflammation has been identified as a critical risk factor for a host of diseases including 
cardiovascular diseases (CVDs) such as atherosclerosis58. One of the many contributors 
to endothelial dysfunction and CVDs are environmental pollutants, e.g., polychlorinated 
biphenyls (PCBs), a class of persistent organic pollutants. Our laboratory has explored 
the role of coplanar PCBs in endothelial dysfunction and atherosclerosis.  PCBs, and 
especially coplanar PCBs, induce inflammation by interaction with lipid rafts called 
caveolae that promote signaling through the aryl hydrocarbon receptor (AhR). Lipid rafts 
are also essential for toll-like receptor 4 (TLR4) signaling, an innate immune receptor 
associated with inflammation and atherosclerosis. Both TLR4 and PCBs induce 
inflammation through NFкB signaling pathways. There is limited evidence to suggest that 
environmental toxins interact with TLR4 or its associated proteins to induce inflammatory 
signaling. Thus, the potential interaction of PCBs with TLR4 to induce endothelial 
dysfunction is not well understood. We investigated the interaction of coplanar PCB 126 
with caveolae based TLR4 signaling to induce NFкB inflammatory targets and 
subsequent initiation of endothelial dysfunction.  
5.2 Introduction 
General Overview 
Environmental toxicants, such as polychlorinated biphenyls (PCBs), promote the low-
grade inflammation that contributes to the development of a host of diseases including 
diabetes and cardiovascular disease (CVD)59, 143, 160, 269. Our laboratory’s work with the 
vascular endothelium promotes the understanding of the molecular mechanisms by 
which coplanar PCBs induce inflammation and promote endothelial dysfunction270. 
These changes in the vascular homeostasis create an ideal environment for the 
development of atherosclerotic plaques151. PCBs initiate endothelial inflammation 
through interaction with caveolae,  a form of lipid rafts which harbor receptors and 
signaling domains126. Caveolae also host innate immune receptors including Toll-like 
receptor 4 (TLR4), which is the receptor of bacterial lipopolysaccharide (LPS), and is 
linked to the development of CVD78.  Evidence suggests that environmental stimuli 
interact with TLR4 to promote an inflammatory response. Here we investigated PCB 126 
interaction with TLR4.  
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PCBs, CVD and Inflammation 
National Health and Nutrition Examination Survey (NHANES) and a study in elderly 
patients revealed that circulating levels of PCBs are significantly associated with 
hypertension271 and atherosclerosis64, respectively. Further, angiotensin II-infused 
apolipoprotein E–deficient mice exposed to coplanar PCBs developed more extensive 
atherosclerotic lesions151. The endothelium is a critical component of inflammation and 
disease progression in atherosclerosis. Our studies using primary endothelial cells (ECs) 
have demonstrated that silencing or deficiency of caveolin-1 (Cav-1), a major structural 
and signaling protein of caveolae, decreases PCB–mediated extracellular signal-
regulated kinase-1/2 (ERK1/2) phosphorylation leading to a reduction in associated 
vascular cell adhesion molecule-1  (VCAM-1) expression and monocyte adhesion126. 
PCB-mediated endothelial dysfunction has classically been attributed to AhR activation 
and subsequent upregulation of cytochrome P4501A1 (CYP1A1) and other xenobiotic 
metabolizing proteins124. CYP1A1 causes an increase of reactive oxygen and nitrogen 
species (ROS/RNS) which promote cellular damage and NFкB activation73, 152. The 
classical model of AhR-induced inflammation has not explained other interactions of 
coplanar PCBs with membrane based domains; our work with caveolae addresses this 
question.  
Caveolae and Molecular Signaling 
Caveolae are a specific sub-class of lipid rafts that form sphingolipid and cholesterol rich 
invaginations on the plasma membrane, and cholesterol depletion or buoyancy 
separation have been  classical methodologies for defining and studying these 
domains272. Caveolin-1 (Cav-1) is the major structural protein located within the rafts of 
endothelial cells, and is required for caveolae formation270.  Caveolae have been 
identified as critical components in vascular homeostasis and tone272, and our work with 
PCBs and endothelial nitric oxide synthase (eNOS) have clearly demonstrated the role 
that caveolae play in mediating environmental pollutant-induced changes on vascular 
homeostasis164. Caveolae are involved in intracellular trafficking in which the endocytosis 
of caveolae is followed by merging to endosomes273-276. PCBs appear to exacerbate 
caveolae endocytosis124. Caveolar endocytosis may act as mitigating response to 
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negative stimuli helping the cell to “sort” and develop a specific response277, and 
caveolae are critical to the signaling of the innate immune response.   
TLR4 and Associated Signaling Outcomes 
Lipid rafts are complex signaling domains that play host to a variety of receptors and 
associated scaffolding proteins including TLR4 and Cav-1. TLR4 signaling requires 
dimerization and migration to lipid domains from which downstream activation of NFкB 
occurs107, 117. It has been proposed that TLR4 scaffolding in caveolae stimulates 
endocytosis of caveolae which is essential for the induction of down-stream 
inflammatory signaling278. Activation of TLR4 promotes signaling through an array of 
pathways. The “classical” signaling pathways include signaling through MyD88 
scaffolding pathway to IRAK/TRAF6/TAK1 pathway to induce both NFĸB and MAP-
kinase family signaling279. A second MyD88-dependent signaling pathway utilizes the 
TIRAP/Mal adapter proteins, which also lead to NFĸB signaling, and both the MyD88-
dependent pathways are associated with “early” phase NFĸB signaling280. Alternative 
and complimentary to the MyD88-dependent pathway is the TRIF-dependent signaling 
pathway281. MyD88-independent TRIF associates with TLR4 via the TRAM adaptor 
molecule which initiates TRAF3/IRF3 for interferon activation and TRAF6 for NFĸB-
induced chemokine and cytokine expression, RIP1/caspase 8-dependent induction of 
apoptosis and RIP3-activated ROS-dependent necrosis282. Together these TLR4 
initiated signaling pathways induce a range of inflammatory responses.  
The nuances of the innate immune response continue to unfold as investigators report 
changing specificity depending on chaperone molecules, adaptor protein recruitment, 
and a host of other modifications that dictate the type of cellular response given to a 
particular ligand. The following studies explore the concept of toxicant interaction with 
TLR4; these interactions may be facilitated by chaperone proteins such as 
lipopolysaccharide binding protein (LBP) and CD14. In a study of macrophages 
stimulated with LPS to induce TLR4, cells demonstrated a hyperactive cytokine 
response when challenged with environmental toxicants283.  In a lung inflammation 
model, cigarette smoke-induced inflammatory cytokine production and neutrophil 
infiltration were attenuated in knockout (KO) mice for TLR4 and interleukin-1 receptor 1 
(IL-1R1)284. (Cigarette smoke contains polycyclic aromatic hydrocarbons (PAHs) which 
like PCBs are AhR ligands.) Inflammation in astroglial cells, which was caused by low 
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concentrations of ethanol, was attributed to the caveolae-dependent endocytosis of IL1-
R1/TLR4 and activation of associated downstream pathways278. Finally, a recent study 
demonstrated that PCBs modified intestinal and blood brain barrier function through 
activation of TLR467. Together these studies indicate that TLR4 plays a critical role in 
environmental pollutant-induced inflammation.  
Hypothesis and Rationale 
We hypothesize that PCB 126-induced inflammation is mediated through caveolae-
based TLR4 signaling. A growing body of literature has associated TLR4 with 
atherosclerotic development285-289.  For example, a study examining human Stage VI 
lesions found that the endothelium and macrophages (MΦ) had increased expression of 
TLR4 and p65, a subunit of NFкB 78. Coplanar PCBs, also, contribute to endothelial 
dysfunction and vascular inflammation. Evidence suggests that both sources of 
inflammation may be sensitive to nutritional modulation, and the proposed mechanism 
would provide a platform with which to test potential nutritional interventions. The 
hypothesis proposed here seeks to clarify the critical role of membrane domains, 
caveolae, in mediating PCB-induced inflammation by studying the activation of TLR4-
associated signaling (Figure 5.1). 
5.3 Methods and Materials 
Reagents and Materials 
PCB 126 was obtained from AccuStandard (New Haven, CT). Western blotting reagents 
were obtained from BioExpress (Kaysville, UT). Reverse transcriptase reagents were 
purchased from Fisher Scientific (Waltham, MA).  Reagents used for mRNA isolation 
and qPCR were purchased from Life Technologies (Grand Island, NY). Unless otherwise 
stated, chemicals were purchased from Sigma-Aldrich (St. Louis, MO).  
Sucrose Gradient  
Discontinuous sucrose gradients were performed to separate caveolae-rich lipid 
fractions129. Primary porcine endothelial cells (ECs) were grown to 90% confluence in 
150 mm culture dishes.  Cells were normalized overnight with 1% FBS M199 and treated 
for 30 min or 16 hr with 0.25 µM PCB 126, 0.1 ug/mL LPS, or DMSO (vehicle).  Treated 
cells were harvested by scraping with morpholine ethanesulfonic acid (MES)-buffered 
saline (MBS), and fractions were separated by layering 45% (equal volume sample:90% 
sucrose/MBS solution), 35% and 5% sucrose/MBS solutions which were centrifuged at 
103 
39,000 rpm with a SW41 rotor.  Western blotting was performed using equal volume 
protein fractions loaded on to 8% SDS-PAGE gels, and blots were probed using TLR4 
(H-80) sc-10741 (1:500 primary and 1:4,000 secondary), Santa Cruz Biotechnology, 
Inc., Dallas, TX) and Cav-1 #3238S (1:10,000 primary and secondary, Cell Signaling 
Technology, Inc,, Danvers, MA), Anti-rabbit secondary antibody was from Cell Signaling.   
Cholesterol Depletion Assay 
M199 treatment media with 1% L-glutamine was prepared with 10 mM methyl-β-
cyclodextrin (MβCD)116, 290-292. Confluent 150 mm culture dishes were conditioned with 
1% FBS M199 overnight and were pre-treated with treatment media with or without 10 
mM MβCD for 30 or 60 minutes at 37°C. Plates were washed three times with HANKS 
buffer and were given 0.5% M199 with 1% L-glutamine and 1% penicillin/streptomycin. 
Samples were treated with DMSO or 0.25 µM PCB 126 in DMSO for 8 hr and were co-
treated with 0.1 µg/mL LPS for an additional 4 hr. Cultures were harvested and 
fractionated by sucrose gradient as described earlier. Sucrose gradient fractions were 
assessed by Western blot using 10% SDS-PAGE gels. 
Inhibition Assays and MCP-1 ELISA 
For the inhibition assays, ECs were grown in 12-well plates. Cardiolipin (CL) was 
suspended in PBS at 0.5 mg/mL stock concentration293. For treatment, CL was diluted 
from 10 to 1000 ng/mL in 1% FBS M199 treatment media. Cultures were treated with 
DMSO, 1000 ng/mL CL, 0.5 µM PCB 126, 10 ng/mL LPS, or co-treatment of PCB 126 or 
LPS with different concentrations of CL. CLI-095, also reported as TAK-242, (InvivoGen, 
San Diego, CA)  was suspended in DMSO and working stocks were diluted to 200 
µg/mL in 1% FBS M199294. Cultures were treated with DMSO, 1000 ng/mL CLI-095, 0.25 
µM PCB 126, 10 ng/mL LPS, or co-treatment of PCB 126 or LPS with 10 to 1000 ng/mL 
CLI-095. After 24 hr incubation, supernatant was collected and centrifuged at 4°C and 
7500 rpm for 5 min. An aliquot was removed and stored at -80°C until analysis by MCP-
1 ELISA. Cell culture supernatants were diluted 1:1 and analyzed using the OptEIA 
Human MCP-1 ELISA Kit (BD Biosciences, San Diego, CA) according to manufacturer 
guidelines.  
Real Time – PCR 
ECs were grown to confluence using 6-well plates, and mRNA was isolated using the 
Trizol® method125, 126. Isolated mRNA was resuspended in RNAse/DNAse free water 
and quantified using UV-vis spectroscopy at 260 nM.  cDNA was made using a reverse 
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transcriptase reaction. SYBR® Green reagent was used to perform the real time-PCR 
reactions, and absolute quantification was run using the7300 Real Time PCR Systems 
(Life Technologies, Grand Island, NY). The housekeeping gene, β-actin, was used to 
normalize VCAM1, and data are presented as a ratio of VCAM1/ β-actin. 
Western Blot 
Western blots were performed as described previously140. ECs were grown to 
confluence in 6-well plates and treated with 0.025%v/v DMSO (vehicle), 0.25 µM PCB 
126, and/or 0.01-1.0 µg/mL LPS for 8 hr. Protein was collected using 1X RIPA buffer, 
sonicated for 10 s, incubated on ice for 30 min, and centrifuged at 4°C and12, 000 rpm 
for 15 min. Supernatants were collected and quantified using the Bradford method. 
Aliquots containing 30 µg of protein were made and run on 10% SDS-PAGE gels.  
Following semi-dry transfer, nitrocellulose membranes were incubated for 2 h in blocking 
buffer (5% non-fat milk in Tris-buffered saline containing 0.05% Tween 20).  VCAM1(C-
19)-R (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) primary antibody was diluted 
1:1000 in 5% milk and incubated overnight at  4°C . Anti-rabbit secondary was applied at 
1:4000 dilution. β-actin primary and secondary antibodies were diluted 1:10,000 125. 
Statistical Analysis 
Comparisons between treatments were made by one-way analysis of variance followed 
by Tukey’s post-hoc test. Statistical probability of P0.05 was considered significant. 
SigmaPlot  version 12.0 software (Systat Software, San Jose, CA) was used to perform 
the data analysis. When letters are used to indicate differences in significance, shared 
marker letters between treatments indicate no statistical difference. Values are reported 
as the mean +SEM.  
5.4 Results 
To investigate the interactions of PCBs with TLR4, EC cultures were treated with PCB 
126 or LPS for 30 minutes (Figure 5.2) or 16 hours (Figure 5.3). Using sucrose gradients 
to separate cellular domains by density, we found that PCB 126 and LPS, the primary 
ligand of TLR4 and positive control, both shifted to a more buoyant lipid raft fraction for 
Cav-1 (Figure 5.2A) and TLR4 (Figure 5.2B) suggesting interaction by both ligands with 
these domains at 30 minutes.  After 16 hr of treatment, both Cav-1 (Figure 5.3A) and 
TLR4 (Figure 5.3B) proteins were distributed throughout the gradient implicating 
association with other proteins either to promote signaling or because of migration into 
the cytoplasm. Looking at endothelial dysfunction markers, cells treated with PCB 126 or 
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LPS showed an increase in VCAM-1 mRNA expression (Figure 5.4). Previous work in 
our laboratory demonstrated that PCBs increase caveolae endocytosis (as does 
activation of TLR4278) and that treatment with PCBs increases the co-
immunoprecipitation of AhR with Cav-1 linking the activation of Cav-1 with the 
downstream consequences of AhR stimulation124. Caveolae activation and trafficking 
provide a link between the diverse NFкB activation pathways of TLR4 and AhR.  
Several groups have explored the protective role of certain long-chain fatty acids, 
phospholipids, and their oxidized products. In one study, the phospholipid cardiolipin 
(CL) was shown to inhibit activation of TLR4 via chaperone protein binding293; we utilized 
CL as an inhibitor of TLR4 activation to determine if downstream inflammatory markers 
were modulated similarly for both PCB and LPS. When cells were co-treated with CL 
and PCB or LPS, monocyte chemoattractant protein-1 (MCP-1) protein, a chemokine 
indicative of endothelial cell activation, was decreased (Figure 5.5). To confirm the 
activity of TLR4 in PCB-induced inflammation, TAK-242, a TLR4-specific inhibitor, was 
tested294.  PCB 126 treated groups displayed a significant increase of MCP-1 over TAK-
242 alone (brand name CLI-095, InvivoGen, San Diego, CA) except for the 250 ng/mL 
CLI-095 treated group, which had a pvalue = 0.055 (Figure 5.6A). In contrast, the LPS 
treated groups displayed only a significant increase for MCP-1 protein  over inhibitor 
alone with 10 and 50 ng/mL CLI-095, which were also significantly increased over the 
1000 ng/mL and LPS co-treated group (Figure 5.6B). The 1000 ng/mL CLI-095 (TAK-
242) showed the greatest inhibition of MCP-1 protein expression in the presence of LPS 
treatment which was not replicated with PCB 126 treatment.  
Though the TLR4-specific inhibitor assay indicates that PCB 126 (at the dose and time 
points studied) does not activate the TLR4 signaling mechanism, similarities exist 
between LPS and PCB-induced Cav-1 localization in the sucrose gradient data and 
inflammatory endpoint expression. We, therefore, focused on caveolae and Cav-1 to 
confirm shared activity. Using a cholesterol depletion assay, we observed changes in the 
localization of Cav-1 following treatment with PCB 126 and/or LPS. Previously, work with 
mRNA indicated that LPS stimulated an increase in VCAM1 expression in half the time 
of PCB 126 (see for example, Figure 5.4); for this reason cultures were treated for 4 hr 
with LPS and 8 hr with PCB 126 and were harvested and subjected to sucrose gradient 
fractionation. In the vehicle treated gradient, Cav-1 had a broad presence including the 
most buoyant fractions to fraction 10 with the highest protein density in fractions 4-6 
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(Figure 5.7A). PCB 126 treatment stimulated a shift from the most buoyant fractions to 
fractions 5-12 (Figure 5.7B); similarly, LPS treatment caused a shift away from fractions 
1-3 (Figure 5.7C). Cholesterol depletion with MβCD reduced the total Cav-1 and forced 
Cav-1 out of the buoyant lipid raft fractions into fractions 5-10 regardless of treatment 
(Figure 5.7). Interestingly, co-stimulation with both PCB 126 and LPS caused a shift in 
Cav-1 localization to fractions 5-11 and was sufficient to overcome the effects of 
cholesterol depletion on Cav-1 expression (Figure 5.7D). To further assess the 
inflammatory response to PCB 126, LPS, or LPS/PCB 126 co-treatment, we probed for 
Cav-1 and VCAM1 protein in the sucrose gradient fractions. All treatments demonstrated 
a shift of Cav-1 away the most buoyant fractions when compared to vehicle, but PCB 
126 and the PCB 126/LPS co-treatment caused tighter grouping of Cav-1 in the less 
buoyant fractions. For VCAM1, vehicle and PCB 126 treated fractions only displayed 
non-specific binding above the protein ladder at fractions 10-13. LPS and the co-treated 
gradients also displayed this non-specific binding. The LPS treated group had a faint 
VCAM1 band around fraction 7, outside of the buoyant membrane fractions; in contrast, 
the LPS/PCB 126 co-treated fractions clearly presented VCAM1 in lipid raft fraction 4 
(Figure 5.8B). To confirm the observation that PCB 126 and LPS strengthened the 
expression of inflammatory markers, we assessed VCAM1 expression following 
treatment with PCB 126 with co-treatment using different concentrations of LPS. Co-
treatment with LPS increased VCAM1 expression in mRNA when compared to control, 
PCB 126 alone, and LPS alone (Figure 5.9), and a similar trend was observed in protein 
expression (Figure 5.10). 
5.5 Discussion 
The data presented here seem to suggest a similar phenomenon, in which PCB 126 
stimulates a TLR4 interaction with the Cav-1 fractions, but we were unable to 
substantiate a clear link between this interaction and an inflammatory response. There 
are multiple explanations for this observation; the following will be discussed (a) 
differences in coplanar PCB structure, (b) differences in signaling pathways with 
overlapping endpoints, and (c) loss of key chaperone proteins. The final discussion 
points will highlight the aspects of this research that are important for future studies of 
protective omega-3 fatty acids.   
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Previous work with PCB 77 and here with PCB 126 demonstrates coplanar PCB-induced 
Cav-1 activity.  PCB 77 promotes Cav-1:AhR interaction 124 and activates endothelial 
nitric oxide synthase (eNOS) through PI3K/Akt signaling164.  MCP-1 expression is 
induced by PCB 77 in a Cav-1-dependent manner through p38 and JNK signaling 125.  
Because of their similar structure and AhR binding activity, both PCB 77 and PCB 126 
are thought to have similar modes of action. However, in this study, PCB 126 did not 
mimic the typically robust inflammation that PCB 77 induces, despite having a higher 
TEF167. PCB 77 is metabolized and excreted; in one study, approximately 85% of the 
original dose was excreted after five days295, 296.  In a similar five day excretion and 
metabolism study, only low levels of a single PCB 126  metabolite were detected, and 
this metabolite was associated with detoxification for excretion rather than toxicity176.  
The resistance of PCB 126 to cellular metabolism may also alter the development of the 
inflammatory response following AhR activation. 
Modulation of the inflammatory response is becoming a field of intense study297, 298. 
Researchers are investigating the immune response and intensity following multiple 
exposures and/or doses of LPS. Environmental pollutants present another set of 
potential stimuli and in concert with other factors such as stress, infection, and diet, are 
likely modulators of body’s ability to cope, protect, and recover from injury.  In this study, 
co-stimulation by both PCB 126 and LPS elicited expression of the inflammatory marker, 
VCAM1. Others have demonstrated that LPS treatment of ECs promotes Cav-1 and 
adhesion molecule co-localization in caveolae299, and our work suggests that PCB 
treatment also enhances VCAM1 and MCP-1 expression in a caveolae-dependent 
manner125, 126.  Similar endpoints do not mandate a common signaling pathway. As 
reviewed in the introduction of this chapter, TLR4 stimulation utilizes multiple sets of 
adapter molecules that initiate different signaling pathways. The research presented 
here was unable to substantiate a productive interaction between TLR4 and PCB 126, 
meaning we could not directly link the membrane interaction observed in the sucrose 
gradients with the cytokine or adhesion molecule response.  However, TLR4 is sensitive 
to ligands other than LPS. For example, hemin, an iron-containing porphyrin with a 
chlorine ligand, also promotes TLR4/Cav-1 binding, but when compared to LPS, different 
signaling pathways are initiated through this interaction123. In addition, caveolae are 
promiscuous domains that harbor multiple receptors and are sensitive to disruptions to 
the lipid balance in the plasma membrane268, 300, 301. These realities further promote the 
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idea of caveolae as a common signaling platform for both LPS and PCB 126 and help 
explain the enhanced suppression of MCP-1 following exposure to lipophilic inhibitors in 
the ELISA assays. We propose that different molecular pathways are activated in 
response to LPS and PCB 126 but both utilize caveolae as a common base for signal 
initiation and both culminate with NFкB-directed inflammation.  
Another puzzling aspect of this study is the relative insensitivity of the ECs to LPS 
stimulation. Multiple forms of LPS were tested, but no differences were observed (data 
not shown). Others have reported that TLR4 is expressed primarily in the cytosol of 
endothelial cells rather than at the cells surface and that membrane and external 
chaperone proteins are required for the internalization of LPS302.  For example, CD14, a 
critical chaperone for LPS trafficking and TLR4 activation/migration, can be lost in 
primary cell lines following passaging303, 304. Further the presence of soluble and 
membrane bound forms of CD14 contribute to the sensitivity of the endothelial response; 
however,  very high doses of LPS, 1000 ng/mL, activated TLR4 signaling without 
CD14305. Here we report that TLR4 is present in the caveolae rich fraction, and LPS or 
PCB 126 stimulation of ECs is sufficient to see TLR4 migration with Cav-1, but it is not 
sufficient to produce a consistent inflammatory response. Therefore, it is possible that 
the necessary chaperone proteins were not expressed in our cell line. Combined 
stimulation of PCB 126 and LPS may have overcome the lack of chaperones; in other 
words, the two stimuli may have promoted sufficient caveolar internalization to initiate 
the inflammatory response without the assistance of chaperone proteins. 
Caveolae are important regulatory platforms that are sensitive to nutritional modulation, 
such as omega-3 lipids105. The phospholipid cardiolipin was effective in disrupting 
caveolae-based chemokine response in the inhibition assay (Figure 5.5).  Others have 
reported that incorporation of omega-3 fatty acids into the plasma membrane alters the 
lipid raft microdomain composition97.  For this reason, we are interested in signaling 
changes caused by omega-3 fatty acid incorporation into caveolae. This localized 
change in lipid content also alters the amount of Cav-1, eNOS, and certain Ras protein 
in the caveolae97.  Our laboratory has observed changes in PCB-induced signaling 
following treatment with differing ratios of omega-3 and omega-6 fatty acids16. Similarly, 
TLR4 signaling is disrupted by omega-3 fatty acids, such as DHA, through inhibition of 
the PI3K/Akt signaling pathway 106. We have demonstrated that PI3K/Akt signaling is 
also critical to the inflammatory signaling induced by the omega-6, linoleic acid, in 
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vascular endothelial cells199. Together both our work with PCBs and the work with TLR4 
indicate polyunsaturated fatty acids, primarily omega-3 fatty acids, as a promising 
nutritional intervention96.  Future work should continue to explore caveolae-based 
signaling mechanisms that are sensitive to nutritional modulation. 
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Figure 5.1 Summary of the proposed mechanism of action. Similar to LPS, PCB 
interaction with TLR4 in caveolae initiates endocytosis. PCB-activated TLR4 causes 
NFкB-induced inflammation, which contributes to AhR-mediated inflammation and 
oxidative stress.  
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Figure 5.2 PCB 126 and LPS treatments stimulate a localization shift in 
caveolae fractions. Sucrose gradient lipid fractions 1-4 of 12 fractions showing 
localization of Cav-1 (A), and TLR4 (B) in lipid raft fractions after 30 minute 
treatment with DMSO vehicle (0.005%), PCB 126 (<1ppm), or LPS (0.1 μg/mL). 
(Higher molecular weight TLR4 bands are glycosylated proteins.) 
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Figure 5.3 PCB 126 and LPS treatments promote Cav-1 and TLR4 
migration within cellular fractions. Sucrose gradient fractions 
showing density localization of Cav-1 (A), and TLR4 (B) in lipid raft and 
non-raft fractions after 16 hr treatment with DMSO vehicle (0.005%), 
PCB 126 (<1ppm), or LPS (0.1 μg/mL). Fractions range from most (1) to 
least (14) buoyant. 
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Figure 5.4 PCB 126 and LPS treatments significantly increase adhesion 
molecule expression. VCAM1 mRNA expression of primary porcine vascular 
ECs treated with PCB 126 (~ 1 ppm) with DMSO, vehicle control, and LPS 
(0.1 μg/mL) with PBS, vehicle control at 8 and 24 hours. Results are the mean 
+ SEM, n=3. Significantly different compared with vehicle control at * P≤0.002 
and significantly different from PCB 126 at + P≤0.05. 
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Figure 5.5 MCP-1 protein expression is attenuated by cardiolipin (CL) in 
(A) PCB 126 and (B) LPS treated cells. ELISA of MCP-1 protein expression 
in cell culture media collected from ECs treated with DMSO, vehicle control, 
(A) PCB 126 (<1ppm), or (B) LPS (10 ng/mL) and co-treated with 10 ng/mL 
cardiolipin (CL) for 24 hours. Significantly different compared with PCB or 
LPS, respectively at * P≤0.002. 
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Figure 5.6 MCP-1 protein expression is not attenuated by CLI-095 in (A) 
PCB 126 but is attenuated in (B) LPS treated cells. ELISA of MCP-1 protein 
expression in cell culture media collected from ECs treated with DMSO, 
vehicle control, (A) PCB 126 (<1ppm), or (B) LPS (10 ng/mL) and co-treated 
with 10 ng/mL CLI-095 (TAK-242) for 24 hours. Significantly different from 
untreated 1000 ng/mL CLI-095, at * P≤0.05, and significantly different from 
1000 ng/mL CLI-095 with LPS treatment, + P≤0.05. 
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Figure 5.8 PCB 126, LPS and PCB126/LPS co-treated cells exhibit 
different patterns of (A) Cav-1 and (B) VCAM1 protein expression. DMSO 
(vehicle control), PCB 126 (0.25 µM), LPS (0.10 µg/mL) or PCB 126/LPS co-
treated cell cultures produced different sucrose gradient fractionation patterns.  
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Figure 5.9 PCB 126 co-treatment with varying concentrations of LPS 
promotes different patterns of VCAM1 mRNA expression. Cell cultures 
were treated with PCB 126 for 16 hr and co-treated with LPS at 10, 100 or 
1000 ng/mL for an additional 8 hr, and LPS treated for 24 hr at 1000 ng/mL. 
Statistical differences at pvalue <0.05 is indicated by different letters; shared 
letters indicate no statistical difference between treatments.  
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Figure 5.10 PCB 126, co-treated with varying concentrations of LPS 
exhibit different patterns of VCAM1 protein expression.  Cell cultures were 
treated with PCB 126 for 16 h and co-treated with LPS at 10, 100 or 1000 
ng/mL for an additional 8 hr. Western blot includes samples a and b of LPS 24 
h treatment at 1000 ng/mL. 
Copyright © Katryn Elizabeth Eske 2013 
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Chapter Six: Final Discussion – coplanar PCB-induced inflammation and 
nutritional modulation 
6.1 Synopsis 
Inflammation links multiple disease processes58. As persistent environmental pollutants, 
coplanar PCBs accumulate in human adipose6, 173, and this toxic body burden promotes 
oxidative stress and endothelial dysfunction73, 306. PCB 77 and its dechlorination products 
are pro-inflammatory and promote oxidative stress in a primary endothelial cell model307. 
The persistence of coplanar PCB 126 in human tissues presents it as a more 
representative model for PCB-induced toxicity. We identified 5 µmol PCB 126/kg body 
weight as a pro-inflammatory but not overtly toxic dose in mice. Mitigating the effects of 
PCB-induced inflammation through nutrition is the most pro-active means of responding 
to environmental stressors. Omega-3 fatty acids and their neuroprostane metabolites 
have effectively attenuated PCB-induced oxidative stress in primary endothelial cells16, 
92. We, therefore, fed mice a DHA-enriched diet and challenged them with PCB 126 to
observe the metabolic and anti-oxidant response. At the same time, we pursued the 
caveolae based-TLR4 inflammatory signaling mechanism as a potential platform for 
better understanding the modulation of PCB-induced signaling through lipid rafts. 
Coplanar PCBs represents one class of many environmental stressors that promote 
inflammation. The anti-oxidant response mediated by Nrf2 and PPARγ and caveolae-
based signaling are both mechanism which are sensitive to nutritional modulation by 
omega-3 fatty acids and as such present viable options for future investigation.   
6.2 Dechlorination and inflammation 
Remediation of persistent organic pollutants has been a significant portion of the 
response to environmental pollution. Our ability to assess the outcome of the 
remediation techniques is critical to verifying the effectiveness of emerging remediation 
strategies. In addition, the field of environmental toxicology needs to develop sensitive, 
high- throughput in vitro models that may be used to test dose, pharmacokinetic and 
toxicological implications of environmental toxins308.  The products of dechlorination that 
were assessed in chapter two reveal the necessity of complete remediation307.   
6.2.2 Limitations and Future work 
The inflammatory capacity of PCB 77 and its remediation products necessitated 
complete dechlorination. Biphenyl, though not toxic to our primary endothelial cell model, 
exhibits toxicity in the renal and neurological systems309, 310. In response to this 
challenge, the Chloro-Organic Degradation Project Research Team at the University of 
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Kentucky, College of Engineering has developed a more complete system that 
remediates the PCBs to biphenyl and biphenyl to mono- and di-hydroxybipheyls and 
benzoic acid311.  
Studying mixture toxicity has been one of the challenges for environmental toxicology. 
Thus, cell models which can be used to assess the total toxicity of a mixture rather than 
select or known constituents are beneficial. One system that is being tested to detect 
polycyclic aromatic hydrocarbons (PAHs), which are AhR agonists, utilizes a reporter 
assay that has an AhR sensitive promoter coupled to luciferase enzyme312. The assay, 
which is based in a mammalian cell line and utilizes benzo[a]pyrene as the reference 
molecule, is reported to produce a more meaningful assessment of complex mixtures 
than current assays which assess only known constituents. An alternative approach to 
the mixture problem is to define calculations that can combine toxicological data from 
individual toxicants and produce an accurate toxicity value for the mixture. In a model 
testing sex hormone synthesis, a generalized concentration addition model was most 
successful in predicting the testosterone effects of a mixture313. Together these 
approaches represent the next generation of toxicity assessment.      
6.2.3 Contribution to our knowledge as a whole 
The inflammatory potential of coplanar PCB 77 was sufficient to induce inflammation in 
our endothelial cell model, and the dechlorination products had reduced inflammatory 
potential but were not inert307. The human environment is saturated with chemical 
mixtures that activate an array of receptors and biological processes. Our work as well 
as the work of others focuses primarily on a specific toxicant or family of toxicants; as a 
result, many chemical stressors are not included in traditional risk assessment314. For 
this reason, a proactive response to environmental stress requires the identification of 
nutritional or lifestyle modulators of toxicological response and inflammatory stress315.  
6.3 PCB 126 as a model toxicant 
PCB 126 distributes throughout the body but is primarily sequestered in liver and 
adipose. The highest doses of PCB 126 (50 and 150 µmol PCB 126/kg body weight) 
promoted wasting syndrome, increased expression of Bax protein, a key regulator of 
apoptosis, and increased VCAM1 protein expression.  In contrast, the lowest dose (0 
and 0.5 µmol PCB 126/kg body weight) did not contribute to weight change, increased 
expression of inflammatory endpoints, or indications of cellular apoptosis. Only the 5 
µmol PCB 126/kg body weight dose produced a significant change in liver to body 
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weight ratio without significant weight lose, promoted the expression of MCP-1 and did 
not initiate Bax protein.   
6.3.2 Limitations and Future work 
As with any study, we had to limit the number of parameters that we examined. We 
choose a wide dose range which included 150 µmol/kg, a concentration that is 
equivalent to the dose of PCB 77 that was utilized in our previous animal work and is 
expected to be overtly toxic for PCB 12691, 125. The acute time point provides a limited 
view of the inflammatory response, and unlike studies of atherosclerosis this window 
was not sufficient to determine vascular outcomes in our animals. Previous work with 
PCB 77, indicates that vessel inflammation and lesion development are increased in 
animals challenged with PCB91, 151. The overview of this study would have been 
improved by some additional measurement. For example, an assessment of oxidative 
stress could have been made using tissue or urinary measures of 8-iso-prostaglandin 
F2α. Measurements of PCB 126 hydroxylated metabolites in the tissues and feces would 
have provided an indication of PCB 126 metabolism. Future optimization of this model 
should include collection of urine and feces for measures of oxidative stress and PCB 
126 hydroxylated metabolites and include later time points to determine the progression 
of inflammation following acute exposure.  
In fact, PCB 126 is very persistent in human tissues. A review of the general population 
revealed that levels of PCB 126 remained relatively static from 1989-2008 which is in 
contrast to decreased population levels of  polychlorinated dibenzofurans (PCDFs) and 
polychlorinated dibenzo-para-dioxins (PCDDs)316. One possible explanation for the 
stable levels of PCB 126 in the human population is a species difference in rodent and 
human CYP1A1 binding pockets that prevents proper orientation of PCB 126 with the 
human heme for hydroxyl- metabolite formation317.  The authors do not comment on 
whether this ineffective binding promotes CYP1A1 enzyme uncoupling and reactive 
oxygen species formation which would promotes cellular oxidative stress and 
inflammation. In a study of human intake, PCB 126 was not one the top congeners 
consumed but did contribute 67% of the TEF value, yet for all the toxicants consumed, 
the subjects did not exceed the current threshold set for allowable human 
consumption318.   
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6.3.3 Contribution to our knowledge as a whole 
As an acute exposure model, two doses of 5 µmol PCB 126/kg body weight are 
sufficient to elicit moderate inflammation. The long-term consequences of this exposure 
level have not been identified.  
6.4 Omega-3 fatty acids and PCB 126-induced inflammation 
Inflammation resolution is a major topic emerging in the omega-3 fatty acid literature. At 
present, there has not been a consensus on the inflammatory profile representing the 
changes expected from omega-3 immunomodulation. In some studies, the data include 
decreases in inflammatory cytokines like tumor necrosis factor alpha (TNFα), IL-6, and 
IL-8101, 127. Alternatively, others have reported sustained cytokine levels but reductions in 
F2-isoprostanes99.  The oxidized products and enzymatic metabolites of omega-3 fatty 
acids are active in inflammation resolution by promoting phagocytosis and class 
switching in leukoctyes and in cellular anti-oxidant and anti-inflammatory response 
processes that utilize nuclear receptors, i.e. Nrf2 and PPAR102, 207, 319.  
Organic pollutants, such as polychlorinated biphenyls, contribute to sustained systemic 
inflammation and promote diseases such as atherosclerosis73, 320. Dietary changes 
present a means of mitigating the inflammatory effects of pollutant exposure92, 320. The 
introduction of polyphenols, such as quercetin from vegetables and epigallocatechin 
gallate (EGCG) from green tea, and omega-3 fatty acids, such as α-linolenic acid from 
flax and DHA from fish oil, promote the expression of anti-oxidant enzymes and 
counteract PCB promotion of NFкB-induced inflammation16, 92, 128, 130. Nutritional 
modulation of Nrf2 and the PPARs is critical to the attenuation of PCB-induced 
inflammation92, 130, 255. 
6.4.2 Limitations and Future work 
The DHA diet was developed following a literature search of diets in which feeding of 
diets with 2%-4% DHA from 4 to 12 weeks improved molecular and inflammatory 
outcomes99, 210-212, 321. In one feeding study, changes in plasma, eye, spleen, brain, and 
liver fatty acid composition were detected in Balb/c mice as early as three weeks of 
dietary feeding230; similarly, in a 10 week feeding study, they observed arachidonic acid 
decreases in lung at 2 weeks and by 3 weeks omega-3 fatty acid levels had reached a 
steady state99.  PCB 126 is a persistent organic pollutant which promotes the 
development of inflammatory diseases over time; therefore, future studies might assess 
the interaction of PCB-induced inflammation and dietary DHA over a broader time range 
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which will allow us to assess when DHA modulates acute inflammation and inflammation 
resolution. Example time points may include submandibular blood collection 24 h and 4 
days after the initial gavage and takedowns 24 h, 2 weeks, and 4 weeks after the final 
gavage. These time points are inferred from a study of impaired glucose tolerance which 
observed glucose intolerance in mice receiving coplanar PCB 77 beginning after the 
second gavage on week 2 through the duration of the 12 week study322. The tissue 
levels of coplanar PCB 77 were decreased well below 50% by week 4 of the study, yet 
the metabolic disturbance and TNFα levels in the adipose persisted322. From these 
observations, we may imply that the inflammatory actions of coplanar PCBs are 
sustained and thus extended observation would be advised. The investigation of PCB 
77-induced glucose tolerance revealed an interesting role for dietary fat which indicates 
that modulation of the PCB-77 induced insulin disturbance and TNFα tissue levels may 
be influenced by dietary fat composition70. Those mice receiving a high fat diet (60% kcal 
from fat) did not experience PCB-induced differences in glucose tolerance; however, 
after weight loss on low fat (10% kcal from fat), the mice experienced coplanar PCB-
induced decreases in glucose and insulin tolerance. The recommended human 
consumption of fat is 30% kcal or less, which makes this diet of 25% kcal from fat a 
moderate representative of human consumption323, yet a recommended rodent diet 
contains only 10% kcal from fat324. The present study of dietary DHA as intervention for 
PCB 126-induced inflammation may be limited by the moderate fat content of 25% kcal 
from fat, which may promote storage rather than metabolism of PCB 126.  Future 
studies of dietary DHA as a modulator of PCB-induced inflammation should consider the 
use of both low and high fat diets and multiple ratios of omega-3 fatty acid to determine 
the most effective intervention252.  
A significant portion of the omega-3 fatty acid literature assesses the changes in 
leukocyte behavior following an inflammatory stimulus85, 207, 225, 325. Continued 
investigation into the role of omega-3 fatty acids in mitigating coplanar PCB-induced 
inflammation should include and assessment of inflammatory capacity, e.g. cytokine 
response/profile, and phagocytic ability in macrophages and natural killer cells. In 
addition, a follow-up DHA feeding study designed to include atherosclerotic lesion 
assessment would enable us to visualize changes in both inflammatory markers, such 
as MCP-1 and VCAM1, and macrophage accumulation. We would expect that the 
improved cellular anti-oxidant environment of DHA-fed mice would reduce lesion 
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formation to model baseline. DHA feeding promotes the expression of PPARγ, which is 
protective against atherosclerotic lesion development326. 
The changes in cholesterol and glucose tolerance are indicative of underlying metabolic 
changes, which may be driven by novel DHA oxidation products103. Identification of the 
novel lipid mediators could be accomplished through a comparison study of the lipid 
mediators produced in mice challenged by PCB 126 or LPS. Our present assessment 
was limited primarily to monohydroxy- metabolites and did not investigate potential 
oxidized DHA metabolites92, 204, 205, 249. Investigation into novel lipid mediators should also 
include nitro fatty acids. Polyunsaturated fatty acid-derived nitro fatty acids are potential 
modulators of PPARγ, Nrf2, and the NFĸB subunit p65327-330. The activities of these 
novel lipid mediators involve interactions with PPARγ and Nrf2 nuclear receptors. For 
this reason, subsequent in vitro studies should begin by exploring the interactions of Nrf2 
and the PPARs with novel lipid mediators following coplanar PCB stimulation.  
6.4.3 Contribution to our knowledge as a whole 
The 25% kcal from fat content of the diet may have mitigated the overall response to 
DHA-enriched diet as was indicated by others in a different model of inflammation252. 
The dietary fat content could also moderate the metabolic and inflammatory response to 
PCB 126 exposure. In a study of coplanar PCB-induced metabolic dysregulation after 
weight loss, the authors demonstrated that mice fed a high fat diet did not experience 
the negative changes in glucose and insulin tolerance that affected mice who underwent 
weight loss and mobilization of PCBs from the adipose depots70. Together dietary fat 
content greater than 10%, low fat, may dampen the effects of both PCBs and omega-3 
fatty acids by promoting storage rather than metabolism.  
The literature emphasizes the role of enzymatic and oxidized metabolites in the 
regulation of inflammation resolution and metabolism205, 207, 331. Research from our 
laboratory has demonstrated the anti-inflammatory potential of oxidized DHA in the 
activation of Nrf2 inflammatory response92. In a similar study, activation of Nrf2 was 
observed with oxidized eicosapentaenoic acid (EPA) neuroprostanes205. 15-deoxy-∆12,14-
PGJ3, an  EPA cyclooxygenase dehydration product, also activates PPAR to induce 
adiponectin, which promotes insulin sensitivity243, 331. Our work supports the activity of 
arachidonic acid-derived,15-deoxy-∆12,14-PGJ2, which activates Nrf2227. These 
observations alter the previous paradigm which focused on the pro-inflammatory effects 
of arachidonic acid metabolism, LDL oxidation and lipid peroxidation332, 333.  The 
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activation of pro-resolving, anti-inflammatory and metabolism stabilizing lipid mediators 
requires dietary supplementation to proactively modulate the inflammatory response334.  
6.5 Synergy of innate immunity and PCB-induced inflammation 
One of the mechanisms by which DHA and other omega-3 FAs provide protection 
involve interactions with lipid domains and may be similar to that of the signaling 
changes induced by the phospholipid cardiolipin267, 293. Lipid rafts, like caveolae, are 
sensitive to changes in membrane lipid homeostasis and are responsive to dietary 
modulation which alters the functional role of lipid rafts in disease335. Caveolae host 
critical signaling domains, which include the LPS receptor toll-like receptor 4 (TLR4)278, 
336.  Caveolae are sensitive to lipophilic pollutants and facilitate the inflammatory 
cascade which leads to NFкB activation124-126.  
Caveolae have been established as critical inflammatory mediators105. In our research, 
response to stimulation from PCBs and LPS required the presence of caveolin-1 in the 
plasma membrane. Activation of caveolin-1 by PCBs displaced TLR4 from the lipid raft 
fractions. The response was not linked to direct TLR4 activation by PCBs but signaling 
changes occurring within the caveolae domain. In this context, we were able to observe 
the additive effect of PCB and LPS co-stimulation.   
6.5.2 Limitations and Future work 
Primary endothelial cells are caveolin-1 (Cav-1) rich, and provide a sensitive model for 
the study of endothelial dysfunction and inflammation126, 276. A comparison of 
immortalized endothelial cell lines and human umbilical vein endothelial cells (HUVECs) 
indicates that certain inflammatory and immunological signaling factors, such as VCAM1 
and MHC class II antigens, are not mutually expressed337. The primary pulmonary 
porcine endothelial cells used for the experiments in chapters two and five have 
inducible expression of key inflammatory markers including VCAM1 and MCP-1125, 126. 
However, primary cell lines may not consistently express certain markers after 
passaging as is the case with CD14, a TLR4 chaperone protein304. Future studies should 
include an immortalized endothelial cell line, such as the EAhy926 cells, which would 
serve as a control for potential loss of key signaling proteins.  In our experience, the 
EAhy926 cells produced similar but less robust MCP-1 protein expression in response to 
PCB 126 or LPS in the cardiolipin inhibition assay when compared to the primary 
endothelial cells (data not shown).  
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Caveolae are critical to the signaling of cellular stressors such as LPS and PCBs, and 
these domains are also necessary for the protective signaling response that comes from 
interaction with certain phytochemicals such as quercetin and EGCG128, 129. The 
signaling controls which modulate the differences between response to environmental 
pollutants and nutritional interventions are not well understood, and thus, the role and 
function of caveolae domains remain an important aspect of future studies.  
The additive nature of PCB 126 and LPS co-stimulation presents an interesting dynamic 
for future study. Others have published that PCBs promote barrier dysfunction and 
PCB/LPS co-stimulation enhances PCB-induced dysfunction of the blood brain barrier67. 
One avenue through which TLR4/MyD88 and TLR4/TRIF signaling are initiated is the 
PI3K/Akt pathway338. LPS induction of TLR4/PI3K has been modulated by the saturated 
fatty acid, lauric acid, which promotes transient Akt phosphorylation; in contrast, the 
polyunsaturated fatty acid, DHA, suppresses NFĸB activation in a TLR4/PI3K-dependent 
manner339. Further, investigation of TLR4/PI3K signaling suggests that PI3K functions as 
a regulator that limits TLR4 signaling through modification of the local phospholipid 
composition340. Our research has also demonstrated both PI3K-associated signaling and 
fatty acid-dependent modulation of PCB-induced inflammatory response, providing PI3K 
as a potential link between the membrane-based TLR4 signaling in caveolae and the 
downstream activities of PCBs. Further lipid rafts are known to be critical modulators of 
Src activated PI3K/Akt signaling341. We established that PCBs modulate the 
phosphorylation of endothelial nitric oxide synthase (eNOS) through Src mediated 
PI3K/Akt activation164. Akt is a critical initiator of many cellular processes and is therefore 
is a potential regulator of PCB/LPS co-stimulatory events. 
The cellular inflammatory response is sensitive to different stimuli and combination of 
stimuli. Emerging research suggests that low level exposure to an inflammatory stimulus 
disengages negative feedback mechanism and prolongs the inflammatory response297. 
When applied to our work, low level chronic exposure to PCBs has the potential to 
disrupt the negative feedback response to inflammatory stimuli and promote chronic 
inflammation that leads to atherosclerosis and other chronic disorders. Further, the 
“deprogramming” of low dose inflammatory stimuli establishes a condition in which a 
higher secondary stimulus initiates a hyperactive response due to insufficient negative 
feedback342. As of yet, the role of environmental pollutants in this mechanism have not 
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been studied, but PI3K and Akt are key regulators of this pathway, the actions of which 
warrant further study in our model.  
6.5.3 Contribution to our knowledge as a whole  
This work substantiates previous research which has indicated the role of caveolin-1 as 
being critical to the inflammatory response to lipophilic environmental stresses, such as 
coplanar PCBs124, 126. Caveolae have the capacity to respond to multiple stressors. The 
strength or specificity of the inflammatory stimuli activates different receptors and 
signaling pathways to culminate in an inflammatory response, yet caveolae are sensitive 
to modulation by omega-3 fatty acids and phytochemicals which activate anti-oxidant 
pathways97, 128.   
6.6 Implications 
The environment that we live in contains a mixture of pollutants that includes legacy 
chemicals like PCBs and newly synthesized toxicants that have not yet been recognized 
as health hazards343. The risk for heart disease, diabetes, liver disease, and other 
inflammation- related disorders increase with exposure to PCBs and other persistent 
organic pollutants59, 62, 64, 66, 71. When studying subjects who have high dietary fish intake 
and as a result have both increased pollutant exposure and increased omega-3 intake, 
the increased pollutant exposure has negative outcomes such as increased arterial 
stiffness, but the vascular inflammation is reduced in response to a high intake of 
omega-3 fatty acids203. Our observations suggest that even low exposures to coplanar 
PCBs, such as PCB 77 and its dechlorination products, promote inflammation in 
vascular endothelial cells.  PCB 77 promotes endothelial dysfunction and vascular 
inflammation, by for example, increasing the expression of VCAM1 in the artery wall14, 91. 
Lipid exposure regulates the extent of the PCB 77-induced inflammatory response with 
omega-6 linoleic acid promoting inflammation while omega-3 α-linoleic acid and high 
oleic acid-olive oil counter regulate the inflammation, respectively15, 16, 91.  
As a coplanar  PCB, PCB 126 is an AhR ligand, and the pro-inflammatory potential of 
PCB 126 is demonstrated by the induction of IL-8 and MCP-1 in pre-adipocytes and 
differentiated adipocytes344. These findings implicate that PCB 126 promotes 
inflammatory markers which are generally associated with obesity and diabetes345, 346. 
PCB 126 affects cardiovascular outcomes as well. For example, in the 1999-2002 
NHANES (National Health and Nutrition Examination Survey) data, heightened serum 
PCB 126 was strongly associated with a risk for hypertension347, and animal models 
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suggest an association between PCB 126 and the development of vascular lesions168. 
PCB 126 is a very stable dioxin-like congener which is detectable in human blood 
samples and is consumed through the human diet 316, 318. These studies substantiate 
human exposure through dietary sources, but implicate a limited human capacity to 
metabolize and excrete PCB 126. The literature does not define whether the toxicity of 
PCB 126 is primarily derived from the parent compound or the hydroxylated metabolites. 
In our in vivo exposure model, PCB 126 activates a moderate inflammatory response 
including the upregulation of CYP1A1 and MCP-1, which we attribute to the activity of 
the parent PCB and the AhR.  The epidemiological literature suggests that PCB 126 
contributes to inflammatory disease states, but the human experience includes exposure 
to mixtures of PCBs and other toxicants.  In a comparison of persistent organic 
pollutants (POPs) and plastic-associated chemicals (PACs), such as bisphenol A and 
phthalates, there was more evidence supporting the role of POPs in cardiovascular 
disease, yet sufficient literature supports a link between the PACs and vascular disease 
that it could not be excluded from consideration348.  In conclusion, avoiding a single 
toxicant over another does not eliminate disease risk.  
For this reason, nutrition and other healthy lifestyle choices are the best option for 
maintaining health. Omega-3 fatty acids and the metabolites resolvin E1 and protectin 
D1 promote insulin sensitization in an ob/ob mouse model239. The protectins and 
resolvins promote inflammation resolution by directing leukocyte class switching which 
promotes cytokine expression patterns that drive wound healing334. The oxidized DHA 
neuroprostanes promote Nrf2 mediated protection against coplanar-PCB induced 
inflammation92, and EGCG, a green tea catechin, provides protection against TNFα-
induced inflammation via a similar mechanism129, 349. Omega-3 fatty acids and 
phytochemicals both inhibit LPS-induced inflammation through TLR4107, 350. The former 
inhibits dimer formation and migration into lipid rafts107, and the latter alters 
phosphorylation patterns of the TLR4 cysteine residues; thus, altering dimer formation, 
which is required for associated inflammatory signaling350. Our data suggest that the 
presence of DHA or its metabolites promote the anti-oxidant activities of PPARγ and 
Nrf2, which increase HO-1 and NQO1 expression to mitigate PCB-induced inflammation. 
Together these studies substantiate the hypothesis that modulation of diet promotes an 
anti-inflammatory environment within a living organism.   
Copyright © Katryn Elizabeth Eske 2013 
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Appendix  
Electrophoretic Mobility Shift Assay (EMSA) 
Harvesting cells for nuclear extraction:  
1) Aspirate media from 10 cm plates. 
2) Rinse 2X with 10 mL cold 1X PBS. 
3) Add 2 mL of PBS and scrap plates. 
4) Transfer to 15 mL conical tubes (on ice) and pelleted cells at 500 x g for 5 min at 
4°C. 
5) Remove the supernatant leaving the cell pellet as dry as possible. 
6) Premade buffers for 10-15 ul cell volume for a 100 mm plate (keep on ice):  
a. Reagent volumes per sample for the NE-PER Nuclear and Cytoplasmic 
Extraction Reagents kit (Thermo Scientific): 
Packed Cell Volume (µL) CER I (µL) CER II (µL) NER (µL) 
10 100 5.5 50 
20 200 11 100 
50 500 27.5 250 
100 1000 55 500 
Protease Inhibitor (Halt) 
Required 
Yes  Yes 
 
7) Add ice-cold CER I buffer and vortex on high for 15 s to suspend the pellet. 
8) Let stand on ice for 10 min. 
9) Add ice-cold CER II to the tube.  
10) Vortex for 5 s on the highest setting and incubate on ice for 1 min.  
11)  Vortex for 5 s on the highest setting. Centrifuge the tube for 5 min at max speed 
in a microcentrifuge. (16, 000 x g, 4°C, 5 min) 
12)  Immediately transfer the supernatant (cytoplasmic extract) to a clean pre-
chilled tube. Hold tube on ice to assess protein concentration or for storage. 
(Measure the protein concentration by BCA or store at -80°C.) 
13)  Suspend the nuclear pellet in ice-cold NER. 
14)  Vortex on high for 15 s. Place the samples on ice and vortex for 15 s every 10 
minutes, for a total of 40 min.  
15)  Centrifuge tubes at 16, 000 x g, 4°C for 10 min. 
16)  Immediately transfer the supernatant (nuclear extract) to a clean pre-chilled 
tube. Place on ice.  
17) Perform BCA or Bradford to determine protein concentration and store at - 80°C.  
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Prepare and run EMSA: 
1) Set up gel cassette molds. 
2) Prepare 6% (or 4.5%) Acrylamide Gel (EMSA does not require a stacking gel): 
Reagent 6% gel 6% gel 4.5% gel 4.5% gel 
diH2O                       
(mL) 
14.1 28.2   
10X TBE buffer     2.5 5.0   
40% bis-acrylamide 3.125 6.25   
10% APS                 
(uL) 
250 500   
TEMED 20 40   
Total 20 mL 40 mL 20 mL 80 mL 
 
3) Fill the cassette to just over the edge and insert comb.  
4) Allow gel to set until solidified and wells are well-formed. (1h-1.5hrs) 
5) Pre-run the gel with 0.5X TBE buffer for 30 min. or more at 60V, RT.  
6) Meanwhile, prepare samples for gel electrophoresis:  
 
a. Set up EMSA reactions in order with a 5 min incubation before adding the 
biotin labeled probe: 
 Reagents 1 2 3 4 5 cold 
no 
extract
Ultrapure Water 11.0 11.4 11.5 11.6 11.6 10.0 15.0 
10X Binding Buffer 2.0 2.0 2.0 2.0 2.0 2.0 2.0 
1 ug/ul Poly(dI*dC) 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
cold (10 µM) or bio-mutant 
(100 nM)           2.0   
Nuclear Ext (5 µg) 4.0 3.6 3.5 3.4 3.4 3.0 0.0 
Incubate 5 minutes. 
Biotin-Probe (100 nM) 2.0 2.0 2.0 2.0 2.0 2.0 2.0 
Total Volume 20 20 20 20 20 20 20 
b. Incubate for 20 min at RT. 
7) Add 4 µL of 6X orange/blue loading dye with triturating to each sample. 
8) Check wells; if not well formed, flush with 0.5X TBE buffer to clear. 
9) Load samples into gel and run at 70 V at RT for ~ 1 h.  
10) Pre-soak the pads and nylon membrane for a minimum of 10 min in 0.5X TBE 
buffer.  
11) Rinse gels in 0.5X TBE buffer and assemble for semi-dry transfer.  
12) Transfer via semi-dry transfer at 300 mA for 30 min at RT.  
13) Remove membrans and allow to dry face up on a Kim wipe. (2-5 min) 
14) Cross-link for ~ 45 s (use automatic setting) at 120 mJ/cm3 using a commercial 
UV cross-linker.  
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Detection of the biotin binding 
1) Block the nylon membrane for 30 min in blocking buffer with shaking on an orbital 
shaker.  
2) Prep the Conjugate/blocking buffer cocktail (66.7 μL stabilized streptavidine-
horseradish peroxidase conjugate to 20 mL blocking buffer (1:300 dilution)).  
3) Decant blocking buffer and  replace with the Conjugate/blocking buffer cocktail for 
15 min on orbital shaker.  
4) Prepare 1X wash solution 30 mL 4X wash solution to 90 mL H2O. 
5) In fresh boxes, wash membranes for 4X at 5 min each with wash solution.  
6) Prepare the substrate working solution. (Start with the following dilution and 
incrementally increase as necessary): 
1 mL each Luminol Enhancer Solution and Stable Peroxide Solution plus 8 mL 
dH2O for a total of 10 mL.  
7) In a fresh box, cover nylon membranes with substrate working solution for 5 min, 
and gently rock by hand to maintain coverage of the membranes.  
8) In a cassette, place membranes in a plastic sheath and photograph in the dark 
room starting with 1 min.  
9) Store nylon membranes in dH2O, if necessary.  
Ordering probe from IDT 
1) Determine probe sequence from literature. If a porcine sequence is not available, 
use a validated human sequence. 
2) On the IDT website select “Custom DNA Oligos.” 
3) Select duplex, and a space will appear for the insertion of a second sequence.  
4) Name the sequence.  
5) Paste the sequence and press the complement button. (The complement should 
appear in the alternate space.) 
6) No additional purification required. Select amount based on needed; generally 
the lowest is sufficient for us.  
7) For each sequence, go to the bottom and select “5’ modification”. 
8) Select /5Biosg/, 5’ Biotin.   
9) To order cold probe, do the same set-up, but do not add the biotin tag.  
Preparing probe for EMSA 
1) Reconstitute the lyophilized stock based on nmol of product, e.g., 94.8 nmol 
make Stock 1: 100 μM with 948 µL of diH2O.  
2) To make Stock 2 for the biotin labeled probe, dilute Stock 1 -  1:1000 to 100 nM 
(for the ChemiEMSA). 
3) To make Stock 2 for the cold probe, dilute Stock 1 -  1:10 to 10 µM (for the 
ChemiEMSA). 
Protein Isolation from Cells  
1) Aspirate media. 
2) Rinse 2X with 2mL cold 1X PBS. 
3) Carefully, remove residual PBS by pipette. 
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4) Apply premade lysis buffer, 200 ul for a 35mm plate (keep on ice); 100-150 uL 
per 6 -well:  
a. Lysis buffer Option A: 
Reagent 1 mL 2.5 mL 5 mL 10 mL 
diH2O                       
(mL) 
0.780 1.95 3.90 7.8 
10X RIPA buffer     0.100 0.25 0.50 1.0 
10% SDS 0.100 0.25 0.50 1.0 
100X EDTA            (uL) 10 25 50 100 
Protease Inhibitor 
(Halt) 
10 25 50 100 
 
b. Lysis buffer Option B: 
Reagent 1 mL 2.5 mL 5 mL 10 mL 
diH2O             (mL) 0.750 2.00 3.92 7.84 
10X RIPA buffer     0.125 0.25 0.50 1.0 
10% SDS 0.125 0.25 0.50 1.0 
Aprotinin        (uL) 0.25 0.50 1.0 2.0 
Pepstatin A 1.25 2.50 5.0 10.0 
PMSF 12.5 25 50 100 
NaF 6.25 12.5 25 50 
 
c. Lysis buffer Option C: 
 1 mL 1.5 mL 2 mL 3 mL 4 mL 5 mL 6 mL 
Lysis (-) (mL) 0.974 1.464 1.948 2.922 3.896 4.87 5.84 
NP-40 (uL) 5 7.5 10 15 20 25 30 
PMSF 10 15 20 30 40 50 60 
Na3VO4 1 1.5 2 3 4 5 6 
Protease Inhib. 
Cocktail 
10 15 20 30 40 50 60 
 
5) Scrap plates, pipette up and down 10-20X, and transfer lysate to 1.5 Eppendorf 
tubes. 
6) Sonicate for 10 sec. with the sonicator set at 20 and 4.  
7) Let stand on ice for 30 min. 
8) Centrifuge for 15 min. @ 13,000rpm and 4°C. 
9) Transfer supernatant to chilled Eppies and freeze on dry ice. 
10)  Store at -80°C. 
11)  Measure the protein concentration by BCA. 
Protein Isolation from Tissues 
Equipment: forceps, scalpel, weigh boats, autoclaved mortar and pestle, power drill, 
labeled 1.5mL tubes on ice, 1X RIPA buffer (no SDS) on ice, 2 mL serological pipettes 
and pipette aid, diH2O & 70% EtOH for cleaning/sterilization 
1) Make 1X RIPA buffer and set on ice. Label tubes and set on ice.  
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2) Tare weigh boat on analytical balance. Quickly open frozen tissue sample and 
remove a piece of tissue with the scalpel using forceps to transfer to weigh boat. 
(Tissue should weigh between 0.04-0.08g.) 
3) Insert mortar into power drill. Add 300uL of 1X RIPA buffer to the pestle and 
insert the tissue sample. Homogenize the sample using the mortar/power drill, 
moving mortar up and down as necessary to homogenize the entire sample.  
4) Carefully, remove the homogenized sample by pipette and place in chilled 1.5mL 
tubes. 
5) Sterilize the equipment with EtOH and remove residual sample matter with diH2O 
after each sample.  
6) Once sample have been collected, sonicate for 10 sec. with the sonicator set at 
20 and 4.  
7) Let stand on ice for 30 min. 
8) Centrifuge for 15 min. @ 13,000rpm and 4°C. 
9) Transfer supernatant to chilled Eppies and add 600uL of DN/RNase free H2O to 
dilute. 
10)  Freeze on dry ice, and store at -80°C. Or, proceed to BCA. 
11)  Measure the protein concentration by BCA. In the BCA plate, dilute each sample 
1:5 (1uL sample: 4uL diH2O).  
 
Sucrose Gradient Procedure 
Harvesting 
1. Cells grown on 150mm x25mm plate/treatment were washed with 1X PBS twice 
(around 5 ml a time), then lysed with 2 mL of ice-cold MES buffered saline (MBS; 
25mM MES (morpholineethanesulfonic acid, pH 6.5) 150 NaCl) containing 500 
mM Na2CO3.  Scrape plates. 
a. Prepare:  
i. 25mM MES: 2.4405g (MEShydride, Sigma # M2933-100g) in 500 
ml water. Adjust PH to 6.5.  
ii. Then add 4.383 NaCl into MES to make MBS. 
iii. For lysis buffer, take 50mL MBS, add 2.65g Na2Co3, get 500mM. 
2. Homogenization was carried out with 10 strokes of a loose-fitting Dounce 
homogenizer (7mL) (aka the adapter homogenizing tips fitted to the power drill, 
10 strokes with samples in the special glass tubes [volume 2mL lower part]). 
Make sure to wash adapters and tubes with DI water and 70% ethanol between 
Reagent 1 mL 2.5 mL 5 mL 10 mL 
diH2O                       (mL) 0.880 2.25 4.40 8.8 
10X RIPA buffer     0.100 0.25 0.50 1.0 
100X EDTA            (uL) 10 25 50 100 
Protease Inhibitor (Halt) 10 25 50 100 
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samples. After homogenizing, pour into 15ml conical tubes for sonication: 15 
strokes set at 4. 
3. After sonication, centrifuge at 3000rpm for 10 min at 4°C. 
4. Collect supernatant into centrifuge tubes (14x89mm), if it’s not exactly 2ml, add 
more MBS to reach 2ml. 
Ultracentrifugation 
1. Make your sucrose solutions 
a. 90% Sucrose: 45g sucrose and make final volume to 50ml using MBS 
solution. Heat in water bath and/or sonicator to dissolve. 
b. 35% Sucrose: 17.5g sucrose and final volume 50 ml. 
c. 5% Sucrose: 2.5g sucrose and final volume 50 ml. 
2. In Ultraclear Centrifuge tubes (14x89 mm Cat#344059, Beckman Coulter, Inc, 
Brea, CA) , combine 2 fractions of lysate sample with 2 fractions of 90% sucrose 
in the bottom of an ultracentrifuge tube. A fraction is 800μl. Be sure to cut the tip 
larger for the thicker 90% sucrose solution. Vortex for 5 seconds on medium 
speed. Volume should now be 3.2 ml. 
3. Carefully layer on 5 fractions of 35% sucrose. The first two fractions should be 
done drop by drop, down the inside side of the tube. Be sure to check for a layer 
for the first 2 fractions, then addition can be faster, but still along the side to keep 
mixing from occurring. Volume should be around 7.2 ml. 
4. Carefully layer on 3 fractions of 5% sucrose in same manner. 
5. Make sure to cool down ultra-centrifuge. Set to program of 39k m/s, 18 hours + 2 
hours at 0 m/s, Max Accel, no brake, 4°C. Should be under “Hennig Sucrose 
Gradient” program name. 
6. Change gloves, wipe outside of tubes with DI water and chemwipes, and slide 
tubes into the swinging buckets (should be cleaned before with DI water and 
70% ethanol). This is to insure there are no sugar grains on the outside of the 
tubes.  
7. Place your first sample on the scale, then add a final fraction of 5% sucrose. 
Rotate through the other tubes, adding the final fraction to all to the point that 
they are within 0.01g of each other. 
8. Place vacuum grease on the threads of all the bucket caps before screwing them 
into place.  
9. Carry out and load onto rotor & into ultracentrifuge. Initiate program. Make sure 
to check back in 30 min or so to assure no problems have occurred. 
Fraction collection 
1. After removing the buckets, remove the first fraction while tube is still in the 
bucket. Fractions are same as before, 800 μl. 
2. Then, remove tube from bucket and place in holder. 
3. Gently remove the remaining fractions. Make sure to keep the tip of the pipette 
just below the surface. There will be a total of 13 fractions. 
a. There is usually a floating mass near the bottom of the 4th fraction. Be 
sure to collect it only in the 4th fraction until it actually seems to be lower, 
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in the 5th fraction. Be careful, because as you collect, the mass may try to 
shift downward. 
4. Aliquot fractions a couple times (7μl sample buffer+ 42μl fraction sample). 
5. Store samples in -80 until ready to use. 
Western blotting for sucrose gradients 
1. For TLR4 and other difficult antibodies, use 8% SDS gels. Run gels as normal. 
Transfer using semi-dry. 
2. During blocking, block the normal 4 hours in 5% milk, then 1 hour at room 
temperature for the primary. Afterwards, place in cold room overnight. 
3. Wash for one 8 minute and two 5 minute session. Then apply secondary and sit 
for 2 hours. 
4. When washing after secondary, wash for two 8 minute and two 5 minute 
sessions before applying ECL. Let rock for at least 1 minute with ECL before 
positioning in cassettes and developing. 
Western Protocol 
1) Make acrylamide gels: 
a. Separating gel 
Reagent 10 mL 20 mL 
diH2O                       (mL) 4.8 9.6 
1.5 M Tris-HCl    pH 8.8 2.5 5.0 
40% Acryl:Bis 2.5 5.0 
10% SDS                 (uL) 100 200 
10% APS 50 100 
TEMED 10 20 
 
b. Stacking gel 
Reagent 5 mL 10 mL 20 mL 
diH2O                      
(mL) 
3.05 6.1 12.2 
0.5 M Tris-HCl    pH 6.8 1.35 2.5 5.0 
40%  Acryl:Bis 0.65 1.3 2.6 
10% SDS                 
(uL) 
50 100 200 
10% APS 25 50 100 
TEMED 5 10 20 
 
2) Combine protein samples (30ug) with 6X loading dye as per BCA results. 
3) Heat samples for 5min. at 100°C. 
4) Set-up the Western apparatus and fill inner chamber with 1X Running Buffer until 
it just overflows. Fill bottom of the chamber until it passes the wire. 
5) Load samples into gel(s) with gel loading tips avoiding the flanking wells when 
possible. Use 6uL of Rainbow Ladder for each gel. 
6) Run for approx. 80min. at 130V. 
7) Prepare the dry transfer blot system: 
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a. Submerge the pads, nitrocellulose membrane, and the Western gel in 
transfer buffer. 
b. Pour a small amount of transfer buffer on the apparatus. 
c. Using a forceps, place the “sandwich,” pad, membrane, gel, and pad on 
the apparatus. After each layer use a plastic wedge, test tube, etc. to 
gently remove bubbles. 
d. Pour a little more transfer buffer over the sandwich and secure both lids. 
e. Run the transfer at 350 mAmps for 1 hour. 
8) Remove the nitrocellulose gel and rinse with TBST.  
9) Cover with Ponceau stain, remove excess, wash 1-2x with TBST to view 
banding, cut as needed. (May store ON at 4°C in TBST if unable to continue.) 
10)  Cover membrane with 5% milk (5g + 100mL TBST) and incubate with shaking 
for 1-3hr at RT. 
11) Remove milk and wash while shaking in TBST for 10 min. 
12)  Remove TBST and apply 4mL of 5% milk or appropriate volume and add 
primary antibody. For most antibodies, add 1:1000 dilution (i.e. 4uL to 4mL, 8uL 
to 8mL) except β-actin antibody add a minimum of 1:10,000 to a max of 1:4000 
dilution.  
13) Either store in primary antibody ON at 4°C with shaking or incubate at RT with 
shaking for 3hrs. 
14)  Wash 3x with TBST for 5-10min. each (on shaker). 
15)  Add secondary antibody in 5% milk to a 1:4000 dilution. Incubate at RT for 1-
2hrs on shaker. 
16) Wash 4x with TBST for 5-10min. each (on shaker). (May store at 4°C in TBST.) 
17)  Combine equal amounts of “black” and “white” ECL reagents making enough to 
apply 2-4mL to each membrane depending on size. Incubate with shaking for 1 
min. 
18) Cut appropriately sized plastic sheath for each membrane and tape into a 
cassette. 
19) Dab the edge of the membrane on some Kim wipes and place in the plastic 
sheath.  
20) In the dark room, bend the upper right corner of the film for orientation and place 
on the membrane for an appropriate length of time.  
21) Develop film and mark rainbow ladder bands.  
22) Label appropriately. 
23) Membranes may be stripped or stored in TBST.  
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